Kongsberg Automotive wins a contract extension worth EUR 56 million in estimated lifetime revenue

Kongsberg, December 20, 2024: Kongsberg Automotive (KA) has won a contract extension worth over EUR 56 million in estimated lifetime revenue for Fluoro-Comp®  and stainless-steel braided hoses. A global Tier 1 automotive supplier awarded this five-year contract renewal. KA’s Suffield, Grand River (USA), and Ramos Arizpe (Mexico) plants will manufacture and supply these products. The Fluoro-Comp® hose is a non-metallic reinforced PTFE hose used for multiple automotive or commercial vehicle applications. It can withstand extreme temperatures, offers low permeation, and has burn-through resistance to give users the performance and properties of a PTFE hose, while still maintaining the forming and routing ease of a nylon or rubber hose. “We are delighted to extend our partnership with KA’s long-standing customer for these critical products for use on both traditional, hybrid, and electric vehicles (EVs),” says David Redfearn, KA’s Chief Sales officer. “As the transition to sustainable transportation continues, it is exciting to note that KA’s existing portfolio supports this journey.” Media and communications contact:Therese Sjöborg Skurdal – Director, Group Marketing and Communicationstherese.skurdal@ka-group.com+47 982 14 059 Investor Relations contact:investor.relations@ka-group.com About Kongsberg Automotive ASAKongsberg Automotive provides cutting-edge technology to the global vehicle industry. We drive the global transition to sustainable mobility by putting engineering, sustainability, and innovation into practice. Our product portfolio includes driver and motion control systems, fluid assemblies, and industrial driver interface products. Find more information at: kongsbergautomotive.com 

Africa Energy Enters Into a Non-Binding Agreement with Arostyle

VANCOUVER, BC, Dec. 20, 2024 /CNW/ - Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (“Africa Energy” or the “Company”) announces that the Company and Arostyle Investments (RF) Proprietary Ltd. (“Arostyle”) (together the “Parties”) have entered into a non-binding agreement (the “Agreement”) to restructure their joint investment in Main Street 1549 Proprietary Ltd. (“Main Street”), which currently has a direct 10% participating interest in Block 11B/12B offshore South Africa. The Company owns 49% of the common shares and 100% of the Class B shares of Main Street. The remaining 51% of the common shares of Main Street are held by Arostyle. In light of the withdrawal of the joint venture partners as announced July 29, 2024, and subject to all relevant regulatory approvals, Main Street expects to hold a 100% participating interest in Block 11B/12B. Under the Agreement, the Parties have agreed that subject to all relevant regulatory approvals, the Parties will restructure Main Street resulting in the Company holding a direct 75% participating interest and Arostyle holding a direct 25% participating interest in Block 11B/12B, with the relationship between the Parties being governed by the existing Joint Operating Agreement in respect to Block 11B/12B. The parties are to negotiate in good faith to conclude the restructuring documents by no later than January 31, 2025. Important information This is information that Africa Energy is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above on December 20, 2024, at 1:00 a.m. ET. The Company’s certified advisor on Nasdaq First North Growth Market is Bergs Securities AB, +46 739 49 62 50, rutger.ahlerup@bergssecurities.se. Forward looking statements Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or the Company’s future performance, business prospects and opportunities, which are based on assumptions of management. There is no certainty that the Parties will execute definitive agreements and that, if executed, the terms in the definitive agreements will be consistent with the terms of the Agreement. Further, there is no certainty that the Parties will obtain all the required regulatory approvals necessary to effect the transfer of the participating interests. The use of any of the words “will”, “expected”, “planned”, “intends” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of certain future events. These forward-looking statements involve risks and uncertainties relating to, among other things, changes in oil prices, results of exploration and development activities, including results, timing and costs of exploration and development activity in the Company’s area of operations and, uninsured risks, regulatory changes, defects in title, availability of funds required to participate in the exploration and development activities, or of financing on reasonable terms, availability of materials and equipment on satisfactory terms, outcome of commercial negotiations with government and other regulatory authorities, timeliness of government or other regulatory approvals, actual performance of facilities, availability of third party service providers, equipment and processes relative to specifications and expectations and unanticipated environmental impacts on operations. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.View PDF version 

Sciety and Sciety Venture Partners invest EUR 3.9 million in PeptiSystems

The market for peptide and oligonucleotide therapeutics is projected to experience substantial growth in the coming years, with some segments seeing annual growth rates of up to 20%. Across Europe, the USA, and Asia, more drug candidates targeting large patient populations are being developed using peptides and oligonucleotides. However, traditional manufacturing methods for peptides remain inefficient, creating production bottlenecks that limit patient access to new treatments.  PeptiSystems automates the production of peptides and oligonucleotides for pharmaceutical use. The company's unique flow technology, solid-phase flowthrough, reduces peptide production time from months to days and integrates real-time monitoring and data-driven process optimisation to ensure high quality and efficiency. The technology is cost-effective and sustainable, with up to 50% lower raw material consumption and carbon emissions – a solution that enables customers to streamline their production and launch drugs faster to meet growing global demand.  "Peptide and oligonucleotide therapeutics are undergoing a transformation, with more drug candidates targeting common diseases such as type 2 diabetes and cancer. This development is driving demand for more efficient production solutions. For peptides, PeptiSystems' technology is a breakthrough that resolves process bottlenecks and enables faster drug development," says Andreas Lindblom, Managing Partner at Sciety.  Since launching its products in 2021, PeptiSystems has seen strong market demand that has driven the company’s rapid revenue growth. PeptiSystems’ revenue increased from 9.8 million SEK in 2022 to 33 million SEK in 2023, and the company has built a broad customer base across major markets including the USA, China, Switzerland, Germany, France and the Netherlands.  The share issue attracted significant interest from new and existing investors, including individuals with deep industry knowledge who will actively contribute to the company's continued development.  "The fact that the company already has customers across multiple continents at an early stage confirms the potential of its solutions. The strong interest in the investment, particularly from individuals with extensive industry experience, is very positive," says Andreas Lindblom.  "The strong support from both new and existing investors is very encouraging. This capital will enable us to scale up production and advance our product portfolio to meet growing global demand. With an established customer base across the USA, Europe and Asia, we are well positioned to accelerate our growth and strengthen our market presence," says Karin Granath, CEO of PeptiSystems. 

Lea bank ASA – Information Regarding Listing of Lea Bank AB on Nasdaq First North Premier Growth Market

Lea Bank AB (100% owned by Lea bank ASA) announces that it has received preliminary approval from Nasdaq Stockholm AB to list its shares on Nasdaq First North Premier Growth Market in Stockholm. Nasdaq Stockholm has determined that Lea Bank AB fulfills its listing requirements, and will approve Lea Bank AB’s application for trading on Nasdaq First North Premier Growth Market provided that outstanding requirements are met. The first day of trading on Nasdaq Stockholm is expected to be January 9, 2025. Lea Bank AB’s shares will trade under the ticker “LEA”, with the ISIN code SE0023261300. Lea bank ASA will be absorbed through a reverse merger with Lea Bank AB on January 2, 2025. Following the merger, Lea bank ASA will cease to exist, and its trading on Oslo Stock Exchange (Oslo Børs) will end. Oslo Stock Exchange (Oslo Børs) has confirmed that the last day of trading for Lea bank ASA shares will be December 30, 2024. During the interim period, from the last trading day on Oslo Stock Exchange (Oslo Børs) to the first day of trading on Nasdaq First North Premier Growth Market, the necessary efforts will be made to ensure the transfer of shares for shareholders holding Norwegian Lea bank ASA shares to Swedish Lea Bank AB shares. A Company Description of Lea Bank AB will be published in due time before listing on Nasdaq Stockholm. Contact information: Oddbjørn Berentsen, CEO Phone: +47 22 99 14 00 Email: ir@leabank.no

Paratus Announces Listing of Senior Secured Bonds on Nordic ABM

Reference is made to the announcement on 5 June 2024 made by Paratus Energy Services Ltd. (the "Company" or "Paratus") published on the Company's website regarding the successful placement of USD 500 million new senior secured bonds (the "Bonds"). On 19 December 2024, Nordic ABM approved an admission document prepared by the Company in connection with its application for registration of the Bonds on Nordic ABM. The Bonds will commence trading on Nordic ABM today, 20 December 2024. The admission document is available on https://live.euronext.com/nb.   For further information, please contact:Baton Haxhimehmedi, CFOBaton.Haxhimehmedi@paratus-energy.com+47 406 39 083 About ParatusParatus Energy Services Ltd. (ticker: PLSV) is an investment holding company of a group of leading energy services companies. The Paratus Group is primarily comprised of its ownership of Fontis Energy and a 50/50 JV interest in Seagems (formerly Seabras). Fontis Energy is an offshore drilling company with a fleet of five high-specification jack-up rigs working under contracts in Mexico. Seagems is a leading subsea services company, with a fleet of six multi-purpose pipe-laying support vessels under contracts in Brazil. In addition, Paratus is the largest shareholder in Archer Ltd, a global oil services company, listed on the Euronext Oslo Børs.

Metso to deliver energy-efficient Vertimill[®][ ]and HIGmill[TM] regrind mills to Reko Diq copper-gold project

Metso has received an order for Vertimill® and HIGmillTM regrind mills for the Reko Diq copper-gold project in Pakistan. The order, which also includes apron feeders and vibrating feeders, is part of the comprehensive equipment delivery frame agreement  announced on August 14, 2024. The order value of the regrind mills and feeders is approximately EUR 50 million, and it is booked in the Minerals segment’s 2024 fourth-quarter order intake. “Following an innovative and collaborative test work campaign, a two-stage regrind circuit consisting of a Vertimill[®][ ]and a HIGmill[TM] operating in series was selected to optimize the overall energy-efficiency and operating cost. In this solution, the robust feed particle size capability of the Vertimill[®] is optimally combined with the efficient fine grinding and particle conditioning of the HIGmill[TM],” says Bjorn Nielsen, Vice President, Stirred Mills and HPGR at Metso. Metso’s stirred milling technologies portfolio consists of Vertimill®, HIGmill™, and Stirred Media Detritor (SMD) mills. These mills are based on gravity-induced and fluidized technologies, allowing for an optimum equipment solution for all comminution circuits in secondary, tertiary, fine, ultrafine, regrind, and lime slaking applications. Metso has over 50 years of experience in developing, testing, and delivering stirred mill technology, including over 500 installations worldwide. All stirred mills are part of the Metso Plus  offering. Read more about Metso stirred mills offering on our website . Further information: Piia Karhu, President, Minerals, Metso, tel. +358 20 484 100, email: piia.karhu(at)metso.com Helena Marjaranta, Vice President, Communications and Brand, Metso, tel. +358 20 484 3212, email: helena.marjaranta(at)metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change. Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. Metso.com, x.com/metsoofficial

SRV will implement right-of-occupancy housing units for Vaso in Kuloistenniitty, Raisio – the units will have an energy class A rating

SRV GROUP PLC     INVESTOR NEWS    20 DECEMBER 2024  9:00 EET SRV will implement right-of-occupancy housing units for Vaso in Kuloistenniitty, Raisio – the units will have an energy class A rating SRV and Varsinais-Suomen Asumisoikeus Oy (Vaso) have signed an agreement for a right-of-occupancy housing project comprising two blocks of flats in Kuloistenniitty, Raisio. It will be carried out as a turnkey contract, including the design and construction of the project. The agreement is valued at EUR 13.6 million. The project will be recorded in SRV's order backlog for December. The construction of As Oy Raision Keisarinviitta and As Oy Raision Hohtosini will be started up immediately in January 2025. The buildings will be completed in summer 2026 at Perhosenkatu 3 and 5. The project will build two six-storey blocks of flats, with a total of 74 tenancy entitlement housing units and shared social and yard areas. In addition to comfort, project planning focuses particularly on energy efficiency. The units will have an energy class A rating. The buildings will also feature electric car charging stations. “We’re very excited to build right-of-occupancy housing units for Vaso in Raisio. Kuloistenniitty is a rising new residential area at the border of Raisio and Turku. We believe that it will develop into one of the most desired residential areas. SRV also plans to build two developer-contracted housing construction projects in this area. The launch of this right-of-occupancy housing project in Kuloistenniitty is especially important for us in terms of not only the startup of our other projects in the area, but also our anticipated return into the Turku housing construction market. Going forward, we seek to keep stepping up our investments in housing production in the Turku region, both through our own housing production and also by means of different kinds of housing construction contracting, such as by implementing homes funded by the Housing Finance and Development Centre of Finland (ARA),” says Jukka Aaltonen, Regional Director, Southwest Finland at SRV. "Vaso sees the properties now under construction in Kuloistenniitty as a great opportunity to offer new, easily accessible homes with good services to our residents," says Maria Aspala, CEO of Vaso. "The identity of Kuloistenniitty is still taking shape, but now all the prerequisites for a highly sought-after residential area are in place. Well-functioning public transport, outdoor terrain that starts at your doorstep, two large shopping centres next door and the area's developing own services are perfect for meeting the housing wishes of our residents," says Maria Aspala. Additional information:Jukka Aaltonen, Regional Director, Southwest Finland, SRV, tel. +358 (0)40 198 1284, jukka.aaltonen@srv.fiHeidi Tetteh, Communications Manager, SRV, tel. +358 (0)40 662 3220, heidi.tetteh@srv.fiMaria Aspala, CEO, Varsinais-Suomen Asumisoikeus Oy, +358 (0)400817950, maria.aspala@vaso.fi Image used in the bulletin: ARCO Architecture Company Oy Distribution:Mediawww.srv.fi You can also find us on social media: Facebook    LinkedIn   X   Instagram  SRV in brief SRV is a Finnish developer and innovator in the construction industry. We are building a more sustainable and responsible urban environment that fosters economic value and takes the well-being of both the environment and people into consideration. We call this approach life-cycle wisdom. Our genuine engagement and enthusiasm for our work comes across in every encounter – and listening is one of our most important ways of working. We believe that the only way to change the world is through discussion. Our company, established in 1987, is listed on the Helsinki Stock Exchange. We operate in growth centres in Finland. In 2023, our revenue totalled EUR 610 million. In addition to approximately 800 in-house staff, we have a network of around 3,300 partners. SRV – Building for life

Håkon Bergsodden appointed new EVP of Renewable Energy at Norconsult

Currently, Bergsodden serves as the Director of Hydropower and Power Transmission at Norconsult and will now join the executive management team. He has previously held other important roles within the company, including Head of Power Plant Construction and Small Hydropower.   “I am pleased that Bergsodden has accepted the role of Executive Vice President. Renewable energy is one of our most important market areas, where we expect further growth in the coming years. With Bergsodden's experience and expertise, I am confident that we are well-equipped to take further steps in the renewable sector," says Egil Hogna, CEO of Norconsult.  Bergsodden will succeed Sten-Ole Nilsen, who will continue at Norconsult in the capacity of Project Director.   “I look forward to being part of the executive management team at Norconsult and contributing to the further development of the business area and the group’s commitment to renewable energy. Norconsult is a leading player in this market area today, and I am excited to further strengthen this position together with the skilled professionals in renewable energy,” says Håkon Bergsodden.   This announcement will take effect on February 1, 2025. Following this, Norconsult’s executive management will consist of:  · President & CEO, Egil Hogna   · EVP & CFO, Dag Fladby   · EVP HR, Marisa Ruiz Retamar   · EVP Communications and Brand, Hege Njå Bjørkmann   · EVP Norway, Head office and Norconsult Digital, Bård Hernes   · EVP Norway, Regions, Vegard Jacobsen   · EVP Renewable Energy, Håkon Bergsodden   · EVP Sweden, Farah Al-Aieshy   · EVP Denmark, Thomas Bolding Rasmussen   · EVP Technogarden, Kathrine Duun Moen  For further information, please contact: Henrik Charlesen, Senior Communication Advisor, henrik.charlesen@norconsult.com About Norconsult Norconsult is a leading pan-Nordic interdisciplinary consulting firm combining engineering, architecture and digital expertise across projects of all sizes, for private and public customers in infrastructure, energy and industry, buildings and architecture. Headquartered in Sandvika, Norway, Norconsult’s delivery model is centred around knowledge hubs and local presence through approximately 6,500 employees across around 140 offices in Norway, Sweden, Denmark, Iceland, Poland and Finland.

Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated

Completed registration and ongoing deliveryThe Company hereby announces that the Convertibles and the Warrants have been registered with the Swedish Companies Registration Office and that the delivery of the Warrants following their connection to Euroclear has been initiated to the custody accounts designated by the Financiers. Main terms of the Convertibles, the Warrants and the Loan The convertible loans of 75 MSEK is represented by convertible promissory notes in the nominal amount of SEK 1 per Convertible. The Convertibles will be due for repayment on 30 April 2026 (the "Maturity Date"), unless Conversion has occurred before that date. The rate of interest on the Convertibles are calculated quarterly and determined at the percentage rate per annum which is the aggregate of STIBOR90 with an additional 11 percentage points. The Company has a right but no obligation to repay the Convertibles, in whole or in part, at any time prior to the Maturity Date without separate costs. In connection with any premature repayment, accrued interest of the amount so prepaid should be paid at the same time. During the term of the Convertibles, the Financiers may demand conversion of all or part of the Convertibles into new B shares in the Company at a conversion price fixed at SEK 6.09. Presuming full conversion of the Convertibles the number of shares in Cereno Scientific will increase by 12,315,270 B-shares and the share capital will increase by SEK 1,231,527 corresponding to a dilution effect of approximately 4.19 per cent of the currently outstanding shares in the company and approximately 4.10 per cent of the currently outstanding votes in the company. In relation to the Warrants, the Financiers are entitled to subscribe for one new B share for each Warrant at a subscription price of SEK 6.82 per B share during the term of the Warrants (up to and including 8 November 2029). Exercise of the Warrants can be done during the whole term of the Warrants. Upon full exercise of the Warrants, the company will receive additional issue proceeds of approximately 39.2 MSEK. Presuming full exercise of the Warrants, the number of shares in Cereno Scientific will increase by 5,749,017 B-shares and the share capital will increase by SEK 574,901.70 corresponding to a dilution effect of approximately 2.00 per cent of the currently outstanding shares in the company and 1.96 per cent of the currently outstanding votes in the company. The Loan is divided into two tranches where Tranche 1 consists of a cash loan of 125 MSEK which was paid out in connection with the signing of the Financing Agreement. Tranche 2 consists of a cash loan of 50 MSEK and is conditional upon the Company having received approval by the FDA regarding CS1 for a phase IIB study or a pivotal study for phase III as well as certain additional financial conditions being fulfilled. The Loan was subject to a customary setup fee amounting to approximately 3,87 per cent of the funding under the Financing Agreement. Parts of Tranche 1 of the Loan have been used to repay the currently outstanding loan to Fenja of approximately 91 MSEK. The interest rate of the Loan under the Financing Agreement is fixed annually starting at the time of payment and bears an annual interest rate set at the percentage rate per annum which is the sum of STIBOR plus 11 percentage points. Repayment of the Loan (both Tranches, if applicable) shall be made on 30 April 2026. Further fundamental information about the Convertibles, the Warrants and the Financing Agreement can be found in the press release of 11 November 2024: Press release | Cereno Scientific . For further information, please contact: Eva Jagenheim, CFO Email: eva.jagenheim@cerenoscientific.com   Phone: +4670492 35 63 Sten R. Sörensen, CEO Email:sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters.An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1.HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases.While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B).The Certified Adviser is Carnegie Investment Bank AB,certifiedadviser@carnegie.se. More information atwww.cerenoscientific.com.

Aker Solutions ASA: Aker Solutions secures new frame agreement with Vår Energi

The five-year agreement includes an option for Vår Energi to extend the contract by up to three additional two-year periods. "This contract renewal reflects our long-term relationship and status as Vår Energi’s preferred partner, highlighting that our commitment to improved deliveries and optimized solutions is highly valued by our customers," said Paal Eikeseth, Executive Vice President and head of Life Cycle, Aker Solutions. Aker Solutions has been providing maintenance and modifications services for Vår Energi’s Jotun, Balder, and Ringhorne assets for more than 20 years. The operator is currently Norway’s second-largest exporter of gas and plays a significant role in providing reliable and affordable access to energy to Europe. "Maintenance and modifications are essential to ensuring the safe and efficient operation of our customers' installations and facilities. We look forward to continuing our good collaboration with Vår Energi to achieve this goal," said Eikeseth. The work will be managed from Aker Solutions' office in Stavanger, Norway while fabrication will be carried out at the company's yard in Egersund.  The work under the frame agreement starts January 2025. The contract will be booked as order intake in the fourth quarter of 2024 in the Life Cycle segment. [1]Aker Solutions defines a sizeable contract as being between NOK 0.5 billion and NOK 1.5 billion. ENDS

Tokmanni Group Corporation has signed a new EUR 325 million long-term financing agreement

Tokmanni Group Corporation has signed a new EUR 325 million financing agreement. The new financing arrangement replaces the financing arrangement that was signed in 2021. The financing arrangement has a maturity of three years with two one-year extension options. The financial package includes a EUR 250 million bank loan and EUR 75 million revolving credit facility (”RCF”), which will be used to repay the current loans and for the Group’s general financing needs. The margin of the financial package is linked to the Tokmanni Group's gearing (net debt / rolling 12-months comparable EBITDA). The financing arrangement was signed with a syndicate consisting of two commercial banks, OP Corporate Bank Plc and Swedbank AB (publ). Both banks act as lead arrangers. Additionally, OP Corporate Bank Plc acts as the coordinator and agent of the financing arrangement. For further information, please contact Tapio Arimo, CFO, tel. +358 20 728 7390, tapio.arimo(at)tokmanni.fi Tokmanni Group in brief Tokmanni Group Corporation is one of the leading variety discount retailers in the Nordics. More than 6,000 employees in Finland, Sweden and Denmark make customers’ everyday life and special occasions easier by offering a versatile and up-to-date assortment of nordic and international brand-name products and other high-quality products at prices that are always affordable. With more than 370 Tokmanni, Dollarstore, Big Dollar, Miny, Click Shoes and Shoe House stores and online stores, the Group is always close to its customers. In 2023, the Group's revenue was EUR 1,393 million and comparable EBIT amounted to EUR 99 million. The Tokmanni Group Corporation's shares are listed on Nasdaq Helsinki. Distribution Nasdaq HelsinkiKey Media

Humana implements changes to Group executive management

The Swedish organisation is led by Sweden Manager Nathalie Boulas Nilsson, who is also President and CEO of Humana Group. The Swedish organisation will be represented in Group executive management also by the business area managers for Individual and family as well as Personal Assistance, respectively.   This means that, Titti Lilja, Business Area Manager Individual and Family, will be a member of Group executive management and Hans Dahlgren, Business Area Manager Personal Assistance and Director of Communications, will remain in Group executive management in the role of Business Area Manager Personal Assistance. Humana intends to implement the change on the 1st of January 2025.   For more information, please contact: Ewelina PetterssonHead of Investor Relations+46 73 074 79 12ewelina.pettersson@humana.se    

Scope downgrades Elkem’s issuer rating to BBB-/Stable

Oslo, 20 December 2024 Scope has today downgraded Elkem’s issuer rating to BBB-/Stable from BBB/Negative. The rating action is driven by a slower-than-expected recovery in credit metrics amid ongoing market headwinds. Elkem’s financial metrics have gradually improved during 2024, however Scope expects leverage (debt/EBITDA) to remain at 2.5x or above in 2024-2025. Elkem remains committed to an investment grade profile targeting a leverage ratio of 1.0 – 2.0x over the cycle. The rating report from Scope is attached. For further information, please contact:Odd-Geir LyngstadVP Finance and Investor RelationsTel: +47 976 72 806Email: odd-geir.lyngstad@elkem.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. About ElkemElkem is one of the world’s leading providers of advanced silicon-based materials shaping a better and more sustainable future. The company develops silicones, silicon products and carbon solutions by combining natural raw materials, renewable energy and human ingenuity. Elkem helps its customers create and improve essential innovations like electric mobility, digital communications, health and personal care as well as smarter and more sustainable cities. With a strong track record since 1904, its global team of more than 7,400 people has a joint commitment to stakeholders: Delivering your potential. In 2023, Elkem achieved an operating income of NOK 35.5 billion and CDP ratings of A on Forests, and A- on Climate Change and Water Security. Elkem is listed on the Oslo Stock Exchange (ticker: ELK), where the company is also included in the ESG Index. www.elkem.com

Image Systems' Business Area RemaSawco Receives Order from Södra Worth Over SEK 12.4 Million

The new system ordered by Södra from RemaSawco will be installed on one of the planing lines at the group's sawmill in Mönsterås. The agreement includes a complete installation of the market-leading full-quality board scanner RS-BoardScannerQ (6 meters), RS-StrengthGrader, a system for strength grading of boards, and systems for moisture measurement and auto-calibration. The delivery also includes commissioning and training. The total order value amounts to over SEK 12.4 million. In addition to the agreed scope, there are several options that may be exercised at a later stage. Delivery, installation, and commissioning are planned for the summer of 2025. “Our long-standing partnership with Södra is something we deeply value. That they once again choose RemaSawco as their supplier confirms that we have Södra's continued trust to deliver critical system solutions” Says Emilien Saindon, CEO RemaSawco

Latour acquires HDS Group GmbH – LSAB Group strengthens their position on Europe’s largest wood market

Investment AB Latour (publ) has, through its subsidiary LSAB Group AB (LSAB), a part of Latour Industries AB, signed an agreement to acquire HDS Group GmbH (HDS). HDS, established in 1999, is a manufacturer of sawblades and sawmill knives towards the sawmill industry. HDS has 64 employees, and the headquarters is situated in Remscheid, Germany. Revenue 2023 was 9.8 MEUR and historical financial performance is in line with Latour’s financial targets. LSAB is a leading provider of tools and services related to chip making in the wood and metal industries. Today LSAB have their own operations in six countries and export to another 40 countries around the world. Through the acquisition of HDS, LSAB Group reinforces its position in Germany (which is the largest market for sawn wood in Europe) as well as broadening the total customer offer. "Together with HDS, LSAB will strengthen its position as a European supplier towards sawmill industry. HDS is a well-run company, and we are excited about them joining LSAB group. We are convinced that the strength of HDS as a specialized manufacturer will be further reinforced by being a part of LSAB and having additional exposure to the markets where LSAB is operating”, says Hans Ekholm, CEO at LSAB Group AB. "I am very grateful that HDS now will be a part of LSAB. The strong market position of LSAB will allow HDS to continue its growth journey while supporting LSAB with our unique knowledge”, says Andreas Hindrichs, CEO HDS Group GmbH. As an effect of the acquisition the net debt (excl. IFRS 16) of the Latour Group increases to almost SEK 13.3 billion compared to the net debt level at the end of September 2024, all else equal. The acquisition will be completed in January 2025. Gothenburg, December 20, 2024 INVESTMENT AB LATOUR (PUBL)Johan Hjertonsson, CEO For further information, please contact:Tina Hultkvist, CEO Latour Industries, +46 706 65 12 88Hans Ekholm, CEO LSAB Group, +46 730 39 97 60Fredrik Lycke, Investment Director Investment AB Latour, +46 793 40 2802 LSAB Group AB, with headquarters in Gothenburg, has an annual turnover of SEK 598 (2023) and employees about 300 persons. Investment AB Latour is a mixed investment company consisting primarily of a wholly-owned industrial operations and an investment portfolio of listing holdings in which Latour is the principal owner or one of the principal owners. The investment portfolio consists of ten substantial holdings with a market value of SEK 90 billion as of 30 November, 2024. The wholly-owned industrial operations have an annual turnover of SEK 27 billion.

Troax Group acquires Safety, Technology & Legislation Limited

Hillerstorp  20th of December 2024, 08:30 CET Troax Group through its subsidiary Troax AB has entered into an agreement to acquire all outstanding shares in the UK-based company Safety, Technology & Legislation Limited (ST&L.) ST&L specializes in machinery safety and risk management solutions. Established in 1998, the company has over two decades of experience providing comprehensive safety assessments and bespoke plans to ensure workplace safety and compliance with legal requirements. Headquartered in Hadleigh, Suffolk, ST&L offers full turnkey solutions for machinery safety, inspections, marking, certification and training. Their innovative safety systems and dedicated team of engineers have made them a trusted partner for businesses across various industries. "I am happy to welcome ST&L into the Troax Group. With a wealth of experience in machine safety and risk assessment, ST&L is an important addition to the Group on our mission to creating safer workplaces. Joining forces will add nicely to our offering and to our ability to suggest even better safety solutions for our customers”, says Martin Nyström, President and CEO of Troax.  "We are excited and privileged to be joining the Troax Group. Working in collaboration with the global Troax team, we will be able to enhance our existing portfolio of professional machinery safety services, deliver continuous growth and work towards our mission of providing our existing and new clients with a quality customer journey that is second to none”, says Adrian Rimmer Managing Director and owner of ST&L. The acquisition will be financed within Troax’s existing cash on a cash-free/debt-free basis. A performance-based additional payment will occur during 2025-2027 conditional on a continued high operating profit and growth. The transaction is expected to close today. The transaction costs occurring during fourth quarter is not expected to be material. The acquisition is not expected to materially affect Troax earnings per share or net debt / EBITDA.  For further information, please contact: Martin Nyström, President & CEO, Troax GroupTel: +46 370 828 31martin.nystrom@troax.com Anders Eklöf, CFO, Troax GroupTel +46 (0)370-828 25anders.eklof@troax.com Mikael Carlsson, VP Strategy & Offering, Troax GroupTel +46 (0)370-828 75mikael.carlsson@troax.com

Viking Line Abp's financial calendar for 2025

Viking Line Abp  FINANCIAL CALENDER  20.12.2024, 9.30 AM Viking Line Abp's financial calendar for 2025 Viking Line Abp will publish its Year-end Report for 2024 on Friday, February 14, 2025. An electronic version of Viking Line's official 2024 annual accounts as well as its corporate governance statement and compensation statement will be published during the week of March 31, 2025, on the Company's website, www.vikingline.com. According to plans, Viking Line's Annual General Meeting (AGM) will be held on Thursday, April 24, 2025. A separate invitation to the AGM will be issued. An announcement of the AGM's decisions will be published after the AGM has ended. The Company's Financial Reports and Statements for 2025 will be published as follows: - Business Review for the period January – March: April 24, 2025 - The Half-Year Financial Report for January – June: August 15, 2025 - Business Review for the period January – September: October 23, 2025 - Year-end report for January – December 2025: February 13, 2026 The Year-end Report, the Half-Year Financial Report and the Business Reviews will be published each respective date in Swedish, Finnish and English. Viking Line Abp   Jan HansesPresident and CEO

Altor divests Nordic Tyre Group to Axcel

In 2019, Altor entered a partnership with the founders of Gummigrossen and Rengasduo with the joint ambition to build a Nordic leader within the tyre wholesaler industry. Today, Nordic Tyre Group is the largest independent tyre wholesaler across the Nordics and Baltics with a diversified group of more than 10,000 customers and long-standing relations with 200 suppliers. The company is built on a proprietary technology platform providing a unique competitive advantage.   “Altor established Nordic Tyre Group with the ambition to build the leading tyre wholesaler across the Nordics and Baltics and they have worked with an entrepreneurial mindset to support the management team to realize that mission. It has been an incredible journey and our achievements have been a result of teamwork and a shared vision. Now, our sights are set on European roads together with Axcel” said Patrick Bergander, CEO of Nordic Tyre Group.  “Nordic Tyre Group has grown from a tech-enabled challenger in Sweden to become the leading independent tyre wholesaler across the Nordics and Baltics. We are truly impressed by the achievements of the management team and employees and we are proud to have been part of this journey. We look forward to seeing the company continue its growth journey together with Axcel” said Stian Tuv, Principal at Altor.

SyntheticMR publishes disclosure document regarding rights issue

Disclosure document In connection with the Rights Issue the Company has prepared a disclosure document in accordance with article 1.4 db Regulation (EU) 2017/1129 of the European Parliament and of Counsil of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the “Prospectus Regulation”). The disclosure document has been drafted in accordance with annex IX of the Prospectus Regulation. Today, SyntheticMR announces that the disclosure document has been registered with the Swedish Financial Supervisory Authority and made available on the Company’s website. Subscription forms for the Rights Issue will be available on the Company's website; https://syntheticmr.com/investors/rightsissue2024_eng/. Timetable Trading in subscription rights 23 December 2024 – 8 January 2025on Spotlight Stock MarketSubscription period 23 December 2024 – 13 January 2025Trading in paid subscribed 23 December 2024 – 22 January 2025shares (BTA) on Spotlight StockMarketIndicative date for announcement 16 January 2025of outcome in the Rights Issue The full timetable is included in the disclosure document and made available on the Company’s website; https://syntheticmr.com/investors/rightsissue2024_eng/. AdvisorsSkandinaviska Enskilda Banken AB ("SEB") acts as Sole Global Coordinator and Bookrunner and Baker & McKenzie Advokatbyrå KB acts as legal advisor to the Company in connection with the Rights Issue. For more information, please contact: Johanna Norén, CFO and Head of Investor Relations Phone: + 46 70 619 21 00Email: johanna.noren@syntheticmr.com IMPORTANT INFORMATION The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in SyntheticMR in any jurisdiction, neither from SyntheticMR nor from someone else. This press release is not a prospectus for the purposes of the Prospectus Regulation. No prospectus will be prepared in connection with the Rights Issue. In connection with the Rights Issue the Company has prepared a disclosure document in accordance with article 1.4 db of the Prospectus Regulation. The disclosure document has been drafted in accordance with annex IX of the Prospectus Regulation. The Swedish Financial Supervisory Authority, which is the national competent authority, has not approved nor reviewed the disclosure document. Each investor is advised to make their own assessment of whether it is appropriate to invest in the Company. This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness. SEB are acting for SyntheticMR in connection with the Rights Issue and no one else and will not be responsible to anyone other than SyntheticMR for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein. SEB are not liable to anyone else for providing the protection provided to their customers or for providing advice in connection with the Rights Issue or anything else mentioned herein. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Canada, Hong Kong, Japan, New Zeeland, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it. Please note that an investment in the Company is subject to regulation under the Foreign Direct Investment Act (2023:560), which requires investors, under certain conditions, to notify and obtain approval from the Swedish Inspectorate for Strategic Products. Investors should make their own assessment of whether a notification obligation exists before making any investment decision regarding the Rights Issue. Forward-looking statements This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release. Information to distributors Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the offered shares have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company. Each distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channels.

Peab reinforces the water and wastewater network in Eskilstuna

The existing wastewater pump station will be replaced with a new building, new pumps and new pipelines running into the pump station. The outgoing pipeline from the pump station to the intake pipeline at the Ekeby Wastewater Treatment Plant will also be replaced, as well as the water and wastewater pipelines in Rinmansgatan. The water and wastewater project is Eskilstuna Energi och Miljö AB's largest to date. The project will result in fewer water shut-offs, reduce the risk of basements flooding and make Eskilstuna's continued growth in the eastern part of the municipality possible. The work will be carried out in stages to maximize efficient construction and minimize disruptions to accessibility and availability. "We’re proud to contribute to improved capacity and reliability in Eskilstuna's pipeline network. We look forward to continuing our collaboration with Eskilstuna Energi och Miljö and carry out the project efficiently, safely and sustainably," says Lars Lind, Region Manager Peab. "The renewal of our largest pump station and connected pipelines is an important step towards a more sustainable future and ensures that our water and wastewater facility is robust and reliable for future generations. We’re pleased that by working together with Peab we can figure out the best solution to this challenge," says Anna Lundell Ekwall, Project Manager Water and Wastewater, Eskilstuna Energi och Miljö. This construction contract was preceded by a so-called phase 1 contract, which means that in 2023 Peab was contracted to work with Eskilstuna Energi och Miljö to map out an optimized product with the right quality and to manage risks and uncertainties. The project is now entering phase 2 which is the implementation phase. The project is a turnkey contract in partnering. Construction will begin immediately and is expected to be completed in the summer of 2027. The project will be order registered in the fourth quarter 2024. Illustration: AQ3 Arkitekter For further information, please contact: Juha Hartomaa, Head of Investor Relations Peab, 072 533 31 45

More than the minimum number of new shares subscribed for and rights issue expected to be completed

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS AN INDICATION OF AN EXPECTATION ONLY AND SHOULD NOT BE INTERPRETED OR CONSTRUED AS A STATEMENT ON THE ACTUAL RESULT OF THE OFFERING NOR A CONFIRMATION THAT IT WILL BE COMPLETED. SEE BELOW UNDER "IMPORTANT INFORMATION". Asetek A/S (the "Company" or "Asetek") today announces that it has received subscriptions during the subscription period exceeding the minimum number of new shares of 150,000,000 offered in the rights issue announced by the Company on 2 December 2024 (the "Offering"), corresponding to gross proceeds of above DKK 60 million. Consequently, it is expected that the Offering will be completed. The total gross proceeds may increase further due to subscriptions made in the subscription period but not yet received by the Company. The subscription period has ended, and the final result of the Offering is expected to be announced on 23 December 2024 when all subscriptions have been processed, and the Company will know the final size of the Offering. Information about the potential completion of the Offering, including settlement of the new shares and registration of the capital increase with the Danish Business Authority, is expected to be announced on 3 January 2025, all as set out in the prospectus dated 2 December 2024 (the "Prospectus"), which is available at the Company's website: http://ir.asetek.com/share-info/prospectus/ (subject to certain restrictions). As stated in the company announcement of 2 December 2024 and the Prospectus, the Offering may be withdrawn by the Company, subject to certain conditions, before registration of the capital increase relating to the new shares with the Danish Business Authority. Moreover, it should be noted that the preliminary results regarding exercise of the pre-emptive rights and subscription undertakings exceeding the minimum number of new shares of 150,000,000 are subject to certain conditions and events not occurring, as further described in the Prospectus. Although not currently expected, any such withdrawal will be notified via Nasdaq Copenhagen A/S should it become relevant. For further information, please contact: Per Anders Nyman, Head of Investor RelationsMobile: +45 2566 6869E-mail: pny@asetek.com Global Coordinator and legal advisors ABG Sundal Collier, Sundal Collier Denmark, Filial af ABG Sundal Collier ASA, Norge, acts as global coordinator in the Offering. Kromann Reumert and Advokatfirmaet Wiersholm AS act as Danish and Norwegian legal advisors, respectively, to the Company in connection with the Offering. Gorrissen Federspiel Advokatpartnerselskab acts as Danish legal advisor to the global coordinator in the Offering. About Asetek Asetek (ASTK), a global leader in mechatronic innovation, is a Danish garage-to-stockexchange success story. Founded in 2000, Asetek established its innovative position as the leading OEM developer and producer of the all-in-one liquid cooler for all major PC & Enthusiast gaming brands. In 2021, Asetek introduced its line of products for next level immersive SimSports gaming experiences. Asetek is headquartered in Denmark and has operations in China, Taiwan and the United States. www.asetek.com IMPORTANT INFORMATION Nothing in this announcement should be interpreted or construed as a confirmation that the Offering will in fact raise gross proceeds of DKK 60 million or more or that the Offering will be completed, nor should it be deemed to be an announcement of the result or expected result of the Offering. The subscription commitments are subject to certain conditions and events not occurring, as further described in the Prospectus, and there is no guarantee that such events will not occur. Moreover, the occurrence of an event requiring that a supplement to the Prospectus be published will entitle investors who have submitted orders to subscribe for new shares in the Offering to withdraw their orders within two working days following publication of the relevant supplement (in addition to such events potentially releasing the subscribers under the subscription commitments from their obligations). If the order is not withdrawn within the stipulated period, any subscription for new shares in the Offering will remain valid and binding. Generally, the Offering may be withdrawn due to a number of circumstances as further described in the Prospectus. This company announcement contains forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties, in particular this announcement should not be construed as a confirmation neither that an offering will complete, nor of the deal size or the price. Therefore, actual future results may differ materially from what is forecasted herein due to a variety of factors. This announcement is intended for the sole purpose of providing information. Persons needing advice should consult an independent financial adviser. This announcement does not constitute an investment recommendation. This announcement is not a prospectus and investors should not purchase any securities referred to in this announcement on the basis of this announcement. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness. The information in this announcement is subject to change. No obligation is undertaken to update this announcement or to correct any inaccuracies, and the distribution of this announcement shall not be deemed to be any form of commitment on the part of the Company to proceed with any transaction or arrangement referred to herein. This announcement has not been approved by any competent regulatory authority. This announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with or act as an inducement to enter into, any contract or commitment whatsoever. Any offering of the securities referred to in this announcement has been made by means of a prospectus approved by the Danish Financial Supervisory Authority and published by the Company as further described above. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information contained in the prospectus. The transactions described in this announcement and the distribution of this announcement and other information in connection with the transactions in certain jurisdictions may be restricted by law and persons into whose possession this announcement, any document or other information referred to herein comes should inform themselves about, and observe, any such restrictions. None of the Company or any of its respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents or any other person accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith. In particular, this announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States (including its territories and possessions, any state of the United States and the District of Columbia, the "United States"), Australia, Canada, Japan or South Africa, or in any jurisdiction to whom or in which such offer or solicitation is unlawful ("Excluded Territories"). Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The securities referred to in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933 as amended (the "U.S. Securities Act") or under the securities laws of any state of the United States, and may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States absent registration except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. Subject to certain limited exceptions, the securities referred to in this announcement would only be offered or sold outside the United States. The securities referred to in this announcement have not been and will not be registered under any applicable securities laws of any state, province, territory, county or jurisdiction of the Excluded Territories. Accordingly, such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the Excluded Territories or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States or elsewhere. This announcement has been prepared on the basis that any offers of securities referred to herein in any Member State of the European Economic Area ("EEA"), other than Denmark and Norway, which has implemented Regulation (EU) 2017/1129 of 14 June 2017, as amended (the "Prospectus Regulation"), (each a "Relevant Member State") or the United Kingdom, will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of securities. Accordingly, any person making or intending to make any offer in a Relevant Member State of securities which are subject of the offering contemplated in this announcement, may only do so in circumstances in which no obligation arises for the Company or the Global Coordinator to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement to a prospectus pursuant to Article 23 of the Prospectus Regulation, in each case, in relation to such offer. Neither the Company nor the Global Coordinator have authorised, nor do they authorise, the making of any offer of the securities through any financial intermediary. Neither the Company nor the Global Coordinator have authorised, nor do they authorise, the making of any offer of securities in circumstances in which an obligation arises for the Company or the Global Coordinator to publish or supplement a prospectus for such offer. The information set forth in this announcement is only being distributed to, and directed at, persons in Relevant Member States or the United Kingdom who are qualified investors (Qualified Investors) within the meaning of Article 2(1)(e) of the Prospectus Regulation. In addition, in the United Kingdom, this announcement is only being communicated to, is directed only at Qualified Investors (i) who are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"),(ii) high net worth entities falling within Article 49(2)(a)-(d) of the Order or (iii) persons to whom it may otherwise lawfully be communicated, all such persons together being referred to as "Relevant Persons". In relation to Russia and Belarus, no securities have been offered or will be offered to any Russian or Belarusian national, any natural person residing in Russia or Belarus (except for EU, EEA or Swiss nationals and persons holding an EU, EEA or Swiss residence permit, subject to available prospectus exemptions), any legal person, entity, or body established in Russia or Belarus (including EU branches of such legal persons, but excluding subsidiaries of Russian or Belarus legal entities organised or incorporated within the EU, subject to available prospectus exemptions, or any natural or legal person where the issuance of securities to such person would result in a breach of applicable sanctions. None of the Company, any managers appointed by the Company for purpose of an offering or any of their respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents or any other person accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith. This announcement does not constitute an investment recommendation. The price and value of securities and any income from them can go down as well as up and you could lose your entire investment. Past performance is not a guide to future performance. Information in this announcement cannot be relied upon as a guide to future performance.

Carbiotix provides Q4 2024 update of ongoing NutraCycle projects

Erik Deaner, CEO of Carbiotix, comments:The increasing number of customer projects that we are accomplishing makes me very proud and optimistic about the future. It is pleasing to see the growth in NutraCycle customer projects since Carbiotix last reported on them at the end of September. We doubled the number of customer projects in one quarter and are now in line with our ambition of adding at least 4 new customers per month, or roughly 50 new customers and at least 100 new side-streams per year. This ambition is supported by the number of qualified leads or companies we are currently in discussions with, which now exceeds 100, as well as over 6,000 prospects or companies we have identified but yet to enter into discussions with. Our trade show participation in Q4, including Future Food Tech London, Supply Side West and Food Ingredients Europe, along with an ambitious digital outreach strategy, has paid dividends with regards to prospects, qualified leads and conversions. I look forward to building on this success and further improving on our cost-effective customer acquisition strategy going forward. This doubling in the number of customer projects in just one quarter is also a clear validation of the level of interest in our value proposition and business model. Food & beverage, ingredient, feed and other companies processing plant-based are showing interest in Carbiotix for three main reasons: 1) the over 10-years of experience we have in the hydrolysis of plant-based materials into not only complex soluble fibers or prebiotics, but also proteins, mono-sugars and other active ingredients based on our technology portfolio and the inclusion of third-party solutions, 2) an ambition to leverage the collective knowledge of our customers and partners (ie. NutraCycle Network) to support continual process optimization and product development activities, and 3) our 100% alignment with the long-term business interests of customers to offer healthier, more profitable and sustainable products. At the end of the day, we don’t earn any money unless our customers do, which is a concept truly appreciated by all customers. With the successful addition of one new customer every week, and delivery of at least one customer laboratory pre-study report in this same timeframe going forward, we are now focusing more attention on elevating customers to revenue generating pilot pre-study projects, joint development agreements and license agreements. We have seen very good progress in this regard, which we anticipate will lead to agreements in Q1 of 2025. This is thanks to the excellent work of our process development and engineering teams and the recent addition of key competencies. With regards to key figures, Carbiotix added 16 new customer projects during Q4, doubling the total number of customer projects from Q3. Among these, Carbiotix has ongoing projects with 4 companies with annual revenues exceeding 10 billion USD, and a relatively even distribution of customer projects across different size categories. Carbiotix also added its first projects in Asia and sees strong interest in the region. Lastly, the Company increased the total number of side-stream projects by 21 in Q4 and now has customer projects across 40 different side-streams.” https://carbiotix.com/assets/img/nutracycle-development-blue-24-12-20.jpg https://carbiotix.com/projects Forward-looking statementsThis communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release. This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 20 December 2024. For further information:Carbiotix ABErik Deaner, CEOTel: +46 (0)738 67 30 85E-mail: erik.deaner@carbiotix.com Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering the onsite upcycling of plant-based side-streams. Carbiotix mission is to improve the health of people by increasing the consumption of prebiotics and other active ingredients from upcycled side-streams. Carbiotix offers one core service today called NutraCycle, an on-site upcycling and fortification service allowing food & beverage, ingredient, and feed producers to turn plant-based products into healthier, more profitable, and sustainable products.

Balco Group strengthens Group Management

As Finland has become a significant market for Balco Group through the acquisitions of Riikku Group Oy and Suomen ohutlevyasennus Oy during the year, and Riikku's products have great potential in several markets, Balco Group will strengthen the Group Management Team with Riikku's Managing Director Joakim Petersen-Dyggve from January 1, 2025. Joakim Petersen-Dyggve has extensive experience from leading positions in national and international project operations, as well as production and personnel management. Balco Group's Group Management from January 1, 2025: Camilla EkdahlPresident and CEO Michael Grindborn CFO, Head of IR, IT, M&A and Sustainability Jesper MagnussonHR Director Johan Fälth COO & Sales and Marketing Director Balco AB Joakim Petersen-DyggveManaging Director Riikku Oy For further information, please contact: Michael Grindborn, CFO och IR-chef, 070-670 18 18, michael.grindborn@balco.se  Balco Group is a leading player in the balcony industry, focused on providing innovative, patented and energy-efficient solutions for multi-dwelling buildings. The company's tailored products contribute to increasing the quality of life, safety, and value of homes. Through a decentralized and efficient sales process, Balco Group has full control over its value chain from production to delivery. Founded in 1987 in Växjö, the company now employs approximately 650 people and is a market leader in Scandinavia with operations in several markets in Northern Europe. The company's revenue for 2023 was 1,215 MSEK, and it is listed on the Nasdaq Stockholm. For more information visit www.balcogroup.se.

Heimstaden AB (publ) Defers Interest Payment on EUR Perpetual Hybrid Securities

In 2021, Heimstaden AB (publ) (“Heimstaden”) issued EUR 300 million perpetual hybrid securities with an annual fixed rate coupon of 6.75% and with ISIN SE0016278352 (the “Hybrid Securities”). According to the terms and conditions of the Hybrid Securities, Heimstaden may, at its sole discretion, elect to defer interest payments.The next interest payment under the Hybrid Securities is due on 15 January 2025, and Heimstaden has decided to defer said interest payment, as well as future interest payments under the Hybrid Securities, until further notice, to improve its credit profile. For further information on the deferral of interest under the Hybrid Securities, see the notice of deferral of interest payment which is available on Heimstaden’s website, and which is sent to directly registered holders of the Hybrid Securities in the debt register as of 19 December 2024. 

Boliden publishes Sustainability-Linked Finance Framework

The Sustainability-Linked Finance Framework incorporates Boliden's climate targets, which have been validated by the Science Based Targets initiative (SBTi). These targets include reducing GHG-emissions by 42% for Scope 1 and 2, and by 30% for Scope 3 by 2030, using 2021 as the base year. Boliden's climate footprint is globally very competitive, and there is a strong focus to continue reducing emissions in line with targets and vision. Danske Bank acted as the structuring advisor on the establishment of the Sustainability-Linked Finance Framework and Sustainalytics were engaged to provide an independent second-party opinion on design and ambition level. Sustainalytics has assessed the Key Performance Indicators as ‘Very Strong’ and the Sustainability Performance Targets as ‘Ambitious’ and ‘Highly Ambitious. The Sustainability-Linked Finance Framework, as well as the second party opinion, are available on Boliden’s website: https://investors.boliden.com/en/investor-relations/debt-information/sustainable-financing For further information, please contact:Klas NilssonDirector Group Communications+46 (0)70-453 65 88klas.nilsson@boliden.com

Carl Granström Appointed as Attendo’s New General Counsel

“Carl brings extensive experience in business law, corporate governance, and leadership from large, complex organizations. His strategic perspective and ability to work closely with the business will be a great asset as we continue to develop the best care in the Nordics. I’m pleased to welcome Carl to our team,” says Martin Tivéus, CEO of Attendo. “Attendo plays an important role in society, and the opportunity to contribute to its development feels truly inspiring. I look forward to working with the team to continue strengthening Attendo and its vital operations,” says Carl Granström. Carl has over 20 years of experience as a business lawyer, both at law firms and as an in-house legal counsel, specializing in corporate governance, M&A, and commercial law. At Telia, he has held key roles across several business areas and has also worked internationally, focusing on corporate governance and acquisitions. Carl Granström holds a law degree from Stockholm University and previously worked as a lawyer at law firm Cederquist. At Telia, he has also served on several boards, both in Sweden and internationally. Carl will officially assume his new role no later than mid-March 2025. Attendo AB (publ) For further information, please contact: Linda Bengtsson, Press Manager, Attendo Telefon: +46722 51 10 06    I   email: linda.bengtsson@attendo.se attendo.com  Attendo - the leading care company in the Nordics   |   For almost 40 years, seeing, supporting and strengthening people with care needs has been the starting point of everything Attendo does. In addition to care for older people, Attendo provides care for people with disabilities and social care for individuals and families. Attendo has almost 35,000 employees and is locally anchored with over 800 units in more than 300 municipalities in Sweden, Finland and Denmark. Every day Attendo has tens of thousands of encounters with its customers. In all these encounters, our employees manifest Attendo’s shared values of care, commitment and competence.

Jaakko Nikkilä appointed President of Billerud Europe

Jaakko Nikkilä holds the position of Executive Vice President at UPM, heading the business area Specialty Paper with global sales of around EUR 1.5 billion, until year-end. Jaakko Nikkilä has extensive experience in both international sales and production of fiber-based packaging materials. He has been employed by the UPM Group since 1995 and served as a member of the UPM Group Executive Team since 2019.  “I am very pleased that Jaakko Nikkilä will join Billerud to lead Region Europe where the focus for the coming years is to strengthen performance through our existing manufacturing assets. I am convinced that his qualities and deep understanding of the paper and packaging industry will be instrumental for Billerud going forward,” comments Ivar Vatne, President and CEO of Billerud.  Jaakko Nikkilä, born 1967, is a Finnish citizen. He will assume the position as President of Billerud Europe on 1 May 2025 and will be based in Stockholm. As previously announced, Matthew Hirst will leave Billerud on 31 January 2025. Ivar Vatne will act as the interim President of Region Europe from 1 February to 30 April.  For more information please contact:Robert Pletzin, Director Global Media Relations, +46 72 516 86 06, robert.pletzin@billerud.com or press@billerud.com. The information was submitted for publication, through the agency of the contact person set out above at 09.00 CET on 20 December 2024.

IK Partners to sell Mecenat to Inflexion

Founded in 1998 and headquartered in Gothenburg, Sweden, Mecenat is a digital marketing platform which connects students, young professionals/alumni and seniors with well-known brands by providing access to exclusive offerings, career services and relevant events. Operating across five main business areas in Sweden and Finland, the Group takes pride in connecting almost three million members with more than 700 local and global brands, creating synergetic exchanges in the areas of brand building, unique discount offerings and marketing. Mecenat’s platform spans diverse industries, including Technology, Fashion, Travel and Entertainment and includes key partners such as Apple, Zalando, Hotels.com and Viaplay. Mecenat’s services are primarily digital, allowing for a two-way exchange between brands and members through its app and website. In recent years, the Group has expanded through the acquisitions of Seniordays in 2021, Frank Students in 2022, and Traineeguiden in 2023. The development of the platform in this way has enabled Mecenat to leverage a unique member acquisition approach which sees students entering organically before automatically progressing to alumni, while retaining members throughout their life by leveraging the top-of-mind habit developed when they were students. Since IK first invested in the business in September 2021, Mecenat has more than doubled its revenue, proving its resilience in the face of challenging global economic conditions. The Group has also: expanded its product offering to attract a more diverse range of members, including alumni and seniors; achieved meaningful geographic expansion beyond the Swedish market; delivered significant technological developments; and executed strategic acquisitions to support the expansion of the product range. Jonas Odéhn, CEO of Mecenat Group, said: “We would like to thank IK for their support during the past three years. This period has seen Mecenat develop into an even stronger business thanks to the hard work and dedication of our employees. The Group has experienced tremendous growth and transformed into a leading marketing technology and brand awareness platform with a unique business model and digital-first approach to fostering brand loyalty. With this solid foundation in place, we look forward to the next chapter which will see us partner with the team at Inflexion.” Carl Jakobsson, Partner at IK Partners and Advisor to the IK SC II Fund, added: “Since investing in Mecenat in 2021, we have been extremely impressed with the professionalism and expertise displayed by Jonas and his team. During our partnership with them, the Group has gone from strength-to-strength, nearly doubling its member base and pursuing geographic expansion through a range of value creation initiatives. We wish Jonas, his team and Inflexion the very best of luck for the next stage in Mecenat’s growth journey.”

poLight ASA to Demonstrate Latest TWedge® Wobulator Pixel-Shifting Technology on Advanced Augmented Reality Projectors at CES 2025

TØNSBERG, Norway – December 20, 2024 -- poLight ASA  (OSE: PLT) will showcase the company’s tunable optics TWedge® wobulator pixel-shifting technology combined with Texas Instruments DLP® digital micromirror device (DMD) and Coretronic light engine projection technology in its executive suite at the Flamingo Las Vegas Hotel at the upcoming CES® event, January 7 - 10, 2025 in Las Vegas, Nevada.  Demonstrating significant microdisplay improvements that deliver the ‘human eye experience’ in augmented reality (AR) head-worn devices, the joint demonstration development effort will highlight compelling user experiences while resolving some AR microdisplay design challenges.   poLight will show a live projection demonstration of its latest ultra-compact TWedge® wobulator TS3 (Technical Samples Revision 3) pixel-shifting technology combined with Coretronic’s light engine/projector and using TI’s 960x540 DLP® DMD running at 120Hz. Featuring the TWedge® wobulator TS3, this live demo reflects the joint development effort between poLight, Coretronic and TI to clearly show dramatic displayed resolution improvements, screen door effect/motion blur removal with no audible noise. poLight’s TWedge® wobulator technology will help resolve these design challenges to deliver an optimal user viewing experience to future AR head-worn devices. “We are excited to collaborate with Texas Instruments and Coretronic, moving one step closer to replicating the real-world human eye viewing experiences on future AR microdisplay applications,” said Dr. Øyvind Isaksen, CEO of poLight ASA. “Our demonstrated capabilities of TWedge® wobulator pixel-shifting technology will be significantly meaningful, especially combined with the potential system level yield improvements it brings to head-worn AR microdisplay systems.”  “We are thrilled to work with poLight ASA and Texas Instruments, leveraging our projection technology to advance near-eye display technology,” said Ken Wang, Vice President of Coretronic Group. “In the next decade, AR smart glasses and microdisplay applications will experience growth in diverse use cases and collaborations such as these are key to achieving progress.” The poLight team invites you to visit our executive suite at the Flamingo Las Vegas Hotel to see this exclusive TWedge® wobulator demo as well as other TLens® AF camera device demos and meet with our CEO and business team to discuss how we can best support your imaging and AR microdisplay development needs. Contact info@polight.com to schedule a meeting.    About poLight ASA poLight ASA (OSE: PLT) offers a patented, proprietary tunable optics technology, starting with its first product, TLens® which replicates "the human eye" experience in autofocus cameras used in devices such as smartphones, wearables, barcode scanners, machine vision systems and various medical equipment. poLight's TLens® enables better system performance and new user experiences due to benefits such as extremely fast focus, small footprint, no magnetic interference, low power consumption and constant field of view. poLight is based in Tønsberg, Norway, with employees in Finland, France, UK, US, China, Taiwan, Japan, and the Philippines. For more information, please visit https://www.polight.com About Coretronic Corporation Coretronic Corporation was established in the Hsinchu Science Park on June 30, 1992. Since the very beginning, it has positioned itself as an innovative display solution provider. Coretronic is the first LCD backlight module manufacturer in Taiwan, and it has taken the lead in developing and mass-producing the smallest and lightest VGA single-panel LCD projectors and XGA DLP projectors in the world through integrated its leading technology, “Optics, Mechanics, Electronic, Thermal Management, Materials and Precision Molds" and other technology. This advancement has opened up a new era for display systems in Taiwan. Coretronic conducts its R&D and innovative efforts with the business philosophy of maintaining secure operations by focusing on its core business. It controls its key patents and core technology via a business strategy of vertical integration. This has made Coretronic the leader in advanced LCD, digital projector and LCD backlight technology in Taiwan and also one of the top manufacturers in the R&D of these products worldwide.

Freetrailer strengthens European expansion through new partnership with RataPlan in the Netherlands

Driving sustainability and community impact The partnership reflects both companies’ shared mission to promote sustainability and social responsibility. Customers visiting RataPlan stores will have access to free trailer rentals, making it easier to transport donations and second-hand purchases. “Partnering with Freetrailer allows us to offer our customers an even more convenient way to shop and donate sustainably,” said Gert-Jan Dekker, Managing Director at RataPlan. “By providing free trailer rentals, we’re making it easier for people to contribute to the circular economy while supporting our mission of reducing waste and benefiting local communities.” Freetrailer shares RataPlan’s vision for sustainability: “This partnership is a perfect match. By combining RataPlan’s strong commitment to sustainability and community impact with Freetrailer’s innovative rental solutions, we’re creating a solution that supports both customers and the environment,” said Nicolai Frisch Erichsen, Group CEO of Freetrailer Group A/S. “We are proud to work with RataPlan as we bring our self-service trailer solution to the Dutch market.” Christian Tepper, Sales Director Netherlands at Freetrailer Group A/S, emphasized the strategic alignment: “RataPlan’s extensive network and deep local expertise make them an ideal partner for our expansion in the Netherlands. Together, we aim to deliver a seamless and sustainable solution that benefits communities, promotes environmental responsibility, and makes mobility more accessible.” Expanding Reach with Proven Expertise RataPlan’s network includes key cities such as Amsterdam, Rotterdam, and The Hague, making them an essential partner in Freetrailer’s Dutch expansion. With over 1.3 million trailer rentals annually and long-standing partnerships with global brands, Freetrailer brings proven operational excellence and customer-focused service to the collaboration. Looking ahead This partnership reinforces Freetrailer’s long-term commitment to the Dutch market and European expansion. By joining forces, both companies aim to redefine sustainable shopping and donations through accessible, environmentally friendly transport solutions — creating long-lasting value for customers and communities alike.

Nordic Capital’s second mid-market fund, Evolution II, closes at EUR 2 billion hard cap after rapid fundraise

Nordic Capital today announced the successful First and Final close of Nordic Capital Evolution II (“Evolution II” or “the Fund”) at the hard cap of EUR 2 billion. Raised within four months from launch with excess demand, the Fund closed at its hard cap and significantly exceeded its target of EUR 1.4 billion. Evolution II attracted excess demand from its launch and benefited from strong support from its current investor base, with a high re-up rate of over 100% by capital, and significant LP commitments from new investors and geographies, including a significant increase from the Americas. Evolution II is 65% bigger than its predecessor fund, Evolution I, which raised EUR 1.2 billion in three months in 2021. Evolution II is the fourth Nordic Capital fund since 2020 to have benefited from a rapid fundraise. The demand for the Fund and the pace of its fundraise underline investors’ confidence in Nordic Capital’s long-standing investment model and portfolio performance.   Nordic Capital’s Evolution strategy expands the firm’s winning subsector model and powerful platform to a broader spectrum of mid-market companies. Evolution II will target investments predominantly in Northern European companies with an EV of EUR 100 million to EUR 400-500 million. Similar to its predecessor, the Fund will focus on control buyouts and non-cyclical growth opportunities in Nordic Capital’s focus sectors, Healthcare, Technology & Payments, Financial Services and Services & Industrial Tech. While it will target lower mid-market opportunities, Nordic Capital’s flagship funds will continue their focus on upper mid-market companies. As a long-established subsector specialist, Nordic Capital is committed to finding and developing non-cyclical companies in fast-growing segments within its well-recognised subsectors. It works in close partnership with founders and management teams to develop companies with the potential to lead their markets and shape industries. As an Article 8 fund, Evolution II will continue to drive sustainability agendas and seek to promote long-term, environmental, social and good corporate governance practices within the companies it backs. Nordic Capital has a strong 35-year history of investing in and successfully growing and developing mid-market companies. This, combined with its repeat sub-sectors strategy, supports a strong investment pipeline and dealmaking for the Evolution Funds. Evolution I, which was raised in 2021, has completed ten investments to date, of which 70% have been made in collaboration with the companies’ founders and 80% completed outside broad auction, demonstrating the Evolution strategy’s strong focus on partnership. Joakim Lundvall, Partner and Co-Head of the Evolution advisory team said: "We are delighted to witness such strong demand for Evolution II from both existing and new investors. Their unwavering support is a testament to their confidence in Nordic Capital’s mid-market strategy. Our strong Evolution team, with its clear focus on business growth driven by local market expertise and deep sector knowledge, has cultivated a robust pipeline and secured partnership investments with growth companies within attractive niches. Over the last three years, a number of founders of companies have formed partnerships with Nordic Capital because they have experienced first-hand how we can help make great companies even better and support their expansion into new markets." Jonas Agnblad, Partner and Co-Head of the Evolution advisory team said: “With the Evolution funds, Nordic Capital’s long-standing sector strategy is now applied to a wider range of mid-sized companies, offering a partnership model that can help scale and professionalise companies. The partnership model includes both our own expertise, our broad network of experts and a platform that can support growth and international expansion. By contributing experience in product innovation, international expansion and long-term sustainable value creation, Nordic Capital looks forward to helping more mid-market companies develop and reach their full potential.” Pär Norberg, Partner and Head of Investor Relations, Nordic Capital Advisors, commented: “We are very pleased with the outcome of Evolution II. This is a great achievement for the team, and we would like to express our sincere gratitude to Nordic Capital’s global investor base. This type of result is only possible with the backing of long-standing existing investors as evidenced by the strong reup rate, combined with the confidence gained in Nordic Capital by new investors. We are humbled that investors have prioritised and partnered with Nordic Capital, and we are enthusiastic about working together during Evolution II and beyond.” The Evolution Funds are advised by a dedicated team of 20+ professionals, with a range of tenure and industry experience. The team also draws on Nordic Capital Advisor’s wider organisational capabilities, including its operational and sector focused expertise and well-established regional network. Evolution II attracted investors from across the globe, including 41% from Europe, 35% from the Americas, 21% from Asia and 3% from the Middle East. The investor base comprises a well-diversified mix of institutional investors: public and private pension funds (c.41%); asset managers and advisers (c.26%); sovereign wealth funds (c.14%); family offices and foundations (c.13%); and financial institutions (c. 6%). Evolution II will continue Nordic Capital’s strong sustainability commitment. This year Nordic Capital received a top ESG rating from the UNPRI for the second consecutive year, and further advanced its climate agenda with the announcement that its greenhouse gas emissions reduction targets have been approved by the Science Based Target initiative. Nordic Capital has a clear commitment to making a positive contribution to society by backing businesses that are solving some of the world’s global challenges or supporting the development of companies with strong sustainable foundations. The fundraising was led by Nordic Capital, supported by Rede Partners who acted as placement agent, with Kirkland & Ellis as lead legal counsel. Press contact:Katarina Janerud, Communications ManagerNordic Capital AdvisorsTel: +46 8 440 50 50e-mail: katarina.janerud@nordiccapital.com About Nordic Capital Nordic Capital is a leading sector-specialist private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and Service & Industrial Tech. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested c. EUR 26 billion in close to 150 investments. The most recent entities are Nordic Capital XI with EUR 9.0 billion in committed capital and Nordic Capital Evolution II with EUR 2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. www.nordiccapital.com.“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”.

Solstad Offshore ASA – Investment in Omega Subsea

Skudeneshavn, 20 December 2024 Solstad Subsea Holding AS ("Solstad"), a wholly owned subsidiary of Solstad Offshore ASA, has today signed certain transaction documents whereby Solstad will acquire a 35.8 percent ownership share in Omega Subsea AS – thereby further strengthening Solstad Offshore’s position in the subsea services segment. Omega Subsea AS is a market-leading provider of ROV, tooling, personnel, survey and project management services to the global subsea industry. Omega Subsea has offices in Norway and the UK and has approximately 400 employees. For 2024, the company is expected to deliver revenue of approximately of NOK 800 million, with a result before tax of approximately NOK 100 million. Omega Subsea’s revenue has more than trebled since 2022, with associated exponential growth in profitability. This growth has to a large degree been driven by its current cooperation with Solstad Offshore, where Omega Subsea delivers ROVs, tools and personnel to vessels operated by Solstad companies. Solstad Offshore’s focus remains being an owner and operator of offshore vessels on dayrate-basis and have no intention of being a contractor, but its Services offering provides clients with access to more complete delivery. "This investment strengthens our Service offering and gives us ownership in the solid competence that Omega Subsea AS holds. The cooperation with Omega Subsea provides customers with easy access to value-added services that they often require," says Lars Peder Solstad, CEO of Solstad Offshore ASA.  TRANSACTION DETAILS Solstad Subsea Holding AS has agreed to acquire a 35.8 percent shareholding in Omega Subsea AS for an undisclosed amount. Solstad Offshore’s investment will be settled partly in cash and partly through contribution-in-kind of its current 49.99 percent ownership in Omega Subsea Robotics AS. "We expect the subsea services market to grow in the coming years, driven by investments in both oil and gas and new subsea infrastructure within renewable energy. The investment in Omega Subsea will enable Solstad Offshore to capitalize more strongly on this projected market growth,” adds Lars Peder Solstad. Following completion of all transactions, Omega Subsea AS will own 100 percent of Omega Subsea Robotics AS. Shareholders of Omega Subsea AS will be Omega AS (60%), Solstad Subsea Holding AS (35.8%) and key employees of Omega Subsea (4.2%). The transaction is subject to customary closing conditions including approval from the Norwegian Competition Authority, satisfactory due diligence and final transaction documentation. Completion of the transaction is expected in the first quarter of 2025. For Solstad Offshore ASA the transaction will be reflected as an investment in associates and accounted for using the equity method in line with IAS 28. The transaction is expected to result in a minor accounting impact.  ABOUT THE COMPANIES Solstad Offshore ASA  The company own and operate a large fleet of offshore vessels, serving clients all over the world. Via the Service segment, the company offers a comprehensive range of services on dayrate basis to its clients, including ROV systems, survey, project manning delivery, engineering, and gangways. Solstad Services has significantly expanded over the years and continues to invest in new technologies and equipment to enhance its offerings. Omega Subsea Robotics AS Omega Subsea Robotics AS was established in 2022 as an industrial collaboration between Solstad Offshore and Omega Subsea, with the goal of making joint investments in ROV systems and associated equipment. The company has an ROV fleet consisting of 12 integrated and ordered ROV systems. 8 ROV systems are already mobilized onboard selected Solstad vessels while the 4 remaining ROVs are planned for integration throughout 2025. Omega Subsea ASOmega Subsea AS is responsible for managing, operating and staffing the ROV systems in the Omega Subsea Robotics fleet. The company was established in 2012 and has 400 employees, including partners and consultants. The company has offices in Bergen, Stavanger and Aberdeen (UK).  Contacts Lars Peder Solstad CEO, at +47 91 31 85 85 Kjetil Ramstad CFO, at +47 90 75 94 89 Solstad Offshore ASA www.solstad.com

Medicover’s Social Finance Investor Report is now published

Medicover has released its Social Finance Investor Report for 2024. The social finance framework was launched in 2021 and in connection with the launch €277m was raised in German schuldschein debt. The social financing framework is a use-of-proceeds structure and aims to contribute to the World Bank’s Universal Health Coverage goals, ensuring that people have access to essential healthcare services. Lack of health infrastructure is one of the global development challenges and improving and increasing access for communities to affordable healthcare requires significant investments in infrastructure. Once a hospital or central laboratory is opened, it is there to serve the population for decades and generations to come. Medicover makes use of debt instruments to finance these investments with allocation of the proceeds from the debt instruments under the Social Bond Framework and adherence to the Framework principles. In 2024 Medicover has issued an additional €45m in social schuldschein debt and increased the outstanding volume of the Social commercial paper programme to €140m, an increase of €65m. The report summarises investments in eligible projects with a total of €60.6m in the 9 months to September 2024, and in total €690.2m since 2016. Some of the highlights of projects in the report include the new Medicover Hospital in Bengaluru and the Cancer institute in Vizag, India, and the new laboratory in Sarajevo, Bosnia Herzegovina. The report can be found on Medicover.com . For further information, please contact: Hanna Bjellquist, Head of Investor Relations +46 703 033 272hanna.bjellquist@medicover.com Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland, Germany, Romania and India. In 2023, Medicover had revenue of €1,746 million and more than 45,000 employees. For more information, go to www.medicover.com

Archer Limited: Approval and publication of listing prospectus

Reference is made to the stock exchange announcement made by Archer Limited (the "Company") on 31 October 2024 regarding the successful private placement (the "Private Placement") of 24,393,100 new common shares in the Company. Reference is further made to the stock exchange announcement made on 14 November 2024 regarding the issuance of 1,174,436 new common shares in the Company (the "Consideration Shares") to enable settlement of the Company's acquisition of an additional 10% of the shares in Iceland Drilling. A prospectus for the listing of (i) 518,718 of the new shares issued in the first tranche of the Private Placement; (ii) the 10,880,263 new shares issued in the second tranche of the Private Placement; and (iii) the 1,174,436 Consideration Shares, was approved by the Norwegian Financial Supervisory Authority today. The aforementioned in total 12,573,417 shares, which were issued on separate ISIN in connection with the Private Placement and the Iceland Drilling transaction, will accordingly be transferred to the Company's ordinary ISIN. The prospectus will be available on the Company's website www.archerwell.com. This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act.

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 277 – 20 DECEMBER 2024 On 1 November 2024, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 1 November 2024 up to and including no later than 22 January 2025. For details, please see announcement no. 235 of 31 October 2024. Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 12 million (approximately DKK 83 million). The following transactions have been made under the programme: Date Number Average purchase price (DKK) Transaction value (DKK) of sharesTotal, last 276,500 216.31 59,809,890announcement12/12/2024 10,000 205.86 2,058,65013/12/2024 10,000 204.20 2,042,00016/12/2024 10,000 199.70 1,997,00017/12/2024 11,000 194.72 2,141,92018/12/2024 9,000 200.67 1,806,03019/12/2024 10,000 199.50 1,995,000Accumulated 336,500 213.52 71,850,440 Since the share buy-back programme was initiated on 1 November 2024, the total number of repurchased shares is 336,500 at a total amount of DKK 71,850,440. With the transactions stated above, NORDEN holds a total of 2,033,478 treasury shares, corresponding to 6.35%. The total number of shares in NORDEN is 32,000,000. Adjusted for treasury shares, the number of shares is 29,966,522. During the same period (12/12-24 - 19/12-24) major shareholder, Motortramp A/S, has sold 18,089 shares. Please see announcement no. 237/24 and daily reporting. Kind regards, Dampskibsselskabet NORDEN A/S Klaus Nyborg Chairman For further information: Therese Möllevinge, Head of Investor Relations, tel.: +45 41 37 16 38, e-mail: thm@norden.com Isabella Zaugg Hansen, Investor Relations Manager, tel.: +45 27 62 90 96, e-mail: izh@norden.com

Immunovia discovery study published in top protein research journal

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research. The study is the largest and most comprehensive pancreatic cancer proteomics study done to date. The discovery study identified 41 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. These protein biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. About 3,000 proteins were evaluated in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays. Results of the discovery study, which was conducted jointly with Immunovia’s research partner, Proteomedix AG, were first announced in November 2023. Five of the 41 biomarkers were selected for inclusion in Immunovia’s next-generation test in a subsequent model-development study. The high-performance test was later clinically validated in a study showing excellent sensitivity and specificity in detecting Stage I and II pancreatic cancer, as announced earlier this month. “This discovery study provided a large number of promising biomarkers from which we built our high-accuracy next-generation test to detect early-stage pancreatic cancer,” said Jeff Borcherding, CEO at Immunovia. “Publication of this study in the prestigious Journal of Proteome Research highlights the quality and novelty of our protein discovery program.” Journal of Proteome Research, published by the esteemed American Chemical Society, is recognized as a top-tier journal for research and reports on global protein analysis and function. Immunovia plans to launch its next-generation test for detection of pancreatic cancer in high-risk individuals in the second half of 2025. For more information, please contact:Jeff BorcherdingCEO and Presidentjeff.borcherding@immunovia.com Karin Almqvist LiwendahlChief Financial Officerkarin.almqvist.liwendahl@immunovia.com Immunovia in brief Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com

Eltel signs a three-year frame agreement with Telia in Finland worth EUR 70 million

The agreement encompasses a wide range of service packages, including the construction, maintenance, and fault repair of fixed and mobile networks, as well as customer deliveries in Finland. This agreement is an extension of the current agreement between the companies. The new agreement will be taken into effect on April 1, 2025, and has a duration of three years, with an option for one additional year.  Further information: Alexandra Kärnlund, Director, Communications Phone: +46 70 910 0903, alexandra.karnlund@eltelnetworks.com About Eltel Eltel is the leading service provider for critical infrastructure that enables renewable energy and high-performing communication networks. In total, we have about 5,000 employees and in 2023 the annual sales was EUR 850.1 million. The head office is located in Sweden and Eltel's shares have been listed on Nasdaq Stockholm since 2015. Read more at www.eltelnetworks.com.

Capsol awarded feasibility study for carbon capture from energy-from-waste plant in Germany

Capsol Technologies aims to make carbon capture technology viable for more emitters, accelerating the transition to net zero. The superior HSE (Health, Safety and Environment) performance, and Capsol’s carbon capture and heat recovery system in one which returns waste heat to the district heating system and increases energy efficiency, is what makes Capsol’s solution particularly attractive for biomass and EfW. With 70% of global waste destined for landfills being potentially recoverable, yet only 11% of this potential is currently being utilized, there's a significant opportunity for waste recovery, according to Wood Mackenzie. This provides a strong backdrop for growth for the EfW industry as government policies are implemented. Energy-from-waste plants that use biomass as an input factor can generate negative emissions credits from carbon capture and storage (CCS) which can be utilized or sold, improving the economics of decarbonization. “We are pleased to have been selected for this feasibility study building on our expertise in biomass and energy-from-waste, and with one of the pioneers in applying carbon capture on waste-to-energy plants. Globally, waste handling represents a major source of greenhouse gas emissions and waste incineration with CCS is part of transitioning to a circular economy,” said Philipp Staggat, Chief Product Officer of Capsol Technologies. Capsol Technologies’ traction within biomass and EfW to date:  · In total, Capsol Technologies has engineering studies and CapsolGo® demonstration campaigns for EfW and biomass plants totaling a potential of more than 7 million tons of CO2 to be captured annually. · In December 2024, Capsol was awarded a feasibility study for an EfW plant in France aiming to capture more than 150,000 tons of CO2 per year, of which approximately 50% of the CO2 is biogenic, enabling negative emissions. · In March 2024, Capsol signed a preliminary license agreement for KVA Linth’s EfW plant in Switzerland. · Capsol has executed a CapsolGo® carbon capture demonstration campaign at Öresundskraft’s EfW plant Filbornaverket in Helsingborg, Sweden. · Capsol has executed a 12-month CapsolGo® demonstration campaign for a major German energy company, including a campaign at an EfW plant. · Capsol has executed a CapsolGo® demonstration campaign at EEW’s Energy from Waste site in Hannover, Germany. · In December 2023, Capsol was awarded a frame license agreement for using CapsolEoP® at an EfW plant of a European utility. · In October 2023, Capsol signed a contract for the delivery of two CapsolGo® demonstration campaigns to be executed at Sumitomo SHI FW’s client base. The first campaign has been completed at Växjö Energi AB's Sandvik biomass plant in Växjö while the second campaign commenced at Swedish Mälarenergi's combined heat and power (bio-CHP) plant in Västerås, Sweden, in November 2024. · In July 2022, Capsol was awarded a license agreement for using CapsolEoP® at Stockholm Exergi’s biomass-powered combined heat and power plant Värtaverket in Stockholm, Sweden.  To receive Capsol’s stock exchange and press releases via email, subscribe at capsoltechnologies.com/investors For further information, please contact:Ingar BerghChief Financial Officer, Capsol Technologies ASA+47 926 20 330 ingar.bergh@capsoltechnologies.com About Capsol Technologies Capsol Technologies ASA is a carbon capture technology provider with a goal of accelerating the world’s transition to a net zero future. The technology combines inherent heat recovery and generation in a stand-alone unit based on a proven and safe solvent. Capsol’s technology is licensed either directly to customers or through industrial partners globally. Key segments include cement, biomass, energy-from-waste and gas turbines. Capsol Technologies is listed on Euronext Oslo Børs (ticker: CAPSL). For more information visit capsoltechnologies.com.  

Career story: “It’s important for me to be able to do work that has a positive impact on people’s lives”

Who?Pauliina Nurminen, B.Sc. (Engineering)Associate Product Manager, Implantology Applications, Digital Imaging and Applications divisionPlanmeca Oy How did you end up working at Planmeca? “I’ve always been interested in technology and mathematics. As an employer, Planmeca was particularly interesting because it’s a Finnish company operating in the field of healthcare technology. After Planmeca hired me for a summer job at the age of 16, I realised that I wanted to study healthcare technology in the future. I continued as a summer trainee every year and became familiar with various tasks related to spare parts, assembly and production. When it was time to choose a career, it was clear that I wanted to study healthcare technology. As my studies progressed, I had the opportunity to start working part-time in the Digital Imaging and Applications division. In other words, I was able to do work that corresponded to my studies and competence even before graduation. I eventually did my bachelor’s thesis for Planmeca on VR technology, and I’m pleased to continue working on projects related to VR.” What does your work involve? “I’m responsible for developing the digital implant library for the Planmeca Romexis® dental imaging software. As an Associate Product Manager for Implantology Applications, I’m specifically responsible for software modules related to implant planning and surgical guide design. My role as product manager involves trying to understand the customer’s needs as well as possible and communicate them to product development. For example, this can mean product feature specification, prioritisation and testing of prototypes. When the product is ready, it’s my job to communicate information about the new product to the export department and customers. In practice, I produce content for marketing materials and instructions, make instructional videos and hold demos and training sessions. My work also involves daily contact with implant manufacturers, distributors and customers.” What is the best part of your job? “The best part is travelling and meeting customers around the world. Among other things, this has helped me learn English, give presentations at events, meet customers in different situations and apply the skills I learned in my studies in practice. It’s also great to be part of developing all kinds of healthcare technology innovations. For example, we’re currently developing a virtual reality product that none of our competitors have yet.” What would you say to someone thinking about applying for a job at Planmeca? “Planmeca offers an international working environment that combines technology, dental science and continuous learning. It’s important for me to be able to do work that has a positive impact on people’s lives. I can say that I’ve had a good employer for more than a decade already.”  Text: Hanna LipiäinenPhoto: Dino Azinur

A Year-end message from Ulf Rask, CEO of Clean Motion

The development of EVIG started just over 36 months ago, with the ambition to transform last-mile transportation today with the cities of tomorrow in mind. And now with the EU type approval now in hand, we are going broad into the market across Europe. To accelerate this, we enhanced our commercial team this fall to boost market presence and strengthen our positioning. Cameron Crisman has joined as Head of Growth, bringing a wealth of experience in business development, growth strategies, and customer relations. Louise Jeansson has stepped in as Chief Communications & Marketing Officer, already elevating our communication and investor relations. Together, they now work alongside our Chief Commercial Officer, Christoffer Sveder to drive our mission forward, expanding our presence and grow the market/sales of EVIG. We know that the key to win in the market is to partner with the right companies. With Valeo we are now showcasing EVIG at the Valeo New Mobility Center where potential customers can experience EVIG in real-world conditions within their facility, ideally located just north of Paris. This facilitates a faster market introduction across Europe to meet the growing demand for zero-emission solutions. Among the customers that have taken advantage of this opportunity is one of Europe’s largest postal carriers, who in December started their testing and evaluation at the Valeo site. The GIANTS project is another excellent example of how we are enhancing our innovation through collaboration and driving the development of sustainable solutions for a future global market. The project is progressing as planned, and while the first year focused on defining the requirements for development, in 2025 we will be building prototypes. In the beginning of the year, the initial batch of specially designed EVIGs arrived to NEOM, but it wasn’t until mid-fall when the grand opening of the luxury destination Sindalah took place that they really started to use them in their operations. Since then, the fleet supplies much of the daily needs of all the resort's restaurants and hotels, as well as assisting in waste collection on the island. This fantastic exposure is already generating new inquiries from neighbouring markets, providing a foundation for future business opportunities and possibly further expansion. The Zbee production in India is advancing through our subsidiary, Clean Mobility Solutions India Pvt Ltd and after a smaller delay due to logistics challenges, the production is set to commence by mid-Q1 2025, with early deliveries to follow. But one of the year's major milestones was relocating and certifying our new production site to Jonsered, marking a new phase in our journey. The move has not only strengthened our production capacity but also enabled us to consolidate our organization and significantly improve our operational efficiency. During the last months we have strengthened the production team with several experienced co-workers to ascertain capacity and quality. In parallel, we have taking important steps forward with our scaling partner Daimler Trucks/Mitsubishi Fuso in Portugal, with a successful trial build of EVIG and component-logistics planning. I am immensely proud of the dedication and commitment our team has shown throughout 2024 and of all we have accomplished. At the same time, I share our shareholders’ disappointment and impatience over the lower-than-expected order intake in Q4. I am not one to wait for success - I prefer to act. The steps we have taken this year, coupled with the momentum we have built, give me confidence that we are ready to propel Clean Motion to the next level. We have a solid foundation to build upon, and our entire team is eager to continue shaping a cleaner, more sustainable future. Thank you for your continued trust and support! Best Regards Ulf Rask, CEO at Clean Motion For further information please contact:Louise Jeansson, Chief Communications & Marketing Officer, Clean MotionEmail: louise.jeansson@cleanmotion.sePhone: +46 704 307400 About Clean Motion ABClean Motion AB is a Swedish company that manufactures and sells truly sustainable vehicles for cities. The vehicles are locally produced and based on energy and resource efficiency to maximize the adoption of electric vehicles globally. The company's vision is to offer city mobility powered by solar energy and therefore provide lightweight electric vehicles with low energy consumption to meet the urban transportation challenges of the 21st century. Clean Motion AB is listed on the First North Growth Market at Nasdaq Stockholm. The Certified Adviser is G&W Fondkommission. For further information, please visit: www.cleanmotion.se

Invitation to presentation of Dustin's interim report on January 8

CEO Johan Karlsson and CFO Julia Lagerqvist will present the financial result for the first quarter 2024/25 and answer questions. The conference call will be held in English. Related presentation material will be available at the corporate website www.dustingroup.com under Investors https://www.dustingroup.com/en/reports before the start of the conference call. Dustin Group will publish the interim report the same morning at CET 8:00 am. If you wish to participate via webcast please use the link below. https://dustin-group.events.inderes.com/q1-report-2025  If you wish to participate via the teleconference, please register on the link below. After registration you will be provided a phone number and a conference ID to access the conference. You can ask questions verbally via the teleconference.https://conference.financialhearings.com/teleconference/?id=5007772  For additional information, please contact: Fredrik Sätterström, Head of Investor Relations: fredrik.satterstrom@dustin.com +46 705 10 10 22 Eva Ernfors, Head of Communication: eva.ernfors@dustin.com +46 702 58 62 94 About Dustin Dustin is a leading online based IT partner in the Nordics and Benelux. We help our customers to stay in the forefront by providing them with the right IT solution for their needs. We offer approximately 280,000 products with related services to companies, the public sector and private individuals. Sales for the financial year 2023/24 amounted to approximately SEK 21.5 billion and more than 90 per cent of the revenues came from the corporate market. Dustin has approximately 2,300 employees and has been listed on Nasdaq Stockholm since 2015, with its headquarters in Nacka Strand just outside the centre of Stockholm.

Kongsberg Automotive: Extraordinary General Meeting held

Oslo, December 20, 2024: Kongsberg Automotive ASA (KA) held an extraordinary general meeting today, December 20, 2024. The extraordinary general meeting elected three new members to KA's Board of Directors in accordance with the proposed candidates announced on November 29, 2024. Following this, KA's Board of Directors consists of the following shareholder elected members: · Olav Volldal · Bård Klungseth · Synnøve Gjønnes · Brian Kristoffersen · Junyang (Jenny) Shao  The members elected by KA’s employees remain unchanged and are as follows: · Siw Reidun Wærås · Knut Magne Alfsvåg · Bjørn Ivan Ødegård  The new Board of Directors elected Olav Volldal as new Chair of the Board of Directors and Bård Klungseth as Deputy Chair immediately after the extraordinary meeting.   Additionally, two new members of the Nomination Committee were elected by the extraordinary general meeting in accordance with the proposed candidates announced on November 29, 2024. Following this, the company’s Nomination Committee consists of: · Arild Christoffersen (Chair of the Nomination Committee) · Endre Kolbjørnsen · Tore Vik Minutes from the extraordinary general meeting is attached and will also be made available on KA’s website: https://www.kongsbergautomotive.com  This information is subject to the disclosure requirements pursuant to Section 5--12 the Norwegian Securities Trading Act.  Media and communications contact:Therese Sjöborg Skurdal – Director, Group Marketing and Communicationstherese.skurdal@ka-group.com+47 982 14 059 Investor Relations contact:investor.relations@ka-group.com

New material could capture millions of tonnes of atmospheric carbon

The material, which is being developed in collaboration with colleagues from the University of Edinburgh, has the potential to capture 3.5–5 million tonnes of CO\2\ in the UK and nearly 30 million tonnes of CO\2\ globally per year by 2030, at a cost of around £100 per tonne CO\2\ – considerably less than current direct air capture (DAC) technologies. Known as CalyChar, the new material is an advanced form of hydrochar, a charcoal-like material formed by using heat and water to treat organic/bio waste in a process known as hydrothermal carbonisation (HTC). By combining hydrochar with materials like amino acids and metal oxides to create CalyChar the researchers aim to overcome the material’s traditional limitations in CO\2\ capture. In doing so, they aim to create a functionalised material that can directly capture CO\2\ for years once carbonised, and permanently store it as a stable carbonate. The project will also explore the environmental impact of adding carbonised material to soils and wetlands, with expert support from the Tees River Trust, a river habitat conservation body in North East England. Additionally, CalyChar could be used in bio-concrete and bio-cement, offering long-term carbon storage while creating jobs and driving growth in construction and agriculture. As the urgency to limit global warming to 2°C intensifies, removing greenhouse gases from the atmosphere is more crucial than ever and was emphasised as essential in the press statements from this year’s COP29 climate change conference.  Dr Humbul Suleman, the project lead and a Senior Lecturer in Teesside University’s School of Computing, Engineering & Digital Technologies, said:  ‘CalyChar represents an exciting step forward in our efforts to combat climate change. By enhancing the ability of hydrochar to capture CO\2\, we can develop a more cost-effective and long-lasting solution for reducing carbon dioxide levels in our atmosphere.’ Professor Ondřej Mašek from the UK Biochar Research Centre at the University of Edinburgh’s School of GeoSciences, said: ‘The integration of advanced materials like CalyChar into climate solutions is vital if we are to meet ambitious net-zero targets. ‘At the University of Edinburgh, we are excited to apply our expertise in biochar technology to help optimise the carbon capture potential of this material. Together with Teesside University, we are exploring ways to accelerate its deployment in real-world applications, from soil enrichment to sustainable construction.’ The project has been funded by the CO2RE The Greenhouse Gas Removal Hub’s Pathfinders III scheme, part of UKRI’s effort to drive a major step towards achieving net zero emissions, and to benefit from the £400 billion future global market in greenhouse gas removal. Paul Rouse, the fund manager, said: ‘With technological synergy at its core, the project aims for amplified capabilities, drive sustainable innovation, and positively support the UK's climate goals. As the world faces the growing challenge of climate change, initiatives like CalyChar offer hope for a cleaner, greener future.’ Net Zero at Teesside University  ENDS Photos: · Dr Humbul Suleman, CalyChar project lead · Teesside University's Net Zero Industry Innovation Centre

Ework Group signs strategic agreement with Svenska kraftnät

The framework agreement initially includes approximately 140 different consultant roles at various competence levels, with potential for expansion as Svenska kraftnät’s operations and responsibilities grow. The agreement is also a key step in Ework Group’s growing focus on technical engineering consulting, an area with significant growth potential for the company. The agreement makes a significant contribution to the revenue and results of Ework Group. “The agreement with Svenska kraftnät is a significant milestone for Ework Group and strengthens our position as a strategic supplier to some of Sweden’s most critical societal functions. Through this collaboration, we contribute to the green transition and secure energy supply – a responsibility we take very seriously and one that aligns with our long-term strategy to create value for both our clients and society,” says Karin Schreil, CEO of Ework Group. The framework agreement is based on Ework Group’s flexible talent solutions, where Ework Group independently matches the client’s needs through its consultant network. Ework Group will also deliver efficient, user-friendly, and relieving administrative services related to the procurement of consultants. “This agreement is a testament to our ability to meet complex requirements from a critical societal actor like Svenska kraftnät. Through close and transparent collaboration, we will contribute to efficient processes, high quality, and cost-effective solutions that help Svenska kraftnät achieve its goals and create maximum value for the state and society,” says Johan Liberson, Business Manager at Ework Group. For more information, please contact: Caroline Lönnquist, CMCO, Ework Group AB+46 76867 05 40caroline.lonnquist@eworkgroup.com About Ework Group Ework Group is a partner for comprehensive talent solutions with a global talent network of over 170,000 consultants specializing in IT/digitalization, R&D, engineering, and business development. The company is a leader in Northern Europe, with around 11,500 consultants on assignment, and is continuously expanding to meet customer needs. With a broad portfolio of talent solutions and deep industry insights, we help public and private clients effectively plan, acquire, and manage their workforce, including both permanent and contingent staff. Ework Group was founded in Sweden in 2000 and has operations in Sweden, Denmark, Norway, Finland, Poland, and Slovakia, with headquarters in Stockholm. Ework Group’s shares are listed on Nasdaq Stockholm (EWRK). www.eworkgroup.com

SLP takes ownership of two logistics properties with a lettable area of 35,500 square meters

The deal has taken place through a so-called "sale and leaseback transaction" with PostNord AB. The rental agreements, which are fully indexed, run for 7 years with an annual rental value of just over SEK 33 million. Both properties have building rights for future expansion. "We are very satisfied with the acquisition of two strategically located and fully leased properties from PostNord. The properties, which are both located along important railway routes, are positioned to play an important role in the future of sustainable freight transport," says Tommy Åstrand, CEO of SLP. The agreed property value amounts to approximately SEK 470 million. The properties are acquired via corporate transactions and are financed with own funds. For further information, please contact:Tommy Åstrand, CEO of SLP, telephone: +46 705 455 997 About SLP – Swedish Logistic PropertySwedish Logistic Property – SLP – is a Swedish property company that acquires, develops, and manages logistic properties with sustainability in focus. Value growth is created through development of the properties which are located in Sweden’s most important logistic hubs. The property portfolio comprises a lettable area of approx. 1,150,000 sqm. SLP is a partner that takes responsibility and through this creates value for both tenants as well as for the company and its shareholders. SLP’s share of series B is listed at Nasdaq Stockholm Mid Cap. For further information about SLP: slproperty.se.

Consultation process completed - Exel Composites will close its factory in Belgium

Exel Composites has completed the consultation process with its employees’ representatives regarding the previously announced intention to discontinue the production at its Oudenaarde factory in Belgium. As a result, Exel Composites will close the factory, and the employment of approximately 50 employees will end. The activities at the Oudenaarde unit will cease by the end of the first quarter of 2025. The closure of the factory is necessary to address loss-making activities.The closure of the unit and the termination of employment of employees is expected to result in annual cost savings of approximately EUR 1.8 million, part of which will become visible in the second half of 2025. Exel Composites will record a one-time cash cost of approximately EUR 1.7 million and a one-time non-cash asset write-down of approximately EUR 2.5 million in the fourth quarter of 2024 as items affecting comparability.The now completed consultation process was launched on 12 September 2024 as a result of a strategic factory review, which thoroughly assessed the factory’s role and future options."Following extensive consultations conducted in a good spirit, we unfortunately have to confirm that the closure of the Oudenaarde plant will proceed. We understand this is a very difficult situation for all employees concerned. I want to thank the employee representatives and the entire staff of the Oudenaarde unit for their constructive approach to this sensitive matter,” says Paul Sohlberg, President and CEO of Exel Composites.  Additional Information: Lilli Riikonen, Head of Investor Relations investor@exelcomposites.com tel. +358 50 351 1128 Mikko Rummukainen, CFO tel. +358 20 754 1335 Distribution: Nasdaq HelsinkiMediawww.exelcomposites.com Exel Composites in brief Exel Composites is one of the largest manufacturers of composite profiles and tubes made with pultrusion and pullwinding technologies and a pultrusion technology forerunner in the global composite market. Our forward-thinking composite solutions made with continuous manufacturing technologies serve customers in a wide range of industries around the world. You can find our products used in applications in diverse industrial sectors such as wind power, transportation and building and infrastructure. Our R&D expertise, collaborative approach and global footprint set us apart from our competition. Our composite solutions help customers save resources, reduce products' weight, improve performance and energy efficiency, and decrease total lifetime costs. We want to be the first choice for sustainable composite solutions globally. Headquartered in Finland, Exel Composites employs over 600 forward-thinking professionals around the world and is listed on Nasdaq Helsinki. To find out more about our offering and company please visit visit www.exelcomposites.com. Exel Composites Plc

Enhanced Capability for Gripen C/D

“The extension of the Gripen C/D contract marks an important step forward for our defence,” says Lars Tossman, Head of Saab’s Aeronautics business area. “The integration of new advanced missile systems demonstrates our commitment to delivering high-quality solutions. We are proud to contribute to Sweden’s defence capability through this contract.” The integration of new missile systems significantly improves Gripen C/D’s operational capabilities. This contract extension will serve to ensure that Gripen C/D remains a cornerstone of Sweden’s military capabilities for many years to come. Contact Saab Press Centre+46 (0)734 180 018 presscentre@saabgroup.com Saab is a leading defence and security company with a mission to help nations protect their populations and contribute to the safety of people and communities. With 24,000 skilled employees, Saab develops technology and solutions for a safer and more sustainable world. Saab develops, manufactures, and maintains advanced aeronautics systems, weapons, command and control systems, sensors, and underwater systems. Saab is headquartered in Sweden but with global operations where Saab is a part of many nations’ defence capabilities.Saab AB (publ)SE-581 88 LinköpingSweden 

NCC to fully refurbish five blocks in Aarhus for SEK 1 billion

Image: Anette Roien The refurbishment is part of a comprehensive plan to raise housing standards in the district. NCC’s assignment is far-reaching and complex and the partners have completed a design and planning process ahead of the project. “We have, for example, carried out two pilot projects to assess different options, innovative solutions and challenges that this type of project can face. We will now use the lessons learned from these pilots to ensure the most efficient and successful project possible. We’re looking forward getting started on the refurbishment,” says Catarina Molén-Runnäs, Head of NCC Building Nordics. Surface finishes, bathrooms, roofs and installations of the residential units will all be renewed and new ventilation will be installed. Facades, windows and doors will also be refurbished. Some of the residential units will be remodeled, and a small number will be adapted for accessibility. The outdoor environments will also be upgraded to create a functional and secure residential environment. “With these upgrades and improvements, this ambitious refurbishment project will ensure that our residential and outdoor environments remain attractive for existing and future residents. This will be done at the same time as we preserve and refine the architecture and housing quality in the modernist-inspired apartment blocks built at the end of the 1960s,” says Kristian Würtz, CEO of Brabrand Boligforening. The refurbishment will begin in spring 2025 and is expected to be completed in 2029. The assignment is a turnkey contract and the order value of about SEK 1 billion will be registered in the NCC Building Nordics business area in the fourth quarter of 2024.

SciBase letter from the CEO

Our new organization in the US is critical to our continued development and the ability to provide more patients with access to better diagnostic methods for skin cancer. Since the second half of the year, we have strengthened the organization with several people, with both broad and deep knowledge in dermatology. They also have extensive experience in commercializing new technologies, a great advantage for reaching new customers and establishing reimbursement. During the year, a new consensus report was published that supports Nevisense for the use in detection and clinical management of melanoma. The report is an important step in the commercialization of Nevisense, to obtain reimbursement and, further on to be included in the clinical guidelines for skin cancer. We have successfully broadened our presence in the US market with more clinics in new states using Nevisense. We have added individual clinics that diagnose and treat a large number of patients with skin cancer to our target groups, which overall expands SciBase business opportunity. In areas with no reimbursement, we now offer the option of paying directly, a so-called cash-pay model. We are currently testing and evaluating this model in California, the model is proven for other technologies. In addition to establish a broader reimbursement in the US, we will initiate a so-called utility study with Nevisense in melanoma in the US to further strengthen our work to establish reimbursement. We have also had success outside our main markets, Germany and the USA. The ambition is to expand with existing resources or with a dedicated partner in each market. The most advanced market / country is Austria with several new customers using Nevisense. During 2025 I expect new installations of Nevisense in both Italy and the United Arab Emirates. Several markets are targeted, but our primary focus remains to accelerate development in the USA and where we are primarily allocating our resources. During the year, we have evaluated alternative ways to use Nevisense to measure the status of the skin barrier function, which is linked to a variety of skin diseases such as atopic dermatitis. Nevisense is now well established in research on the skin barrier function and there is great interest from industrial partners. We have set the strategy for the way forward and are focusing on certain indications that will be supported through studies. Initially, we will collaborate with clinics in Germany to evaluate atopic dermatitis. The planned study is expected to start in the first quarter of next year with the ultimate goal of being able to launch a new clinical application. In 2024, we have laid the foundation for continued growth, and I look forward to the coming years with confidence. In 2025, we will continue to drive our commercialization strategy in the US with investments in our marketing organization and continue with the work to establish reimbursement and coverage thereby building for future sales growth. We continue to invest in the skin barrier segment with the goal of launching a clinical indication/application as well as improved production processes and increased capacity to meet future expected sales volumes. I am grateful for the support from our existing shareholders as well as from our new long-term shareholders who have joined during the year. We further strengthen our owner base with new long-term shareholders through the recently announced capital raising. I look forward to including them and you on SciBase journey to broaden the use of Nevisense and thereby contribute to the early detection of skin cancer and save lives. With best regards and happy holidays,Pia Renaudin, CEO of SciBase For information related to the ongoing/announced capital raise, please visit: https://investors.scibase.se/en/mid-disclaimer/107/83   For additional information, please contact:Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.comCertified Advisor (CA): Carnegie Investment Bank AB (publ)Phone: +46 (0)73 856 42 65E-mail: certifiedadviser@carnegie.se About SciBaseSciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. Important information Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Acquisition of Units in the Rights Issue should only be made on the basis of the information in the formal Prospectus published by the Company in connection with the Rights Issue and which is made available on the Company's website, www.scibase.com. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement. This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act") and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation. Forward-looking statements This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.

Bittium Corporation Updates Its Strategy and Long-Term Financial Goals

Bittium CorporationOther information disclosed according to the rules of the Exchange Bittium Corporation Updates Its Strategy and Long-Term Financial Goals Bittium Corporation, Stock Exchange Release, December 20, 2024, at 2.30 pm (CET+1) The Board of Directors of Bittium Corporation has today approved the company's updated growth strategy for the years 2025–2028 and long-term financial goals. The growth strategy is built on four basic pillars: 1) strengthening the leading secure embedded technology expertise as the cornerstone of the competitive advantage, 2) building up the capabilities required for sales and commercialization to enable growth, 3) strengthening the technology base by focusing R&D investments closer to customer needs, and 4) ensuring the delivery capabilities to enable trust and scalability. Bittium's main goals are an average annual net sales growth of more than 10 percent and an operating profit level of more than 10 percent. To enable profitable growth, Bittium updated its strategy at the end of 2023, focusing on the change from a R&D-oriented organization to a sales and customer-oriented segment organization. The goal of the growth strategy announced today is profitable growth in all three independent Business Segments: Medical, which focuses on the measurement and processing of biosignals, Defense & Security, which offers products and services to the defense and security markets, and Engineering Services, which offers R&D services and wireless embedded solutions. "Bittium is known for its reliability and innovative products and solutions. In the coming strategy period, we will focus on comprehensive customer orientation and increasing sales in all our Business Segments. The utilization of AI (artificial intelligence) in the operational development of businesses will be strongly as part of building the future. In addition, we will continue improving profitability and efficiency systematically. With these measures, we believe that we are well equipped to achieve the goals set for us", says Johan Westermarck, CEO of Bittium Corporation.  Medical Business Segment The Medical Business Segment offering focuses on solutions for measuring biosignals. The business consists of four product areas, which are the already known measurement and analysis of electrical activity of the heart (ECG), measurement and analysis of electrical activity of the brain (EEG), a solution for sleep apnea testing at home, and as a new area, measurement of muscle activation (EMG). EMG measurement has been in the company's product portfolio before, and at the beginning of next year the company plans to introduce a new version of its EMG measuring device to the market. The EMG device is intended for measuring the electrical activity of muscles and is used e.g. in monitoring the progress of rehabilitation or identifying various muscle or movement disorder related diseases, such as Parkinson's disease. The remote diagnostics market is expected to grow significantly in the coming years. Diagnostics are being carried out at home rather than in a hospital environment at an increasingly early stage. Reducing hospital and treatment days would increase efficiency in healthcare processes and reduce costs. The prerequisite for remote diagnostics is enabling accurate and high-quality measurements in home conditions. Bittium's competitive advantage is based on high-quality and reliable measurement of biosignals using embedded wireless technology. The devices are designed to be easy to use and patient-friendly. In addition to the products, the company offers its customers both its own and third-party biosignal analytics software and accessories. In the upcoming strategy period, the business will focus especially on continuous improvement of the competitiveness and productivity of its products, as well as the efficiency of operations. Customer-orientation will be emphasized in both sales and other operations. Bittium's customers include global device manufacturers, service providers and traditional medical device distributors. Bittium will focus on collaborating with existing international key customers and partners to grow market shares together and open new customer relationships. The company will focus on the selling of environmentally sustainable, disposable accessories to increase recurring revenue. The regulatory approvals of medical devices are demanding processes, and during the past year the company has invested in increasing the necessary expertise. Bittium has several ongoing development projects that aim at obtaining medical device regulatory approvals in different countries. The most important development projects are the European medical device approvals (MDR approvals, Medical Device Regulation) of the Bittium Faros™ ECG monitor and the Bittium BrainStatus™ EEG measuring device. These approvals must be received at the latest in 2028, after which the current medical device approvals of these products will no longer be valid. The EMG measuring device to be released at the beginning of next year is a medical device in accordance with the MDR requirements, but it does not require evaluation by a notified body. At-home sleep apnea testing device Bittium Respiro™ has a medical device approval according to the new MDR requirements, and sales of the solution will be focused on the European market in the coming next years. In the background, fulfilling the requirements of the FDA (US Food and Drug Administration) for the sales license required for the US market will continue, however obtaining the license requires some development of the product's algorithms and extensive clinical tests, which is why the company does not expect to receive the license in the next few years.  Defense & Security Business Segment The Defense & Security Business Segment consists of two business areas, which are defense products and services (Defense) and information security products and services (Security). The business consists of solutions for tactical communication aimed at the defense market and solutions for highly secure mobile communications aimed at the authority market. The products and systems offered to the defense market are globally at a very competitive level both in terms of the wide range of the portfolio and technical capabilities. In R&D, the focus is on the continuous improvement of the quality of existing products and the development of performance to maintain competitiveness, as well as the refinement of existing products and solutions for new use cases. For the authority market, Bittium offers information security solutions on both the hardware and software side. Customers are governments and authorities of different countries, as well as technology integrators who are well-known in their own country's authority networks. Bittium's security expertise is world-class, and the company is a recognized manufacturer of secure mobile phones. In the coming strategy period, Bittium aims to increase sales of security software along with device sales. Bittium will invest strongly in key customers and international sales and marketing to pursue new customers. The company will improve and increase its production capacity to enable future growth. Bittium's goal is to grow significantly the international product business and achieve an internationally significant position as a provider of tactical communication and highly secure communication solutions. Global geopolitical instability has increased countries' defense budgets and increased the interest of states to modernize their tactical communications systems. Modern warfare requires a new kind of tactical data transmission, where increasingly mobile network users can reliably and securely transfer ever larger amounts of data. Finland's accession to the defense alliance NATO has increased the visibility of Bittium's products on the international defense and security markets. Bittium has superior waveform quality and secure wireless technology integrated with hardware and software intended for military and authority use. The long-standing cooperation and the partnership agreement signed this year with the Finnish Defense Forces form a significant reference for Bittium’s internationalization both through the system solution and the operating environment perspective.  Engineering Services Business Segment In the Engineering Services Business Segment, Bittium offers its customers R&D services and wireless connectivity solutions for the development of innovative products in a secure and evolving wireless environment. The company has focused its R&D service offering around radio technology and embedded devices. Bittium has world-class expertise in embedded wireless technologies and comprehensive product development. In wireless communication, investments in the development of new products and features continue, and the need for product variants of radios continues. With digitization, secure IoT (Internet of Things) is a significant development area in almost all industries, where demand is created by the growing need for companies to digitize their operations, collect data wirelessly and transfer data to the Internet and cloud services, as well as monitor and control devices and systems remotely. Bittium's goal is to create value for its customers in the digitalization transition. To support this, the company will invest in strengthening AI (artificial intelligence) expertise in its own operations. In the coming strategy period, Bittium will invest strongly in the development of sales, focusing especially on global customers in Europe. The company will also invest in deepening partnerships with its current customers.  Long-Term Financial Goals Bittium aims for an average annual net sales growth of more than 10 percent and an operating profit level of more than 10 percent. Earlier long-term financial goals were an average annual net sales growth of more than 10 percent and an operating profit level of 10 percent. Oulu, December 20, 2024 Bittium CorporationThe Board of Directors  Further information: Johan WestermarckCEOTel. +358 40 344 2789 (group communications)  Distribution Nasdaq Helsinki OyMain media  Bittium Bittium specializes in the development of reliable, secure communications and connectivity solutions leveraging its over 35-year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. Complementing its communications and connectivity solutions, Bittium offers proven information security solutions for mobile devices and portable computers. Bittium also provides healthcare technology products and services for biosignal measuring in the areas of cardiology and neurophysiology. Net sales in 2023 were EUR 75.2 million and operating loss was EUR -4.3 million. Bittium is listed on Nasdaq Helsinki. www.bittium.com

Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial

December 20, 2024 – Stockholm, Sweden – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, announces that the independent Data Safety Review Board that is monitoring the safety and efficacy of the current clinical study, has agreed to allow investigators to exceed the previously established maximum dose of 1.5 mg/kg/day in the ongoing second cohort of its clinical trial for BSG005. This decision was made following a request from the Principal Investigator, supported by compelling preliminary data, reflecting the investigator team’s expectation that BSG005 will deliver even greater clinical benefits at higher doses with no severe side effects. The independent Data Safety Review Committee reviewed and approved this request. “This request for a further dose escalation represents an unexpectedly quick acceleration in the daily dosing level at this early stage in the development of BSG005,” said Tine Olesen, CEO of Biosergen. “With patients currently undergoing treatment and in urgent need of further improvements in their condition, the only appropriate course of action is to support the investigator team. We are encouraged that no severe side effects have been observed at the planned maximum dose of 1.5 mg per day, and we are excited by the investigators’ eagerness to explore higher dosing levels to maximize the potential benefits for these patients.” Preliminary Data Supporting the Protocol Amendment The decision to increase the dose was based on outcomes from the patients enrolled in the second cohort so far: 1) Patient with Mucormycosis:This patient presented with Mucormycosis, a severe fungal infection that had spread across multiple lobes in both lungs. After reaching the planned maximum dose of 1.5 mg/kg/day, the infection had significantly decreased; however, it had not completely disappeared. The absence of severe side effects prompted investigators to request permission to further escalate the dose, aiming for a best-case scenario: potential complete recovery, as seen in the first patient from cohort 1, who fully recovered from a Mucormycosis infection. The promising results with BSG005 could potentially replace the standard-of-care for such a patient, which typically involves surgical removal of large portions of the lungs. In this particular case, surgery would not have been a viable option, as removing extensive areas of affected lung tissue in both lungs would have made post-surgery survival unlikely. 2) Patient with Aspergillosis:A second patient with a severe invasive Aspergillus infection showed significant improvement at 1.5 mg/kg/day. Investigators believe that further dose increases could enhance this patient’s potential for complete recovery. 3) Patient Withdrawal:A third patient opted to leave the trial due to experiencing shortness of breath (dyspnea) and a drop in blood pressure during dosing. While these events were not classified as severe side effects, the patient independently chose to discontinue participation. 4) Patient with Aspergillosis: A fourth patient was included based on failure of first line therapy. He was diagnosed with Aspergillus infection and was dosed first time 19 December without any severe side effects. Dr. Pawan Kumar Singh, an associate professor specializing in pulmonary medicine, thoracic oncology, and critical care, and the trial’s principal investigator remarked:“The positive impact we have witnessed of BSG005 on several patients in this trial is extraordinary. We are pleased that we can escalate beyond the prior dose limit for the three patients, as well as the remaining one patient yet to be enrolled in this cohort, as I believe it will strongly impact their chance of reaching a state where they can go on with their lives free from major complications of their infections.” The increased dosing levels are unexpected, and it is due to a favorable tolerability profile.  It is anticipated to result in a higher volume of BSG005 being consumed during the study than planned. Furthermore, the adjustment is likely to lead to higher maintenance doses in the planned third dose-escalation cohort, significantly increasing the total quantity of BSG005 needed and may result in an insufficient stock of BSG005 to complete the study as scheduled. Biosergen is currently evaluating the best way forward. By virtue of the efficacy of BSG005 we have seen in already treated patients the possible delay in dosing the last patient is not expected to jeopardize the plan for the following phase 2/3 studies earlier communicated.

A Sysadmin’s Holiday Checklist: Keep Your Company Safe This Festive Season

The guide goes beyond basic tips, diving into the most common holiday scams and offering videos with real-life examples of Christmas cyber scams and prevention measures. Key Tips to Protect Your Business This Holiday Season: 1. Strengthen endpoints: Keep devices updated with antivirus and endpoint protection software; consider Endpoint Detection and Response (EDR) and application whitelisting. 2. Prepare for phishing spikes: Train staff to spot suspicious emails, enforce robust email filters, and encourage prompt reporting of anything unusual. 3. Secure remote access: Mandate VPN usage, monitor unusual logins, and temporarily deactivate inactive accounts. 4. Segment and shield your network: Isolate sensitive areas, deploy DNS security and advanced firewalls, and maintain full visibility over network traffic. 5. Patch, patch, patch: Regularly update all systems and test patches in a controlled environment to avoid disruptions. 6. Tackle supply chain risks: Vet vendors and limit their access to essential systems only. 7. Have a response plan ready: Tailor incident protocols for the holidays, create an on-call rotation for your IT team, and enable swift action against suspicious activity. "Cybercriminals thrive on holiday distractions, but with proactive measures like phishing training, secure endpoints, and network segmentation, you can stay one step ahead and keep your defenses strong," said Alex Panait, System Administrator at Heimdal Security. Common Holiday Scams to Watch Out For: Cybercriminals don’t just rely on general vulnerabilities—they exploit the festive season with tailored scams designed to catch businesses off guard. Here are the most common holiday scams to be aware of: · Spear phishing: Emails disguised as holiday bonuses or event invitations that steal credentials or spread malware. · Malicious holiday E-Cards: Festive greetings that contain links deploying ransomware or spyware. · Fake E-Commerce sites: Fraudulent websites offering discounts to steal payment information. · Insider threats: Distracted or disgruntled employees mishandling or exploiting sensitive data. · Corporate travel scams: Fake booking platforms targeting business travelers. · Business email compromise (BEC): Fraudulent requests for urgent wire transfers during year-end financial rushes. For more, read the full article here  or watch the detailed video on YouTube  to see how these threats unfold and learn how to stop them. About Heimdal:Established in Copenhagen in 2014, Heimdal® empowers CISOs, security teams, and IT administrators to improve their security operations, reduce alert fatigue, and implement proactive measures through a unified command and control platform. Heimdal’s award-winning cybersecurity solutions span the entire IT estate, addressing challenges from endpoint to network levels, including vulnerability management, privileged access, Zero Trust implementation, and ransomware prevention. For more information, visit Heimdal’s website . For further press information: Madalina PopoviciMedia Relations Managermpo@heimdalsecurity.com 

Vestas announces three new orders for a total of 92 MW in Japan

News release from Vestas Asia PacificSeoul, 20 December 2024 Vestas is proud to announce the following orders as part of our Q4 order intake: Country Region Customer Project name MW Turbine Service Delivery & variant agreement commissioningJapan APAC Undisclosed Undisclosed 38 9 x Long-term Delivery and project V117 service commissioning -4.2 MW agreement in 2026Japan APAC Undisclosed Undisclosed  34 8 x Long-term Delivery and projects V117 service commissioning -4.2 MW agreement in 2026Japan APAC GK JRE Shin JRE Sakata 21 5 x Long-term Delivery and Sakata Wind Farm V136 AOM 5000 commissioning Furyoku (Jointly Replace -4.2 MW service in owned by ENEOS agreement 2026 Renewable Energy Corporation and Tohoku Electric Power Co., Inc) For more information, please contact:Megumi SakumaMarketing & Communications ManagerMail: mgskm@vestas.comTel: +81 90 6723 5325About VestasVestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service onshore and offshore wind turbines across the globe, and with more than 185 GW of wind turbines in 88 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled more than 154 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 33,000 employees are bringing the world sustainable energy solutions to power a bright future. For updated Vestas photographs and videos, please visit our media images page on: https://www.vestas.com/en/media/images. We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels: · www.twitter.com/vestas  · www.linkedin.com/company/vestas · www.facebook.com/vestas  · www.instagram.com/vestas   · www.youtube.com/vestas

Lagercrantz acquires Van Leeuwen Test Group

VLT, offers a complete range of equipment for testing of mainly heavy vehicles and are particularly known for its robust and reliable brake testers and integrated software for testing stations. Operating from modern facilities in Etten-Leur in the Netherlands and Buckingham in the UK, the company currently generates annual revenues of about EUR 20 million with a good profitability. For more information about VLT, please visit https://www.vltest.com  Magnus Nilsson, Head of division Niche Products, says: “We are pleased to welcome VLT to the Lagercrantz family. The company has built an impressive market position through its reliable technology and deep industry expertise. We look forward to supporting VLT in its continued growth journey, both geographically and by further developing its product range.” “It is reassuring to entrust VLT to Lagercrantz, who I know will uphold VLT’s core values and support our staff in continuing to deliver high-quality products and a high level of service to our customers,” says Mr. Theo Van Leeuwen, Managing Director and owner, who will stay on as an advisor to the company. The acquisition is subject to regulatory approval in the UK, with completion expected by January/February 2025. VLT will become part of the Niche Products division. The acquisition will not have any major impact on Lagercrantz' earnings per share. Stockholm, 20 December 2024 Lagercrantz Group AB (publ)

AQ Group acquires mdexx magnetronics unit from Lafayette Mittelstand Capital

AQ Group has on December 20, 2024, reached an agreement with Lafayette Mittelstand Capital to acquire mdexx inductive electronics GmbH, mdexx Magnetronic Devices GmbH, mdexx Magnetronic Devices s.r.o. and Michael Riedel, Transformatorenbau GmbH. The enterprise value is appr. 5 x EBITDA for fiscal year 2023 on a cash and debt free basis. Closing is expected in the first quarter 2025 pending governmental approvals. mdexx is a leading supplier in design and manufacturing of specialized inductive components such as reactors, transformers and filters in the low to medium power and frequency range. The customers are demanding industrial customers within electrical automation, medical technology and railway. mdexx has manufacturing in Czech Republic and sales and design engineers in Germany, Czech rep., and France.  The turnover in 2023 was EUR 47 m and the EBITDA margin was 4%. Film from mdexx . Michael Riedel, Transformatorenbau is a leading supplier in the design and manufacturing of custom-made transformers, reactors and filters in the small to medium power range. The customers are demanding industrial customers, and the company is situated in Ilshofen, Germany. The turnover in 2023 was EUR 17 m and the EBITDA margin was 8%.  “The purpose of this acquisition is to extend AQ’s customer base and broaden our technology and market presence in inductive components. mdexx and Michael Riedel have more than 60 years’ experience of working with demanding industrial customers and these companies complement AQ’s business area inductive components in a very good way. This deal continues AQ’s strategy to become the number one company globally for custom inductive components for demanding industrial customers. We believe that mdexx and Michael Riedel fits very well into the AQ business model, and we see many synergies in production, purchasing and in the market. We gladly welcome our 400 new colleagues in mdexx and Michael Riedel into AQ Group” says James Ahrgren CEO of AQ Group. ______________________________________________________________________________________________________­­­­­_­­­­­________________ For further information, please contact:CEO and IR, James Ahrgren, tel. +46 76 052 58 88 or CFO, Christina Hegg, tel. +46 70 318 92 48 The information was released by James Ahrgren for publication at 15:00 CET on December 20, 2024. ________________________________________________________________________________________________________________________ AQ is a global manufacturer of components and systems to demanding industrial customers and is listed on Nasdaq Stockholm’s main market. The Group consists mainly of operating companies each of which develop their special skills and in cooperation with other companies, striving to provide cost effective solutions in close cooperation with the customer. The Group headquarter is in Västerås, Sweden. AQ has 8,000 employees in Bulgaria, Poland, Lithuania, Sweden, China, Estonia, Hungary, Mexico, Finland, India, Canada, USA, Germany, Italy, Brazil, and Great Britain. In 2023 AQ had net sales of SEK 9 billion, and the Group has since its start in 1994 shown profit every quarter. www.aqgroup.com 

Berenberg acquires shares in BPC

The Berenberg European Micro Cap Fund has acquired 500,000 shares from Gustaf Olsson, the Chairman of BPC’s Board. The transaction was executed as a block trade with no impact on the market share price. Prior to the transaction, Gustaf Olsson held 1,096,389 shares, corresponding to approximately 10.5 percent of BPC ownership. He now holds 596,389 shares, equivalent to approximately 5.7 percent. The Berenberg European Micro Cap Fund now owns 500,000 shares, corresponding to approximately 4.8 percent of BPC. Julian Demmel, Portfolio Manager for Small and Micro Caps at Berenberg: "BPC is a clear leader in its field with potential for sustainable growth. This investment underscores our confidence in BPC’s business model and strategic direction, and we look forward to supporting the company’s future growth." Carnegie Investment Bank AB (publ) acted as bookrunner in connection with the transaction. For more information, please contact: Dr. Jing Liu, CEO BPC Instruments AB Tel: +46 (0) 46 16 39 51 E-mail: ir@bpcinstruments.com About BPC Instruments AB BPC Instruments is a global Swedish-based pioneering technology company developing and offering analytical instruments enabling more efficient, reliable, and higher quality research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also a significant reduction in time consumption and labor requirement for performing analysis. BPC Instruments' innovative products offer high-quality hardware and software based on deep knowledge and experience of target applications. The solutions are the first of their kind, making the company a pioneer in its field. Today, BPC Instruments exports to nearly 70 countries around the world. BPC is listed on the Spotlight Stock Market in Sweden. For more information, please visit BPC's webpage: www.bpcinstruments.com

Invitation to the Extraordinary General Meeting of Boliden AB (publ)

The shareholders of Boliden AB (publ) (company registration number 556051–4142) are summoned to the Extraordinary General Meeting to be held on Thursday, January 23, 2025 at 14:00 (CET). The Extraordinary General Meeting will be held at the offices of Advokatfirman Vinge, Smålandsgatan 20, Stockholm, Sweden. The meeting facilities will be open for registration from 13:30 (CET). The Board of Directors has resolved that the shareholders will be able to exercise their voting rights at the Extraordinary General Meeting also in advance (postal voting) in accordance with the provisions of the Articles of Association, see below under “Advance Voting (Postal Voting)” for further information. Participation A) Shareholders who wish to participate in the Extraordinary General Meeting in person or by proxy must be recorded as a shareholder in the share register prepared by Euroclear Sweden relating to the circumstances on Wednesday, January 15, 2025 (see below regarding re- registration of nominee registered shares), and must give notice of participation to the company on the company’s website, www.boliden.com, by telephone +46 8 402 91 75 or by mail to Boliden AB, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. When giving notice of participation, shareholders shall state their name, identification or registration number, address and telephone number as well as the number of attending assistants (maximum of two). Notice of participation must be received by the company no later than Friday, January 17, 2025. B) Shareholders who wish to participate in the Extraordinary General Meeting by postal voting must be recorded as a shareholder in the share register prepared by Euroclear Sweden relating to the circumstances on Wednesday, January 15, 2025 (see below regarding re- registration of nominee registered shares), and must give notice of participation to the company by casting their postal vote so that the postal voting form is received by the company no later than Friday, January 17, 2025 (see below under “Advance Voting (Postal Voting)” for further information). The information provided in the notice of participation will be processed and used only for the purpose of the Extraordinary General Meeting. Shareholders who wish to participate at the Extraordinary General Meeting in person or by proxy must provide a notification of attendance in accordance with item A) under “Participation” above. A notification by postal voting only is not sufficient for shareholders wishing to attend the Extraordinary General Meeting at the meeting facilities. Nominee Shares For shareholders who have their shares registered through a bank or other nominee, the following applies in order to be entitled to participate in the Extraordinary General Meeting (at the meeting facilities or through postal voting). Such shareholder must register its shares in its own name so that the shareholder is recorded in the share register prepared by Euroclear Sweden AB as of the record date Wednesday, January 15, 2025. Such re-registration may be temporary (so-called voting rights registration) and the request for such registration shall be made to the nominee, in accordance with the nominee’s routines, at such a time in advance as decided by the nominee. Voting rights registrations that have been completed by the nominee no later than Friday, January 17, 2025 will be taken into account in the preparation of the share register. Proxy Shareholders that are represented, or submit their postal vote, by proxy must issue a power of attorney. A form for power of attorney is available on the company’s website www.boliden.com. A power of attorney is valid for one year from its issue date or such longer time period as set out in the power of attorney, however not longer than a maximum of five years. A power of attorney issued by a legal person must be accompanied by a certified copy of the legal person’s certificate of registration. The certificate of registration shall evidence the circumstances on the date of the Extraordinary General Meeting and should not be older than one year at the time of the Extraordinary General Meeting. Power of attorney, certificate of registration and other documents of authority are submitted by email to GeneralMeetingService@euroclear.com or by mail to Boliden AB, ”EGM”, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23, Stockholm, Sweden, well in advance of the day of the Extraordinary General Meeting. Advance Voting (Postal Voting) A special form must be used for the postal votes. The form is available on the company’s website www.boliden.com. Completed forms must be received by Boliden no later than Friday, January 17, 2025. The completed postal voting form can be sent by e-mail to GeneralMeetingService@euroclear.com or by mail to Boliden AB, “EGM”, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. Shareholders may also cast their votes electronically through verification with BankID via the Euroclear Sweden AB’s website https://anmalan.vpc.se/EuroclearProxy. Such electronic votes must be submitted no later than Friday, January 17, 2025. If the shareholder submits its postal vote by proxy, a power of attorney for the proxy must be attached to the postal voting form according to instructions under “Proxy” above. If the shareholder is a legal person, a copy of a certificate of registration or a corresponding document must be attached to the postal voting form. The shareholders may not provide special instructions or conditions to the postal vote. If so, the entire postal vote is invalid. Further instructions and conditions can be found in the postal voting form. In order to receive the form for postal voting by mail, please contact Euroclear Sweden at telephone +46 8 402 91 75, Monday to Friday between 09.00 a.m. and 4.00 p.m. Proposed Agenda 1. Opening of the Extraordinary General Meeting 2. Election of the Chairman of the Meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of two persons to verify the minutes together with the Chairman 6. Determination whether the Meeting has been duly convened 7. Resolution on authorisation for the Board of Directors to resolve on new share issues 8. Closing of the Extraordinary General Meeting Election of the Chairman of the Meeting (item 2) The Board of Directors proposes that Karl-Henrik Sundström be elected Chairman of the meeting. Preparation and approval of the voting list (item 3) The voting list proposed for approval is the voting list drawn up by Euroclear Sweden AB on behalf of the company, based on the Extraordinary General Meeting's register of shareholders, shareholders having given notice of participation and being present at the meeting venue, and postal votes received. Resolution on authorisation for the Board of Directors to resolve on new share issues (item 7) The Board of Directors of Boliden proposes that the Extraordinary General Meeting authorizes the Board of Directors to, on one or more occasions during the period up to the Annual General Meeting 2025, resolve on a new issue of shares with or without preferential rights for the company’s shareholders. If a share issue is carried out without preferential rights for the company’s shareholders, the total number of shares that may be issued may not exceed the number of shares which corresponds to 15 percent of the number of shares as of the date of the Extraordinary General Meeting. The purpose of a share issue shall be to raise proceeds to achieve an efficient capital structure and refinance approximately half of the bridge loan secured to finance the acquisition of Neves-Corvo and Zinkgruvan. The President and CEO is authorised to make such minor adjustments to this resolution that may be necessary in connection with the registration. Majority requirements A resolution in accordance with the proposal in item 7 above shall only be valid where supported by not less than two-thirds of both votes cast and the shares represented at the meeting. Shares and Votes The company’s share capital amounts to SEK 578,914,338 distributed among 273,511,169 shares and votes. The company holds 40,000 own shares. Further Information Relevant documents pursuant to the Swedish Companies Act are available on www.boliden.com and at the company’s head office, Klarabergsviadukten 90 in Stockholm, Sweden, as of Thursday, January 2, 2025. The documents may also be ordered from the company. Shareholders’ right to information The Board of Directors and the President shall, if requested by a shareholder and if the Board deems that it can be done without material harm to the company, provide information regarding circumstances that may influence the assessment of an item on the agenda. Processing of personal data For information on how personal data is processed in connection with the Extraordinary General Meeting, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Stockholm, December 2024 Boliden AB (publ) The Board of Directors For further information, please contact: Klas Nilsson Director Group Communications +46 70-453 65 88 klas.nilsson@boliden.com

Logistri successfully lease a project property with a 10-year lease

The project will increase the leasable area by approximately 1,000 m2 compared to the previous building, which was destroyed in a fire in 2023. The building will have a general design with 12 meters of free ceiling height and a flexible floor plan that makes the building manageable efficient and will meet the needs of tenants both now and in the future. The building is planned to be environmentally certified and achieve BREEAM-SE Excellent. The lease agreement with Movator AB covers the entire premises area and all land on the property and is conditional upon a building permit being obtained for the planned building. Occupancy is expected to take place around the turn of the year 2025/2026  Movator AB is a profitable, modern and specialized company that, by managing the total customer need, offers complete solutions and has an understanding of key factors to achieve efficiency, quality and sustainability. Movator has a market-leading position with solutions for all logistics flows and relocation. "We at Movator are very happy to have been involved from the start and have had the opportunity to influence the property and look forward to moving into our new terminal. With the move, we are connecting our existing terminals in the Stockholm region and taking another step in our growth journey as the modern and sustainable transport partner for moving and logistics services," says Kalle Saajakari, CEO, Movator AB. "We are very pleased to be able to develop Skyttbrink 29 into a fantastic property together with Movator and to welcome them as a new tenant to us at Logistri. Throughout the planning process, we have had a very good collaboration and look forward to breaking ground together for their new facility." says the company's CEO, David Träff For further information, please contact: David Träff, CEO Logistri fastighets AB (publ) Phone: + 46 (0) 70 089 04 66 david.traff@logistri.se About Logistri Logistri Fastighets AB (publ) is a real estate company that invests in commercial properties primarily in the light industry, warehousing and logistics segments. The vision is to be a stable and long-term partner to companies that demand business-adapted and sustainable premises. The company's overall objective is to generate a stable cash flow and a high risk-adjusted return with high customer confidence. Our tenants are active in various industries, most of which are Swedish and international industrial and engineering companies. The properties are located in Stockholm, Gothenburg and in southern and central Sweden, in close proximity to strategic infrastructure such as major roads, railways and ports. The company is headquartered in Stockholm. The company's share was listed on the Spotlight Stock Market in 2017. Logistri is included in the MSCI Global Micro Cap index. For more information regarding Logistri Fastighets AB, please visit www.logistri.se.

YIT signs agreement with XTX Markets to build large-scale data centre in Kajaani

YIT signs agreement with XTX Markets to build large-scale data centre in Kajaani YIT and XTX Markets have signed an agreement to construct a new large-scale data centre in Kajaani, Finland. The total value of the contract for YIT is approximately EUR 100 million. The project will be entered in YIT’s order book for the last quarter of 2024. The agreed construction project will span approximately 15,000 m² and includes a data hall building on the campus area, the adjacent loading and office building for personnel and a maintenance building. The new data centre will be an impactful addition to Kajaani’s growing data centre ecosystem. XTX Markets is a leading algorithmic trading firm which uses state-of-the-art machine learning technology to produce price forecasts for over 50,000 financial instruments. The firm chose Kajaani to construct its large-scale data centre to future-proof its significant computational capabilities.  “We are delighted to sign this agreement and start this exciting data centre project in close cooperation with XTX Markets. This is the latest chapter of YIT’s strong experience of executing extensive industrial construction projects in Finland. Receiving a contract on a construction project of this scale from a large international firm is testament to our project management capabilities as well as our leading technical expertise. Overall, an investment of this scale from XTX Markets is a substantial boost to the local region of Kajaani and is further evidence of Finland’s excellent offering as an investment destination for large scale data centre projects”, stated Aleksi Laine, EVP of Infrastructure segment at YIT. For further information: YIT’s Corporate communications, tel. +358 44 743 7536, press@yit.fi XTX Markets, Richard Hillary, richard.hillary@xtxmarkets.com Distribution: Nasdaq Helsinki, major media, www.yitgroup.com YIT is a leading construction and development company. Building on over 110 years of experience, we develop and build sustainable living environments: functional homes, future-proof public and commercial buildings, and infrastructure to support the green transition. We employ approximately 4,300 professionals in eight countries. Our revenue in 2023 was EUR 2.2 billion. YIT Corporation's shares are listed on Nasdaq Helsinki.  Read more: www.yitgroup.com and follow us on Linkedin  I X  I Instagram  I Facebook 

GENETIC ANALYSIS AND FERRING PHARMACEUTICALS ANNOUNCE A COLLABORATION TO DEVELOP A NEW MICROBIOME RAPID DIAGNOSTIC TEST

Oslo, Norway – 20 December, 2024 – Ferring Pharmaceuticals and microbiome diagnostics specialists Genetic Analysis will bring together two established technologies – Genetic Analysis’ PCR-based microbiome diagnostics platform (GA-map[®1]) and Ferring’s research-validated biomarker algorithm for a healthy human microbiome (the ‘Microbiome Health Index™[2]’) – to develop a rapid test. Biomedical research is increasingly establishing the link between diversity and composition of types of microbial life in a human gut and a range of diseases including infections, IBD, cancer, and even mental health. Much of this knowledge has been unlocked by genomics and the use of genetic sequencing to track microbiota in detail. However, sequencing can take days to weeks to complete – limiting the pace at which researchers can investigate these links or leverage them in a clinical setting. In characterizing and developing the Microbiome Health Index™, Ferring Pharmaceuticals have created a ‘shorthand’ that researchers can use to establish which patients have a healthy microbiome and which are experiencing ‘dysbiosis’ – a state where the gut microbiome is disrupted which predisposes to disease. By putting this into a simple rapid test, clinical researchers would have a tool that can be used to support more projects at less expense and potentially enable faster clinical studies. The source of funding for this development is from Ferring and GA, in addition to a grant from Innovation Norway. No additional capital will be required by GA for this development. The diagnostic test is planned to be launched as a Research Use Only (RuO) test during H1-2025 and GA will have the exclusive commercialisation rights with no obligations to pay running royalties and milestones to Ferring. The diagnostic product meets Ferring’s and GA’s strategic focus on being in the forefront of Microbiome treatment and diagnostics. Ronny Hermansen, CEO of Genetic Analysis said: “Genetic Analysis and Ferring Pharmaceuticals are driving vital changes in microbiome diagnostics. Our collaboration merges Genetic Analysis' PCR expertise and the GA-map[®] platform with Ferring's Microbiome Health Index™, revolutionizing rapid testing of the human microbiomes. The need for accurate clinical routine diagnostics in the microbiome field is becoming more pressing with the first microbiome altering drugs now entering the market. With the emerging knowledge of how the gut bacteria profoundly impact well-being, our technology condenses weeks into hours, accelerating research and clinical responses.” Ken Blount, VP of Microbiome Research, of Ferring Pharmaceuticals said: “We really are still at the foothills of understanding the impact the microbiome has on our health. We feel strongly that sharing what we have learned on characterizing dysbiosis, in a way that can be used easily in a clinical setting, is the next step on climbing that mountain. We believe this PCR test will have a lot of applications for industry, clinical, and academic researchers alike, giving all of us in this space a tool we can use in the next phase of developing our understanding of how the microbiome can be harnessed to combat disease.” Applications for the new test include use in predicting which patients with serious conditions might be more prone to complications and to screen and identify patients for microbiome therapy clinical trials[3]. The introduction of biomarker tests for the microbiome into routine clinical research practice is also an important development to building the volume and specificity of data for regulatory authorities to assess future microbiome-based medical therapies. For more information, please contact: Ronny HermansenCEO, Genetic Analysisrh@genetic-analysis.com Björn LindströmCorporate Communications, FerringBJLI@ferring.com This disclosure contains information that Genetic Analysis AS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, at the time indicated by Genetic Analysis AS news distributor upon publication of this press release. About Genetic Analysis:Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering. For more general information: www.genetic-analysis.comInterested in reading more about GA's products? Please visit ga-map.com  Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/ About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health and is also pioneering innovation in microbiome and uro-oncology therapies, based on a long heritage in specialty areas within gastroenterology and urology. Founded in 1950, privately owned Ferring employs over 7,000 people worldwide, has its own operating subsidiaries in more than 50 countries, and markets its products in over 100 countries. Learn more at www.ferring.com [1 ]https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.13236 [2 ]https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.781275/full [3 ]Microbiome Diagnostics - PubMed (nih.gov)

Regarding review by UK Gambling Commission

Evolution has been informed by the UK Gambling Commission (‘Commission’) that it has commenced a review of Evolution Malta Holding Limited’s operating licence under Section 116 of the Gambling Act 2005. The review was initiated after the Commission identified Evolution games being accessible from the UK through operators not holding a Commission license. The review can have a range of outcomes, which include no action being required, conditions being imposed on the licence, financial sanction, suspension and revocation of the licence to operate. Evolution is cooperating fully with the Commission and has taken requested immediate actions to remedy the situation.  Games on the identified websites not holding a Commission license have been made unavailable from the UK. Evolution continues to actively work with the Commission to resolve this matter. About 3% of Evolution’s revenue is from the UK market. Martin Carlesund, CEO of Evolution said,“Evolution embraces the objectives of the review by the Commission.  We are committed to support the licensed UK market as well as preventing unlicensed traffic.  We are now taking forceful action using all technical tools available to us to ensure that our games only are available in the UK through Commission licensed operators.  We believe that a close collaboration to address our joint concerns will lead to swifter and better results. As always we remain committed to an open and transparent relationship with our regulators. “ For further information, please contact:Jacob Kaplan, CFO, ir@evolution.com This information is such that Evolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above on 20 December 2024, at 17:45 CET.

Mandatory Notification of Trade

Hamilton, Bermuda, December 20, 2024 - Paratus Energy Services Ltd. (ticker "PLSV") (the "Company") has been notified of a trade completed by a fund managed by Lodbrok Capital LLP, a close associate to board member Joachim Bale. For further information, please see the attached mandatory notification of trade. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For further information, please contact:Baton Haxhimehmedi, CFOBaton.Haxhimehmedi@paratus-energy.com+47 406 39 083

Tips for Keeping Your Houseplants Alive During Winter

Winter can be a challenging time for houseplants. The colder temperatures, reduced daylight, and dry indoor air can all take a toll on their health. However, with a few simple tips, you can keep your houseplants thriving throughout the winter months. [A group of potted plants Description automatically generated] Below, gardening and plants expert Fiona Jenkins at MyJobQuote.co.uk  explains why winter is so harsh on houseplants and provides some tips on how to keep your houseplants alive during this challenging time. Understanding Winter’s Impact on Houseplants As the days grow shorter, the amount of natural light available to your houseplants decreases. This can lead to slower growth, weaker stems, and pale, leggy foliage. Central heating systems can significantly reduce the humidity levels in your home. Dry air can cause your plants to lose moisture through their leaves, leading to brown tips, wilting, and a decline in overall health. Draughts from windows, doors, and heating vents can expose your plants to sudden temperature changes. These fluctuations can stress your plants, making them more susceptible to diseases and pests. Tips for Keeping Your Houseplants Healthy in Winter There are several things that you can do to ensure that your houseplants remain healthy and thriving during the winter months. Below is a list of steps that you should take to keep your houseplants in top shape during this time of the year… Adjust Your Watering Routine First of all, your houseplant growth will slow down during winter. At this time, the plants will require less water. Overwatering can result in root rot. This is a fatal condition for many houseplants. Before watering, insert your finger into the soil to check its moisture level. You should only water when the top inch of soil feels dry. Cold water can shock the roots of your plants. Instead, use lukewarm water to maintain optimal soil temperature. Provide Adequate Light It’s important to ensure that your plants get enough light at this time of the year. Position your plants near South-facing windows to maximise exposure to natural light. If the natural light in your home is insufficient, consider using artificial grow lights to supplement the light your plants receive. Look for full-spectrum grow lights that mimic natural sunlight. Be sure to rotate your plants regularly to ensure even growth and prevent them from leaning towards the light source. Maintain Optimal Humidity Humidity is important to ensure good health for many houseplants. Consider using a spray bottle to mist your plants with lukewarm water, especially those with delicate foliage. This helps to increase humidity levels around the plants. Grouping plants together can create a microclimate with increased humidity. The plants release moisture into the air, which helps to maintain a humid environment. A humidifier is also an effective way to increase the humidity levels in your home. Consider using a cool mist humidifier to avoid scalding your plants. Monitor for Pests and Diseases It’s important to monitor your plants to ensure they are surviving the winter months well. Regularly inspect your plants for signs of pests and diseases. If you do notice any infestations, make sure to isolate the infected plant to prevent the spread of pests or diseases to other plants. Consider using a natural pesticide or insecticidal soap to treat infestations. Avoid using harsh chemical pesticides that can harm your plants and the environment. Protect Your Plants from Draughts Draughts can be harmful to plants, so it's important to keep your houseplants away from them. Move your plants away from draughty areas, such as near windows, doors, or heating vents. Draughts can cause sudden temperature fluctuations, which can stress your plants. Consider grouping your plants together to create a warmer microclimate. This can help protect them from cold draughts and temperate fluctuations. Final Thoughts Winter doesn't have to be a death sentence for your houseplants. With a little bit of understanding of how the season affects them and some proactive care, you can help your leafy companions thrive even in the colder months. Remember, the key lies in mimicking their natural environment as much as possible. By adjusting your watering routine, providing adequate light, maintaining optimal humidity, and protecting them from draughts, you can ensure your plants stay vibrant and healthy all winter long. So ditch the brown leaves and drooping stems and enjoy the company of your flourishing greenery throughout the entire year! FIONA JENKINS FionaJenkins is a UK-based landscaper with over twenty-five years of experience in the industry. As a gardening expert for MyJobQuote , one of the UK's top trades-matching sites,Fiona offers her expert advice to MyJobQuote's tradespeople and homeowners and has also been featured as a gardening expert for a range of reputable publications. MyJobQuote is one of the UK's top trades matching sites that helps individuals find a reputable tradesperson in their local area. MyJobQuote  also has a wide range of experts with extensive knowledge in interior design, cleaning, gardening, property, construction and more. MyJobQuote's experts have been featured in over 700 publications, including Woman and Home, The Times, House Beautiful, BBC News and more. For more information on MyJobQuote's release or comment requests, please email the PR team atContentTeam@ICMEnterprises.co.uk. Copyright © 2024. MyJobQuote.co.uk. All reserved.

Aker ASA: Mandatory Notification of Trade

Aker ASA today bought 6,526 own shares at an average price of NOK 534.53 per share. The shares were acquired on the Oslo Stock Exchange as part of the company's share program for employees. This gives Aker ASA a new holding of 29,111 own shares. Investor contact:Fredrik Berge, Head of Investor Relations Aker ASATel: +47 45 03 20 90E-mail: fredrik.berge@akerasa.com This information is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.

What is The Ideal Thermostat Temperature for Winter Warmth?

Finding the perfect thermostat temperature setting can often be a delicate balance between your personal comfort and energy efficiency. As the days get colder and colder, understanding the ideal thermostat temperature becomes crucial. [A device on a wall Description automatically generated] In this article, heating expert Matthew Jenkins at MyJobQuote.co.uk  explores the factors influencing the ideal temperature setting. He will also provide tips for energy-efficient heating and will discuss potential health concerns related to indoor temperatures. The Factors That Influence Your Ideal Temperature There are several factors that can influence your ideal thermostat setting. Below is a list of the things that may affect it: Personal Preference Individual comfort levels can vary significantly. Some people prefer warmer temperatures, often opting for a cosy 21 degrees Celsius or higher. Others are more comfortable with cooler settings and may find a temperature closer to 18 degrees Celsius more comfortable. It is essential to consider your personal preferences and adjust the thermostat accordingly. Home Insulation The insulation  quality of your home plays a crucial role in determining your ideal thermostat setting. Well-insulated homes can retain heat more effectively. This means that you can lower your thermostat setting without compromising comfort. If your home is poorly insulated, you may need to set your thermostat higher to maintain a comfortable indoor temperature. Outdoor Temperature The external temperature can significantly impact your indoor comfort levels. During extremely cold periods, you may need to increase your thermostat settings in order to maintain a comfortable indoor environment. However, it is important to strike a balance between comfort and energy efficiency. Activity Levels Your activity level can also influence your ideal thermostat setting. When you are more active, your body generates more heat, so you may be comfortable with a lower thermostat setting. Conversely, when you are less active, you may need to increase the temperature to stay warm. Health Considerations Certain health conditions, such as respiratory issues or arthritis, may require specific temperature settings. Consult with a healthcare professional to determine the optimal temperature for your individual needs. The Ideal Thermostat Temperature for Energy Efficiency and Comfort While there is no one-size-fits-all answer to the question of "What is the ideal thermostat temperature?" there are some good general guidelines. It's generally a good idea to set your thermostat between 18 degrees Celsius and 21 degrees Celsius during the day. At night time, you can lower the settings to around 16 degrees Celsius to save energy. However, it is essential that you consider your personal comfort preferences and the specific needs of your household. Energy-Efficient Heating Tips: · Programmable Thermostats – You should consider investing in a programmable thermostat to automate your heating schedule. This will allow you to set specific temperatures for various different times of the day, helping to optimise energy efficiency. · Regular Maintenance – It’s important to ensure your heating system is well-maintained. Regular servicing can help to improve its efficiency and reduce energy consumption. · Bleeding Radiators – Bleeding your radiators can improve their energy efficiency by removing trapped air. This can help your home heat up faster and more evenly. · Insulation – Proper insulation in the home can significantly reduce heat loss, allowing you to lower the thermostat settings without compromising comfort. Health Considerations and Indoor Temperatures Maintaining a comfortable temperature inside your home is not only about energy efficiency but it is also about your health and well-being. Exposure to extreme temperatures, whether you are too hot or too cold, can have significant health implications. Below is an overview of how temperature can affect certain areas of your health: Respiratory Health Cold, dry air can irritate your respiratory system, which can then lead to symptoms such as coughing, sneezing, and congestion. People with existing respiratory conditions like asthma or allergies may be particularly susceptible to these effects. Immune System Lower temperatures can weaken your immune system, making you more susceptible to things like colds, flu, and other infections. Maintaining a comfortable indoor temperature can help boost your immune system and protect you from illness. Cardiovascular Health Exposure to extremely cold temperatures can put a strain on your cardiovascular system. This is especially true for individuals with heart conditions. Maintaining a comfortable indoor temperature can help reduce the risk of heart-related problems.  Muscle and Joint Pain Cold temperatures can make conditions like arthritis and muscle pain much worse. By maintaining a warm indoor environment, you can alleviate discomfort and improve your overall quality of life. Mental Health A comfortable indoor temperature can also positively impact your mental health. Some studies have shown that exposure to colder temperatures can lead to increased feelings of anxiety, stress and depression. By maintaining a warm and cosy environment in your home, you can improve your mood and your overall well-being. Conclusion: Finding Your Perfect Balance Finding the ideal thermostat temperature for winter warmth is truly a balancing act between comfort and energy efficiency. This article has gone over the various factors that influence this setting, from personal preferences and home insulation to activity levels and health considerations. Remember, the key is to find a temperature that keeps you comfortable without breaking the bank on heating bills. Utilise the tips provided, such as programmable thermostats and proper insulation, to optimise your heating system. Ultimately, there is no single 'perfect' temperature. Experiment with the recommended range of 18 – 21 degrees Celsius during the day and around 16 degrees at night and see how you feel. Consider your personal preferences and the needs of your household. Don't forget to take advantage of natural heat sources like sunlight during the day and layer up with cosy clothes in the evenings for extra warmth. With a little bit of planning and awareness, you can achieve a warm and comfortable winter haven while keeping your energy consumption in check. So, snuggle up with a good book or a cup of hot cocoa and enjoy the cosy winter months with your perfect heat settings. MATTHEW JENKINS Matthew Jenkins has worked as a self-employed tradesman in the domestic heating industry for over fifteen years. Matthew is a gas-safe engineer specialising in heating and plumbing. He also works closely with MyJobQuote to provide expert knowledge to homeowners and tradespeople and has been featured in a range of established news outlets. MyJobQuote is one of the UK's top trades matching sites that helps individuals find a reputable tradesperson in their local area. MyJobQuote  also has a wide range of experts with extensive knowledge in interior design, cleaning, gardening, property, construction and more. MyJobQuote's experts have been featured in over 700 publications, including Woman and Home, The Times, House Beautiful, BBC News and more. For more information on MyJobQuote's release or comment requests, please email the PR team atContentTeam@ICMEnterprises.co.uk. Copyright © 2024. MyJobQuote.co.uk. All reserved.

Zwipe AS – Preliminary results of the Rights Issue

Reference is made to the stock exchange announcement published by Zwipe AS (the "Company") on 6 December 2024, regarding the commencement of the subscription period in a new issue of units (the "Units"), consisting of shares and warrants, with preferential rights for existing shareholders raising gross proceeds of approximately NOK 40 million (the "Rights Issue"). The subscription period for the part of the Rights Issue taking place on Nasdaq First North Growth Market expired yesterday, on 19 December 2024 at 16:30 hours (CET) and the subscription period for the part of the Rights Issue taking place on Euronext Growth Oslo expired today, on 20 December 2024 at 16:30 hours (CET). Preliminary results indicates that the Company has received subscriptions for 85,757,930 Units. 397,213,376 Units were offered in the Rights Issue. The preliminary counting consequently indicates a subscription rate of approx. 21.6 %. The final allocation of the Units will take place on Monday 23 December 2024, in accordance with the allocation criteria set out in the Company's prospectus dated 4 December 2024 (the "Prospectus"). The final results of the Rights issue will be published shortly thereafter. Notification regarding allocation of Units and the corresponding subscription amount to be paid by each subscriber, are expected to be distributed on or about 23 December 2024. For more information, please refer to the prospectus dated 4 December 2024, prepared by the Company in connection with the Rights Issue, which is available at the Company's website, www.zwipe.com and the Swedish Financial Supervisory Authority's website, www.fi.se. For further information contact: Robert Puskaric, CEO of Zwipe E-mail: ir@zwipe.com This information is information that Zwipe AS is obligated to make public pursuant to the continuing obligations of companies admitted to trading on Euronext Growth Oslo (Euronext Growth Oslo Rule Book - Part II) and on Nasdaq First North Growth Market. Certified Adviser on Nasdaq First North is FNCA Sweden AB, info@fnca.se. The information was submitted for publication, through the agency of the contact person set out below, at 19:30 on 20 December 2024. About Zwipe Zwipe believes the inherent uniqueness of every person is the key to a safer future. We work with great passion across networks of international organizations, industries and cultures to make convenience safe and secure. We are pioneering next-generation biometric card and wearables technology for payment and physical & logical access control and identification solutions. We promise our customers and partners deep insight and frictionless solutions, ensuring a seamless user experience with our innovative biometric products and services. Zwipe is headquartered in Oslo, Norway, with a global presence. To learn more, visit http://www.zwipe.com  Important information Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Zwipe in any jurisdiction, either from Zwipe or from anyone else. This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. A prospectus regarding the Rights Issue described in this press release has been registered with the Swedish Financial Supervisory Authority and is kept available at, inter alia, Zwipe's website. This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (the "Securities Act"), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish and Norwegian law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation. Offers to the public will be permitted in Sweden and Norway from and including the date of approval of the prospectus by the competent authority in Sweden and the competent authority in Norway has been notified in accordance with the Prospectus Regulation, through to and including the end of the subscription period in the Rights Issue. Forward-looking statements This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Euronext Growth Oslo or Nasdaq First North Growth Market's rules for issuers.

Nordea Bank Abp: Repurchase of own shares on 20.12.2024

Nordea Bank AbpStock exchange release – Changes in company’s own shares20.12.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 20.12.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |148,712|10.25 |1,523,851.86 |+----------+-------+-------------------+-------------------+|XSTO |117,253|10.27 |1,204,318.24 |+----------+-------+-------------------+-------------------+|XCSE |29,046 |10.25 |297,654.62 |+----------+-------+-------------------+-------------------+|Total |295,011|10.26 |3,025,824.72 |+----------+-------+-------------------+-------------------+ * FX rate used: SEK to EUR 11.4423 and DKK to EUR 7.4591** Rounded to two decimals On 17 October 2024, Nordea announced a share buy-back programme of up to a maximum of EUR 250 million based on the authorisation granted by Nordea’s Annual General Meeting 2024. The repurchase of own shares is executed in public trading in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. After the disclosed transactions, Nordea holds 1,553,320 treasury shares for capital optimisation purposes and 11,513,966treasury shares for remuneration purposes. Details of each transaction are included as an appendix to this announcement. On behalf of Nordea Bank Abp,Morgan Stanley Europe SE For further information: Ilkka Ottoila, Head of Investor Relations, +358 9 5300 7058Media inquiries, +358 10 416 8023 or press@nordea.com

ZINZINO AB (PUBL.): ENTERS INTO AGREEMENT TO PROVIDE DIP FINANCING TO ZURVITA INITIATING CHAPTER 11 PROCESS

Zinzino has in a press release dated 20240617 announced that a letter of intent to acquire 100% of the shares in the North American direct selling company Zurvita Inc. “Zurvita or the Company” was signed. Since then, Zinzino has negotiated with the owners of Zurvita Inc. and instead concluded that the purchase of Zurvita’s assets in a Chapter 11 proceeding for the Company is in Zinzino's best interest. Zinzino is providing a debtor-in-possession (DIP) financing to Zurvita, which filed for Chapter 11 bankruptcy proceedings on the 20th December 2024. By entering as a financier in Zurvita's Chapter 11 with loans totaling USD 4.5 million, Zinzino simultaneously makes an offer to acquire the company's assets via a so-called stalking horse bid. If the bid is accepted, the DIP loan will be converted into part of a debt-settled purchase price, which will be determined after Zurvita has completed the sale process that is subject to higher and better offers in accordance with the applicable terms of Chapter 11. Other bidders have the right to submit bids for Zurvita during the process and if another bid is accepted, Zinzino's loan will be repaid and certain of its costs associated with the process will be reimbursed.  Zurvita is a direct selling health company with operations in the United States, Canada and Mexico. The brand portfolio offers a range of innovative health and wellness products. The business has total annual sales of approximately USD 30 million with good gross margins. A potential transaction with Zinzino is expected to add growth through the synergies arising from the joint networks, combined with Zinzino's test-based product concept. The profitability of the Company will thus be able to develop well by utilizing Zinzino's existing technical platform and organization. A visionary mindset, tech first perspective, test-based nutrition at the cellular level and a strong position to capitalize on current trends will form the basis of the new partnership. Following the acquisitions of VMA Life in 2020, Enhanzz in 2022, the strategic partnership with ACN and the recently completed asset acquisition of Xelliss, Zinzino has been looking for further strong investments to maintain its sustainable, profitable growth, strengthen its distribution power, expand into new markets and leverage the product portfolio in new consumer areas. - “Individualized advice and tailored solutions are the future, and not just in health and wellness,” says Dag Bergheim Pettersen, CEO of Zinzino. “Together, we have years of combined industry experience and everything it takes to drive the modern, personalized shopping experience through direct sales”. Jay Shafer, CEO and co-founder of Zurvita, states “After considering multiple options for the company and under the guidance of our attorneys and third-party advisors, we feel this presents the best opportunity to continue Zurvita’s mission, deliver the highest quality products, and provide continuity for our staff and consultants. We are excited to see what the future holds for Zurvita.”  For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, www.zinzino.com Pictures for publication free of charge:marketing@zinzino.comCertified Adviser:Carnegie Investment Bank AB (publ.)

Borr Drilling - Update on Share Repurchase Program

Hamilton, Bermuda, December 23, 2024 – Borr Drilling Limited (“Borr Drilling” or the “Company”) (NYSE & OSE: BORR) initiated a share repurchase program on December 13, 2024 to repurchase USD 10 million of the Company’s common shares in open market transactions (“the First Tranche”) on the OSE and NYSE until no later than December 31, 2024 pursuant to an agreement with DNB Markets, a part of DNB Bank ASA (“DNB Markets”). This was the second step under the Board of Directors authorized commitment to repurchase $20 million worth of shares before the end of 2024. For the period from and including December 13, 2024 through December 20, 2024, the Company purchased a total of 2,279,305 shares at an average price of USD 3.763 per share, equal to a total of USD 8,575,975. The transactions effected through the agreement with DNB Markets comprise all the share buybacks effected by or on behalf of Borr Drilling during the period. The issuer's holding of repurchased shares: 4,745,586. Following the completion of the above transactions, the Company had repurchased a total of 4,745,586 shares, corresponding to 1.80% of the Company’s total issued share count. Appendix: An overview of all transactions made under the Company’s repurchase program and its agreement with DNB Markets that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Africa Energy Announces Non-Brokered Private Placement

VANCOUVER, BC, December 23, 2024 /CNW/ - Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (“Africa Energy” or the “Company”) is pleased to announce that it intends to complete a non-brokered private placement of up to 988,000,000 common shares (the “Shares”) to be sold at a purchase price of Canadian $0.02 per Share for aggregate gross proceeds of up to approximately US$13,750,000 (Canadian $19,760,000) (the “Private Placement”). In connection with the Private Placement, certain lenders under the Company’s existing debt have committed to supporting the Private Placement. Deepkloof Limited (“Deepkloof”) has agreed to subscribe under the Private Placement for a minimum amount of US$12,306,250 and up to a maximum amount of US$13,750,000 (the “Deepkloof Commitment”). The net proceeds from the Private Placement will be used by Africa Energy to repay in full existing indebtedness of the Company held by Deepkloof (approximately US$4.5 million), Africa Oil Corp. (approximately US$4.5 million) and each of Lorito Doraline S.à.r.l., Lorito Floreal S.à.r.l., Lorito Arole S.à.r.l. and Lorito Orizons S.à.r.l., (together the “Lorito Group” approximately US$1.7 million). The balance of the funds will be used for general working capital purposes, completion and submission of the Environmental and Social Impact Report, securing the Production Right and to advance the development in relation to the Company’s interest in Block 11B/12B offshore South Africa. The Deepkloof Commitment will result in Deepkloof owning approximately 36.9% assuming the minimum commitment and 41.2% assuming the maximum commitment of the issued and outstanding Shares and becoming a “control person” of the Company. Accordingly, pursuant to the policies of the TSX Venture Exchange (“TSXV”), the Company must obtain shareholder approval for the Private Placement (the “Required Shareholder Approval”). As of the date of this press release, Africa Energy has entered into customary voting support agreements with Africa Oil Corp. and Impact Oil and Gas Limited representing in aggregate approximately 55.8% of the Company’s issued and outstanding Shares, where such shareholders have agreed to vote in favour of the Required Shareholder Approval. Completion of the Private Placement is subject to certain conditions including, but not limited to, the receipt of the Required Shareholder Approval and the receipt of all necessary regulatory approvals including the approval of the TSXV. Important information This is information that Africa Energy is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above on December 23, 2024, at 1:00 a.m. ET. The Company’s certified advisor on Nasdaq First North Growth Market is Bergs Securities AB, +46 739 49 62 50, rutger.ahlerup@bergssecurities.se. This press release is not for distribution to United States news services or for dissemination in the United States, and does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any State securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom. THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES. Forward Looking Statements This press release contains certain statements that constitute forward-looking information within the meaning of applicable securities laws. All information, other than information regarding historical fact, that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. Forward-looking information contained within this press release includes, but is not limited to, statements regarding the terms of the Private Placement, completion of the Private Placement and the Company’s anticipated use of proceeds. The use of any of the words “will”, “expected”, “planned”, “intends”, “may” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information. The forward-looking information contained in this press release are based on a number of assumptions made by management of the Company. Readers are cautioned that assumptions used in the preparation of such information may prove to be incorrect. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. View PDF version 

SBB announces successful completion of tender and exchange offers and publishes an outcome presentation

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has completed its previously announced tender and exchange offers. On 10 December 2024, SBB launched tender and exchange offers for selected securities. The results of the offers were announced on the 18 December 2024. For more information, please see the Outcome presentation available as an attachment to this announcement and on the company’s website. The outcome significantly reduces the risks in regard to the ongoing litigation in the English High Court. The majority of bondholders who has pursued legal threats or litigation has given up on their right to continue given the amount participated in the bond exchange. The new structure also gives SBB a stronger financial position and opens up better financing opportunities. Brief summary of the tender and exchange offer outcome: Exchange offer outcome for existing senior unsecured · Bonds in Samhällsbyggnadsbolaget i Norden Holding AB (publ) replaced bonds in Samhällsbyggnadsbolaget i Norden AB (publ) · 95 percent of the outstanding bonds participated in the offer and 93 percent of the outstanding bonds got exchanged · The new bonds are not subject to cross-acceleration due to the outcome of the current lawsuit against Samhällsbyggnadsbolaget i Norden AB (publ) and SBB Treasury Oy in English High Court · New covenants are incurrence based (i.e. only tested upon the event of incurring more debt) Exchange offer outcome for existing EUR hybrid bonds · 326,778,000 € of hybrid bonds exchanged for 154,429,000 € new unsecured bonds with 5 percent fixed interest and maturity in 2029 · Equity to shareholders increased by 172,319,000 €, equivalent to SEK 2.0 billion or SEK 1.23 per ordinary share[1] Tender offer outcome for existing senior unsecured · Only accepted maturities in January 2025 · In total 111,007,358 €[1] accepted with a discount of 0.68 percent or 756,502 €[1], excluding accrued interest, against nominal value The newly issued bonds have been rated CCC/CCC+ post exchange by S&P and Fitch, respectively. Meaning that bond investors have received an uplift in rating and a structurally improved position in relation to the assets of the group by participating in the bond exchange. For further information, please contact:Helena Lindahl, Treasury Director, ir@sbbnorden.se, press@sbbnorden.se Samhällsbyggnadsbolaget i Norden AB (publ) (SBB) is the Nordic region’s leading property company in social infrastructure. The Company’s strategy is to long term own and manage social infrastructure properties in the Nordics and rent regulated residential properties in Sweden, and to actively work with property development. Through SBB’s commitment and engagement in community participation and social responsibility, municipalities and other stakeholders find the Company an attractive long-term partner. The Company’s series B shares (ticker SBB B) and D shares (ticker SBB D) are listed on Nasdaq Stockholm, Large Cap. Further information about SBB is available at www.sbbnorden.se. [1] Applying the conversion rate of EUR/SEK: 11.47

HydrogenPro ASA: Secures NOK 70 million from existing investors and conditionally NOK 70 million from new strategic partner

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 23 December 2024 - HydrogenPro ASA (OSE: HYPRO): HydrogenPro ASA ("HydrogenPro" or the "Company") has secured approx. NOK 70 million in new equity through a private placement of new shares (the "Private Placement") towards its existing shareholders ANDRITZ AG ("ANDRITZ") and Mitsubishi Heavy Industries, Ltd. ("MHI"). The Company is further pleased to announce that it has entered into an investment agreement (the "Investment Agreement") regarding a conditional equity investment of approx. NOK 70 million (the "LONGi Investment") by LONGi Hydrogen Technology (Xi'an) Co., Ltd. ("LONGi Hydrogen") and a cooperation agreement (the "Cooperation Agreement") with LONGi Hydrogen. Thus, provided successful completion of the LONGi Investment, the total gross proceeds to the Company from the Private Placement and the LONGi Investment amount to approx. NOK 140 million. The subscription price in the Private Placement and LONGi Investment is NOK 5.50 per share (compared to NOK 4.50 per share as of close on 20 December 2024). LONGi Hydrogen is engaged in the development and manufacturing of green hydrogen equipment and solutions. It is a holding subsidiary of LONGi Green Energy Technology Co., Ltd., a world leader in solar PV products and solutions, listed on the Shanghai Stock Exchange. Jarle Dragvik, CEO of HydrogenPro, comments: "We are grateful for the trust and vote of confidence from our two largest industrial shareholders. Over the past few years, we have demonstrated the importance of our strong partnerships with MHI and ANDRITZ, delivering two of the world’s largest green hydrogen projects. This investment further strengthens the solid cooperation within technology and market development.” Mr. Dragvik adds: “We are further delighted to welcome LONGi Hydrogen as a strategic partner as we continue to execute on our vision of delivering sustainable hydrogen solutions globally. They bring first-class industrial and technical expertise. We see a great strategic fit that together with all of our industrial partners on board we will broaden our opportunities to further optimize our current offering on the market.” The Private Placement Through the Private Placement, ANDRITZ and MHI will each subscribe for 6,350,000 new shares (the "New Shares") at a subscription price of NOK 5.50 per share (the "Subscription Price"). The total subscription amount for the New Shares is approx. NOK 70 million. The New Shares will, following their issuance, represent approx. 15.3% of the Company's outstanding shares. In connection with the Private Placement, both ANDRITZ and MHI have agreed to a 6-month lock-up for its shareholding, subject to customary exemptions. 5,281,300 of the New Shares will be issued to ANDRITZ and MHI on a temporary ISIN blocked from trading on Euronext Oslo Børs pending publication of a listing prospectus. The net proceeds from the Private Placement will be used for general corporate purposes. The Private Placement and issuance of the New Shares is expected to be concluded during the first half of January 2025. Share capital increase In connection with the Private Placement, the board of directors of HydrogenPro (the "Board") has resolved to increase the share capital of the Company with NOK 254,000 by the issuance of 12,700,000 new shares, each with a nominal value of NOK 0.02 pursuant to an authorization granted by the Company's annual general meeting on 23 April 2024. Investment Agreement and Cooperation Agreement with LONGi Hydrogen Pursuant to the Investment Agreement, LONGi Hydrogen shall subscribe for 12,703,209 new shares in the Company at the Subscription Price. Completion of the LONGi Investment is subject to LONGi Hydrogen obtaining a necessary Overseas Direct Investment (ODI) regulatory approval in China to carry out its investment in the Company (the "Approval"), and the Company's shareholders, following and provided LONGi Hydrogen obtaining the Approval, resolving to approve, or facilitate via a board authorisation, the share issue pertaining to the LONGi Investment at a general meeting. It is expected that the LONGi Investment will be consummated during the first half of 2025. Subject to completion of the LONGi Investment, LONGi Hydrogen has agreed to a 6-month lock-up for its shareholding (subject to customary exemptions). Moreover, LONGi Hydrogen intends to nominate one candidate to the Company's board of directors in connection with the general meeting to be held for the purposes of consummating the LONGi Investment. The net proceeds to the Company from the LONGi Investment will be used for general corporate purposes. The primary purpose of the Cooperation Agreement is for the Company and LONGi Hydrogen to leverage their respective strengths to provide superior quality and cost-efficient products to customers, supporting their long-term vision for global decarbonization. The Cooperation Agreement specifically enables collaboration on relevant projects, broadening the scope of projects the Company and LONGi Hydrogen can bid on and enhancing the quality of products and services delivered. Additionally, the Cooperation Agreement will improve HydrogenPro and LONGi Hydrogen's manufacturing footprint in China and Europe, ensuring optimized production and supply chain efficiency. Equal treatment considerations - Subsequent Offering The Private Placement entails a deviation from the shareholders' pre-emptive rights pursuant to Sections 10-4 and 10-5 of the Norwegian Public Limited Companies Act. The Board has diligently considered the deviation from the shareholders' pre-emptive rights to be in the best interest of the Company and its shareholders. Moreover, the Private Placement has been considered by the Board in light of the equal treatment obligations under the Norwegian Securities Trading Act section 5-14, section 2.1 of the Oslo Rule Book II, and Oslo Børs' Circular no. 2/2014, and the Board is of the opinion that it is in compliance with these requirements and guidelines. In reaching these conclusions, the Board emphasized that the Private Placement enables the Company to efficiently raise new equity, and thereby improve the liquidity situation of the Company. Furthermore, the New Shares are issued above the volume-weighted average price (VWAP) of the Company's shares the last 30 trading days prior to this date, and therefore, based on the current market price, the Private Placement does not result in financial dilution for the Company's existing shareholders. Alternative structures to the Private Placement have been considered. To facilitate equal treatment, including to limit the dilutive effect of the Private Placement and provide shareholders who did not participate in the Private Placement the opportunity to subscribe for shares at the same price, the Board proposes that a subsequent offering (the "Subsequent Offering") is carried out by the issuance of up to 6,350,000 new shares, at the Subscription Price, which equals up to NOK 34.925 million in gross proceeds, directed at shareholders of the Company as per 20 December 2024 (as registered with the VPS two trading days thereafter) (except for Andritz and MHI) who are not resident in a jurisdiction where such offering would be unlawful or would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action (the "Eligible Shareholders"). The subscription period for the Subsequent Offering will commence following the approval and publication of an offering prospectus, expected during Q1 2025. The Subsequent Offering is subject to, inter alia, completion of the Private Placement, relevant corporate resolutions (including necessary resolutions by an extraordinary general meeting of the Company), prevailing market price and traded volume of the Company's shares, and approval of an offering prospectus. Further information on any Subsequent Offering will be provided in a separate stock exchange release. The Board reserves the right in its sole discretion to not conduct or to cancel the Subsequent Offering. The Board also notes that the LONGi Investment, if and when completed, will entail a deviation from the shareholders' pre-emptive rights pursuant to Sections 10-4 and 10-5 of the Norwegian Public Limited Companies Act. The Board will therefore consider applicable equal treatment obligations in relation the LONGi Investment following fulfilment of the conditions for consummation of the LONGi Investment, taking into account the prevailing market price and trading volumes of the Company's shares at such points in time. Advisors Wikborg Rein Advokatfirma AS is acting as legal counsel to the Company in connection with the Private Placement and LONGi Hydrogen Private Placement. About HydrogenPro: HydrogenPro is a technology company and an OEM for high pressure alkaline electrolyser systems for large-scale green hydrogen plants, all ISO 9001, ISO 45001 and ISO 14001 certified. The Company was founded in 2013 by individuals with background from the electrolysis industry which was established in Telemark, Norway by Norsk Hydro in 1927. We are an experienced engineering team of leading industry experts, drawing upon unparalleled experience and expertise in the hydrogen and renewable energy industry. About LONGi: LONGi Green Energy Technology Co., Ltd. (LONGi) is committed to being the world’s leading solar technology company, focusing on customer-driven value creation for full scenario energy transformation. Under its mission of “making the best of solar energy to build a green world” and brand positioning of “the most trusted, reliable solar company that blazes the trail for green technology”, LONGi has dedicated itself to technology innovation and established five business sectors, covering mono-crystalline silicon wafers, mono-crystalline silicon cells/mono-crystalline silicon modules, distributed photovoltaic solutions, utility plant system solutions, and green hydrogen equipment solutions. LONGi Hydrogen Technology (Xi'an) Co., Ltd. is a holding subsidiary of LONGi, and is committed to becoming the world's leading large-scale green hydrogen equipment and solution provider. At present, the principal business scope of the Company covers large-scale hydrogen production equipment by alkaline water electrolysis and green hydrogen production solutions by green power. About Mitsubishi Heavy Industries (MHI) Group:  Mitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. About ANDRITZ: International technology group ANDRITZ offers a broad portfolio of innovative plants, equipment, systems, services and digital solutions for a wide range of industries and end markets. Sustainability is an integral part of the company's business strategy and corporate culture. With its extensive portfolio of sustainable products and solutions, ANDRITZ aims to make the greatest possible contribution to a sustainable future and help its customers achieve their sustainability goals. ANDRITZ is a global market leader in all four of its business areas - Pulp & Paper, Metals, Hydropower and Environment & Energy. Technological leadership and global presence are cornerstones of the group's strategy, which is focused on long-term profitable growth. The publicly listed group has around 30,000 employees and over 280 locations in more than 80 countries. This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and the Norwegian Securities Trading Act sections 4-2 and 5-12. This stock exchange announcement was published by Petter Gjessing Bakken on the time and date provided. IMPORTANT INFORMATION The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. Neither this announcement nor the information contained herein is for publication, distribution or release, in whole or in part, directly or indirectly, in or into or from the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada, Japan, Hong Kong, South Africa or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The publication, distribution or release of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This announcement is not an offer for sale of securities in the United States. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act, and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission or an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any securities referred to herein in the United States or to conduct a public offering of securities in the United States. Any offering of the securities referred to in this announcement will be made by means of a set of subscription materials provided to potential investors. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned subscription material. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e. only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "EU Prospectus Regulation" means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (together with any applicable implementing measures in any Member State). This communication is only being distributed to and is only directed at persons in the United Kingdom that are "qualified investors" within the meaning of the EU Prospectus Regulation as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 and that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "aim", "expect", "anticipate", "intend", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. Forward-looking statements speak only as of the date they are made and cannot be relied upon as a guide to future performance. The Company and its respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice.

Successful amendments to terms and conditions for Nobia’s long-term funding agreement

Nobia has, together with its financing partners, successfully amended its existing long-term funding facilities agreement, initially established in connection with Nobia’s rights issue in April 2024. The amendments will better reflect the forecasted recovery of the kitchen market and provide financial flexibility to support Nobia’s strategic initiatives. This includes Nobia’s investment in a world-class automated factory in Jönköping, Sweden, to provide Scandinavian designed, high quality kitchens on shorter lead times to its Nordic customers. The factory, set to become operational in 2025, will solidify Nobia's position as the leading kitchen provider in the Nordics. Amendments include extending the current EBITDA covenant over 2025 until it is replaced with a leverage covenant from 2026, as well as adjustments to the covenant levels. As before, the specific covenant levels will not be disclosed. The size and maturity of the funding remain unchanged, with a facility of SEK 3.45 billion with maturity on June 30, 2027. For further informationHenrik Skogsfors, CFO+46 70 544 21 12henrik.skogsfors@nobia.com Tobias Norrby, Head of Investor Relations+46 706 647335tobias.norrby@nobia.com

Spermosens carries out directed issues of approx. MSEK 5.59, takes up credit facility of MSEK 1.00, and receives proposal of directed issues of approx. MSEK 0.39

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTHKOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The Board of Directors (the “Board”) of Spermosens AB (publ) (“Spermosens” or the “Company”) has today decided to carry out directed issues of shares and warrants pursuant to the authorization granted by the extraordinary general meeting on 4 November 2024. Additionally, the Company has today entered into an agreement regarding a credit facility with JEQ Capital AB (the “Lender”) of up to MSEK 1.00 (the “Credit Facility”). The warrants are conditional on subsequent approval from an extraordinary general meeting that is intended to take place in February 2025. For every two (2) subscribed shares, the subscriber receives one (1) warrant of series TO5 and one (1) warrant of series TO6. The Lender will, free of charge, receive 50,000,000 warrants of series TO5 and 50,000,000 warrants of series TO6. The investors and the Lender have subscribed for all shares and warrants in the directed issues. Through the directed issues of shares and warrants, the Company will initially receive approximately MSEK 5.59 before set-off and deduction of transaction costs. Given that the extraordinary general meeting approves the Board's resolution and upon full exercise of the warrants, the Company will receive additional maximum proceeds of approximately MSEK 8.24 before deduction of transaction costs. Furthermore, following a proposal from a shareholder, Ulrik Nilsson, the extraordinary general meeting will address the directed issues of shares and warrants to Sporcon Lifescience Advisors ApS (owned by Ulrik Spork, Chairman of the Board), Duvold Holding ApS (owned by Tore Duvold, CEO), SML Holding ApS (owned by Søren Melsing Frederiksen, Board member), Care & Communication i Lund AB (owned by Christina Östberg-Lloyd, Board member), and Nested Bio AB (owned by Kushagr Punyani, Board member). Through the directed issues of shares and warrants proposed by the shareholder, the Company will initially receive approximately MSEK 0.39 before intended set-off and deduction of transaction costs and upon full exercise of the warrants, the Company will receive an additional maximum amount of approximately MSEK0.49 before deduction of transaction costs. The proceeds from the directed issues and potential disbursed amounts under the Credit Facility will primarily finance ongoing expenses for clinical trials, business development and collaboration with partners, as well as IP, QA, IR, and administrative costs. The Company's Scottish partner, Flexmedical Solutions limited, is participating in the directed issues with approximately SEK 0.74 million, which is to be paid by way of set-off. The notice of the extraordinary general meeting will be published through a separate press release. Tore Duvold, CEO of Spermosens, comments: "I am very pleased that we have successfully secured the equity needed to continue Spermosens' positive journey. I would like to extend my gratitude to our shareholders for their support and trust in our vision. This milestone enables us to proceed with our strategy of gathering valuable clinical data through our ongoing clinical study, where we recently reported positive interim results. These findings strengthen our position as we continue discussions with strategic partners to establish license agreements for our JUNO-Checked technology. We remain committed to advancing fertility diagnostics and creating value for patients, partners and shareholders." The directed issues The Board has today decided to issue 558,953,200 shares (“Tranche 1:a”) and resolved on a directed issue, conditional on subsequent approval by an extraordinary general meeting (the “Extraordinary General Meeting”), of 329,476,600 warrants of series TO5 and 329,476,600 warrants of series TO6 (“Tranche 1:b”), free of charge, to several external investors, existing shareholders and the Lender, Tranche 1:a and Tranche 1:b collectively referred to as (“Tranche 1”). Through the directed issues of shares and warrants, the Company will initially receive approximately MSEK 5.59 before set-off and deduction of transaction costs. Tranche 1:b require an amendment of the Articles of Association and is subject to approval from the Extraordinary General Meeting. The investors and the Lender have subscribed for all shares and warrants in Tranche 1. Furthermore, following a proposal from Ulrik Nilsson, a shareholder in the Company, the Extraordinary General Meeting will resolve on the directed issues of 39,433,600 shares, 19,716,800 warrants of series TO5, and 19,716,800 warrants of series TO6, free of charge, on the same terms as in Tranche1 (“Tranche 2”). Sporcon Lifescience Advisors ApS (owned by Ulrik Spork, Chairman of the Board), Duvold Holding ApS (owned by Tore Duvold, CEO), SML Holding ApS (owned by Søren Melsing Frederiksen, Board member), Care & Communication i Lund AB (owned by Christina Östberg-Lloyd, Board member), and Nested Bio AB (owned by Kushagr Punyani, Board member) will participate in Tranche 2. Upon the execution of Tranche 1 and Tranche2 (the “Directed Issues”), the Company will initially receive a maximum of approximately MSEK5.98 before intended set-off of approximately MSEK 1.13 and deduction of transaction costs. Upon full exercise of the warrants of series TO5 and TO6 issued in the Directed Issues, the Company will receive an additional maximum amount of approximately MSEK 8.73 before deduction of transaction costs. The notice of the Extraordinary General Meeting will be published through a separate press release. Tranche 1, through which 558,953,200 shares, 329,476,600 warrants of series TO5, and 329,476,600 warrants of series TO6 are issued, is partially carried out with the support of the authorization obtained from the extraordinary general meeting on 4 November 2024, and partially conditional upon subsequent approval from the Extraordinary General Meeting and is directed to external investors, certain existing shareholders and the Lender. Prior to the Board's decision to implement the Directed Issues, the Board has also placed great emphasis on ensuring that the subscription price is marketable in relation to the current share price. The subscription price has been determined through arm's length negotiations, in consultation with financial advisors, with the external investors and amounts to SEK 0.01 per share, corresponding to a discount of approximately 28.57 percent compared to the closing price of the Company's share on Spotlight Stock Market on 20 December 2024. As the subscription price has been determined through arm's length negotiations, in consultation with financial advisors, the Board makes the assessment that the subscription price is market-based and reflects the demand for the Company's shares. Tranche 1:a and Tranche 1:b is directed to and has been subscribed by and allotted to: Investors Shares Warrants of series TO5 Warrants of series TO6Flexmedical 73,953,200 36,976,600 36,976,600SolutionslimitedJEQ Capital AB 50,000,000 25,000,000 25,000,000JEQ Capital AB 0 50,000,000 50,000,000(as lender)RSG Stockholm 50,000,000 25,000,000 25,000,000ABStefan 30,000,000 15,000,000 15,000,000LundgrenJinderman & 25,000,000 12,500,000 12,500,000Partners ABJJV Investment 25,000,000 12,500,000 12,500,000Group ABJohn Moll 25,000,000 12,500,000 12,500,000Peter Nilsson 25,000,000 12,500,000 12,500,000Dividend 20,000,000 10,000,000 10,000,000Sweden ABPronator 20,000,000 10,000,000 10,000,000Invest ABTommy Ure 20,000,000 10,000,000 10,000,000Johan Kjell 15,000,000 7,500,000 7,500,000Magnus Boberg 15,000,000 7,500,000 7,500,000Niklas 15,000,000 7,500,000 7,500,000EstenssonRichard 15,000,000 7,500,000 7,500,000KilanderSandante 15,000,000 7,500,000 7,500,000Invest ABSebastian 15,000,000 7,500,000 7,500,000ClausinAnders Wiger 10,000,000 5,000,000 5,000,000BGL Management 10,000,000 5,000,000 5,000,000ABChristian 10,000,000 5,000,000 5,000,000MånssonGhanem Chouha 10,000,000 5,000,000 5,000,000Henrik Nilsson 10,000,000 5,000,000 5,000,000Ironblock AB 10,000,000 5,000,000 5,000,000Jesper Hurtig 10,000,000 5,000,000 5,000,000Jimmie 10,000,000 5,000,000 5,000,000LandermanJosephine 10,000,000 5,000,000 5,000,000PertotTony Chouha 10,000,000 5,000,000 5,000,000Mattias 5,000,000 2,500,000 2,500,000Ekström Total number of shares: 558,953,200Total number of TO5: 329,476,600 Total number of TO6: 329,476,600 Tranche 2, through which 39,433,600 shares, 19,716,800 warrants of series TO5, and 19,716,800 warrants of series TO6 are issued, is intended to be carried out on the same terms as in Tranche 1 and is proposed to be directed to Sporcon Lifescience Advisors ApS (owned by Ulrik Spork, Chairman of the Board), Duvold Holding ApS (owned by Tore Duvold, CEO), SML Holding ApS (owned by Søren Melsing Frederiksen, Board member), Care & Communication i Lund AB (owned by Christina Östberg-Lloyd, Board member), and Nested Bio AB (owned by KushagrPunyani, Board member). Tranche 2 is intended to be resolved upon at the ExtraordinaryGeneral Meeting, following a proposal from Ulrik Nilsson, a shareholder in the Company. A separate notice of the Extraordinary General Meeting will be issued. The directed share issues in Tranche2 require an amendment of the Articles of Association. Tranche 2 is material to the investors in Tranche 1, execution of Tranche 1 is not conditional upon the execution of Tranche2. Regarding Tranche 2, the proposed investors have accrued receivables from the Company in respect of deferred consultancy fees totaling approximately MSEK 0.39, which they intend to set-off against shares in the Company. These investors have provided subscription undertakings regarding the subscription of shares and warrants in Tranche 2 for the below number of shares and warrants. The subscription undertakings are conditional upon the Extraordinary General Meeting resolving on Tranche 2. Tranche 2 is directed to: Investors Shares Warrants of Warrants of series TO5 series TO6 Sporcon Lifescience Advisors ApS (owned 12,892,400 6,446,200 6,446,200by Ulrik Spork, Chairman of the Board) Duvold Holding ApS (owned by Tore 11,500,000 5,750,000 5,750,000Duvold, CEO) SML Holding ApS (owned by Søren Melsing 6,446,200 3,223,100 3,223,100Frederiksen, Board member) Care & Communication i Lund AB (owned 4,297,500 2,148,750 2,148,750by Christina Östberg-Lloyd, Boardmember) Nested Bio AB (owned by Kushagr 4,297,500 2,148,750 2,148,750Punyani, Board member) Total number of shares: 39,433,600Total number of TO5: 19,716,800Total number of TO6: 19,716,800 The Credit Facility The Company has today entered into an agreement regarding a Credit Facility of up to MSEK 1.00. The Credit Facility will be disbursed no earlier than 1 April 2025 but no later than 31 May 2025 and amounts to a maximum of MSEK 1.00. Disbursed amounts under the Credit Facility will carry an interest rate of 2.00 percent for each commenced thirty-day period, along with a set-up fee of 5.00 percent. The Lender has the right, but not the obligation, to refrain from disbursing the loan if, at the time of the drawdown, it exceeds 10 percent of the borrower's then-current market value. Disbursed amounts under the Credit Facility will fall due six months from the disbursement date. As part of the compensation, the Lender will receive 50,000,000 warrants of series TO5 and 50,000,000 warrants of series TO6. The Lender has the right to convert disbursed amounts under the Credit Facility, in whole or in part, however to a value of at least SEK 300,000 for each conversion request, at a subscription price corresponding to the lower of (i) 70 percent of the lowest daily volume-weighted average share price during a 14-day period leading up to the conversion date, or (ii) SEK 0.01, which corresponds to the subscription price per share in the recently completed rights issue. However, the subscription price may never fall below the share's quota value. The Board has ensured the marketability of the subscription price and the other terms and conditions in consultation with financial advisors based on the prevailing market conditions for raising capital and after arm's length negotiations between the Company on the one hand and the investors and the Lender on the other hand. In light of the above, the Board is of the opinion that the subscription price and the other terms and conditions has been secured at market conditions. Terms for warrants of series TO5 and series TO6 For every two (2) shares subscribed for in the Directed Issues, one (1) warrant of series TO5, and one (1) warrant of series TO6 is received free of charge. The Lender will, free of charge, receive 50,000,000 warrants of series TO5 and 50,000,000 warrants of series TO6. One (1) warrant of series TO5 entitles the holder to subscribe for one (1) new share in the Company during the period 2 June - 16 June 2025. The subscription price for the subscription of shares by exercise of warrants of series TO5 will correspond to 70 percent of the volume-weighted average price paid for the Company's share during the period from and including 19May 2025 to and including 30 May 2025, however not lower than the share's quota value, and not higher than SEK 0.01, corresponding to 100 percent of the subscription price per share in the recently completed rights issue. One (1) warrant of series TO6 entitles the holder to subscribe for one (1) new share in the Company during the period 30 November - 14 December 2026. The subscription price for the subscription of shares by exercise of warrants of series TO6 will correspond to 70 percent of the volume-weighted average price paid for the Company's share during the period from and including 16 November 2026 to and including 27 November 2026, however not lower than the share's quota value, and not higher than SEK0.015, corresponding to 150 percent of the subscription price per share in the recently completed rights issue. The Board has ensured the marketability of the subscription price and the other terms and conditions in consultation with financial advisors based on the prevailing market conditions for raising capital and after arm's length negotiations between the Company on the one hand and the investors and the Lender on the other hand. In light of the above, the Board is of the opinion that the subscription price and the other terms and conditions has been secured at market conditions. As the terms and conditions for the warrants in Tranche 2 corresponds to the terms and conditions for the warrants in Tranche 1 determined in consultation with financial advisors through arm's length negotiations with the external investors and the Lender, it is the proposer’s assessment that the subscription price and the terms and conditions reflects the prevailing market conditions and demand and is thus market-based. The warrants are of the same series as those warrants that were issued in connection with the recently completed rights issue. The new warrants are intended to be admitted to trading on Spotlight Stock Market in February/March 2025. The Board's considerations regarding Tranche 1 Prior to the Board's decision on the implementation of Tranche 1, the Board has conducted a comprehensive assessment and carefully considered the possibility of raising capital through a rights issue. However, the Board believes that an issue deviating from shareholders' preferential rights is a better option for the Company and its shareholders. The reasons for deviating from shareholders' preferential rights are i. the rights issue of shares and warrants resolved by the Board on 3 October2024, approved by the extraordinary general meeting on 4 November 2024, and whose subscription period ended on 25November 2024, was subscribed to a total of approximately 20.90 percent. Consequently, a significant part of the Company's capital requirement remains unmet;ii. that the Company is in an important development phase and has an imminent need for financing, and to secure the Company's long-term operations, and that a rights issue would require significantly more time and resources to carry out and also entail a higher risk of a negative effect on the share price, especially in light of today's volatile and challenging market conditions, as a rights issue, compared to a directed issue, would likely need to be carried out at a lower subscription price given the discounts that have been offered in recent rights issues on the market;iii. that the implementation of Tranche 1 can be done at a significantly lower cost and with less complexity than a rights issue. The reason why existing shareholders participate in the directed issues of Tranche 1 is that these shareholders have expressed and shown a long-term interest in the Company, which, according to the Board, creates security and stability for both the Company and its shareholders. Without the participation of existing shareholders, it would not have been possible for the company to secure the financing. Considering the above, the Board is of the overall opinion that a directed issue of shares and warrants deviating from shareholders' preferential rights is the most advantageous option for both the Company and all its shareholders. Prior to the Board's decision on the implementation of Tranche 1, the Board has also placed great emphasis on ensuring the market-based nature of the subscription price in relation to the prevailing share price. The subscription price has been determined through arm's length negotiations, in consultation with financial advisors, with the external investors and amounts to SEK 0.01 per share, corresponding to a discount of approximately 28.57 percent compared to the closing price of the Company's share on Spotlight Stock Market on 20 December 2024. Given that the subscription price has been determined through arm's length negotiations, in consultation with financial advisors, with the external investors, the Board’s assessment is that the subscription price reflects the prevailing market conditions and demand and is thus market-based. The proposer’s considerations regarding Tranche 2 The proposer believes, after an overall assessment and careful consideration, that an issue deviating from shareholders' preferential rights is a better option for the Company and its shareholders than a rights issue. The reasons for deviating from shareholders' preferential rights are i. that the rights issue of shares and warrants resolved by the Board on 3October2024, approved by the general meeting on 4 November 2024, and whose subscription period ended on 25 November 2024, was subscribed to a total of approximately 20.90 percent. Consequently, a significant part of the Company's capital requirement remains unmet;ii. that the Company is in an important development phase and has an imminent need for financing, and to secure the Company's long-term operations, and that a rights issue would require significantly more time and resources to carry out and also entail a higher risk of a negative effect on the share price, especially in light of today's volatile and challenging market conditions, as a rights issue, compared to a directed issue, would likely need to be carried out at a lower subscription price given the discounts that have been offered in recent rights issues on the market;iii. that the implementation of Tranche 2 can be done at a significantly lower cost and with less complexity than a rights issue. The reason why existing shareholders participate in the directed issues of Tranche 2 is that these shareholders have expressed and shown a long-term interest in the Company, which, according to the proposer, creates security and stability for both the Company and its shareholders. Without the participation of existing shareholders, it would not have been possible for the company to secure the financing. Considering the above, the proposer is of the overall opinion that a directed issue of shares and warrants deviating from shareholders' preferential rights is the most advantageous option for both the Company and all its shareholders. As the subscription price in the Tranche 2 corresponds to the subscription price in the Tranche 1 determined through arm's length negotiations, in consultation with financial advisors, with the external investors, it is the proposer’s assessment that the subscription price reflects the prevailing market conditions and demand and is thus market-based. Rationale and use of issue proceeds The Company recognizes a current gap in effective diagnostic tools for assessing sperm quality. Enhancing the ability to personalize treatment options leads to higher fertilization success rates, which benefits couples undergoing treatment, strengthens clinics' competitiveness, and has positive effects on society. Spermosens is focused on global commercialization with comprehensive patent protection for its products. The Company's second-generation patented product, JUNO-Checked, has been developed with improved performance and faster readout times, making it ready for the ongoing clinical study at RMC in Malmö. This new version of JUNO-Checked will play a pivotal role in the study, which has been approved by the ethics committee. The study aims to demonstrate the diagnostic value of the product, a key step toward building credibility with potential partners and licensees. The positive interim results not only validate the diagnostic potential of JUNO-Checked but also reinforce its role as a promising tool for improving IVF outcomes, offering new hope to couples undergoing fertility treatments. Spermosens is prioritizing the identification of strategic partners and licensing opportunities for JUNO-Checked to broaden its use. The need for improved sperm quality assessment tools is significant, and JUNO-Checked has the potential to enhance IVF treatments, reduce waiting times, and improve outcomes for both patients and fertility clinics. The Company's strategy for further development and commercialization of JUNO-Checked follows a structured five-step approach: 1. Delivery of the first-generation product for research purposes (completed) 2. Delivery of the second generation with enhanced performance for clinical studies (completed) 3. Ongoing verification and validation through clinical trials 4. Establishing licensing agreements and strategic partnerships for global commercialization 5. Full-scale commercialization through partners and licensees Spermosens aims to achieve market acceptance and positive cash flow within two years through licensing agreements and partnerships. The Board sees significant long-term potential, positioning JUNO-Checked as a leading product in global fertility diagnostics. Through the Directed Issues and the Credit Facility, the Company can receive gross proceeds of approximately MSEK 6.98 which is intended to be used for the following purposes stated in order of priority: · Ongoing expenses for clinical trials · Business development and partnership collaboration · IP, QA and administrative costs In the event that all warrants of series TO5 and TO6 issued in the Directed Issues are exercised for subscription of shares, the Company will receive maximum additional proceeds of approximately MSEK 8.73 which, after deduction of issue costs, are intended to be used for the following areas of use: · Proceeds from TO5 will strengthen the financing of the above-mentioned activities · Proceeds from TO6 will finance business development, including distribution and marketing in collaboration with partners Shares, share capital, and dilution Assuming that the Extraordinary General Meeting resolves to approve Tranche 1:b and Tranche 2, the Directed Issues will result in the number of outstanding shares in the Company potentially increasing by 598,386,800, from 757,794,616 to 1,356,181,416, and the share capital potentially increasing by SEK1,196,773.600, from SEK 1,515,589.232 to SEK 2,712,362.832, resulting in a dilution effect of approximately 44.12 percent. In the event that all warrants of series TO5 and TO6 issued in the Directed Issues are exercised, the number of outstanding shares will increase by an additional 698,386,800, from 1,361,181,416 to 2,054,568,216, and the share capital will increase by SEK 1,396,773.600, from SEK 2,722,362.832 to SEK4,109,136.432. This will result in an additional dilution effect of approximately 33.99 percent and a total dilution effect of approximately 63.12 percent. Extraordinary General Meeting The Board' resolution on Tranche 1:b and the proposed amendments to the Company's articles of association concerning the limits on the number of shares and share capital is conditional upon subsequent approval at the Extraordinary General Meeting intended to take place in February 2025. The directed issues in Tranche 2 are subject to Chapter 16 of the Swedish Companies Act (2005:551) (the so-called Leo rules). Accordingly, a resolution of the Extraordinary General Meeting is only valid if it has been supported by shareholders representing at least nine-tenths (9/10) of both the votes cast and the shares represented at the Extraordinary General Meeting. The notice of the Extraordinary General Meeting will be published through a separate press release. The FDI Act Spermosens has made the assessment that the Company conducts activities worthy of protection according to the Act (2023:560) on the review of foreign direct investments, why certain investments in the Company must be notified to the ISP. Through the Directed Issues, no investor will exceed the thresholds of 10 percent, respectively, which is why no investment will be subject to notification. Advisors Eminova Partners Corporate Finance AB act as financial advisor, and Eminova Fondkommission AB has been appointed as issuing agent, in connection with the Directed Issues. Moll Wendén Advokatbyrå AB is legal advisor to Spermosens. For more information Tore Duvold, VD info@spermosens.com About Spermosens Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com. Important information The publication, release or distribution of this press release in certain jurisdictions may be restricted by law and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe any such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction in which such offer or solicitation would be unlawful. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved or reviewed by any regulatory authority in any jurisdiction. A prospectus will not be prepared in connection with the Directed Issues. This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States of America, Canada, Australia, New Zealand, Japan, Hong Kong, South Korea, Singapore, South Africa, Switzerland, Russia or Belarus or any other jurisdiction where such announcement, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities laws. This press release does not identify or purport to identify any risks (direct or indirect) that may be associated with an investment in new shares. This press release does not constitute an invitation to underwrite, subscribe or otherwise acquire or transfer securities in any jurisdiction. This press release does not constitute a recommendation for any investor's decision regarding the Directed Issues. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities may go down as well as up and past performance is no guide to future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release. Forward-looking statements This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as “believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “anticipates”, “should”, “could” and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialize or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required to do so by law or the rules of Spotlight Stock Market.

HydrogenPro ASA: Key information regarding potential subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 23 December 2024: Reference is made to the stock exchange announcement by HydrogenPro ASA (the "Company") earlier today regarding a private placement of 12,700,000 new shares in the Company directed towards Andritz AG ("ANDRITZ") and Mitsubishi Heavy Industries, Ltd. ("Mitsubishi") at a subscription price of NOK 5.50 per share (the "Subscription Price"), raising gross proceeds of approx. NOK 70 million (the "Private Placement"), and a potential subsequent share offering of up to 6,350,000 new shares at the Subscription Price (the "Subsequent Offering"). Subject to certain conditions, as described below, the Company's board of directors (the "Board") may resolve to carry out the Subsequent Offering, which, if applicable and subject to applicable securities law, will be directed towards shareholders of the Company as per 20 December 2024 (as registered with the VPS two trading days thereafter (the "Record Date"), except for ANDRTIZ and Mitsubishi, and who are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action (the "Eligible Shareholders"). In accordance with the continuing obligations of companies listed on Euronext Oslo Børs, the following key information is given with respect to the Subsequent Offering: · Date on which the terms and conditions of the repair issue were announced: 23 December 2024 · Last day including right: 20 December 2024 · Ex-date: 23 December 2024 · Record date: 27 December 2024 · Date of approval: On or before 14 February 2025 (date of an extraordinary general meeting to be held in the Company) · Maximum number of new shares: 6,350,000 new shares · Subscription price: NOK 5.50 per share Any Subsequent Offering is subject to, inter alia, completion of the Private Placement, relevant corporate resolutions (including necessary resolutions by an extraordinary general meeting of the Company), and approval and publication of an offering prospectus. Furthermore, the Company's board of directors may, in its sole discretion, decide to not carry out the Subsequent Offering, for example, in the event that the prevailing market price and traded volume of the Company's shares makes a subsequent offering redundant. The subscription period for the Subsequent Offering, if applicable, will commence as soon as possible following the publication of an offering prospectus, expected during Q1 2025. The Company reserves the right, in its sole discretion, to not carry out the Subsequent Offering. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. IMPORTANT INFORMATION The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. Neither this announcement nor the information contained herein is for publication, distribution or release, in whole or in part, directly or indirectly, in or into or from the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada, Japan, Hong Kong, South Africa or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The publication, distribution or release of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This announcement is not an offer for sale of securities in the United States. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act, and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission or an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any securities referred to herein in the United States or to conduct a public offering of securities in the United States. Any offering of the securities referred to in this announcement will be made by means of a set of subscription materials provided to potential investors. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned subscription material. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e. only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "EU Prospectus Regulation" means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (together with any applicable implementing measures in any Member State). This communication is only being distributed to and is only directed at persons in the United Kingdom that are "qualified investors" within the meaning of the EU Prospectus Regulation as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 and that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "aim", "expect", "anticipate", "intend", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. Forward-looking statements speak only as of the date they are made and cannot be relied upon as a guide to future performance. The Company and its respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice.

HydrogenPro ASA - Ex. right to participate in subsequent offering today

Reference is made to the stock exchange announcement published by HydrogenPro ASA (the "Company") earlier today, 23 December 2024, regarding key information on a potential subsequent offering of shares in the Company. The shares in Company will be traded exclusive of the right to participate in a potential subsequent offering from and including today, 23 December 2024. Ex. date: 23 December 2024 This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

HydrogenPro ASA - Disclosure of large shareholding

Reference is made to the stock exchange announcement by HydrogenPro ASA ("HydrogenPro" or the "Company") on 23 December 2024 regarding the private placement of 12,700,000 new shares in the Company at a subscription price of NOK 5.50 per share, raising total gross proceeds of approx. NOK 70 million (the "Private Placement"). Prior to the Private Placement, Andritz AG ("Andritz") held 9,644,036 shares in the Company, representing 13.75% of the share capital and votes in the Company. Andritz has subscribed for, and been allocated, 6,350,000 new shares in the Company in the Private Placement. Subject to the completion of the Private Placement, Andritz will hold 15,994,036 shares in the Company, equal to 19.31% of the issued share capital and votes, and thereby exceed the 15% threshold pursuant to Section 4-2 (1) of the Norwegian Securities Trading Act. Andritz AG has no other rights to shares in the Company. This disclosure is made pursuant to Section 4-2 of the Norwegian Securities Trading Act.

Vestas secures 108 MW order in Australia

News release from Vestas Asia PacificSeoul, 23 December 2024 Vestas is proud to announce the following order as part of our Q4 order intake: Country Region Customer Project MW Turbine Service Delivery & name variant agreement commissioningAustralia APAC Bright Warradarge 108 30 x 30-year Delivery Energy Stage Two V136 AOM 5000 expected Investments Wind -3.6 service in Q2 2026 and Farm MW agreement and Synergy commissioning expected to commence Q4 2026 For more information, please contact:Kilani FisherAPAC Head of Marketing & CommunicationsMail: klafs@vestas.comTel: +61 436 855 159About VestasVestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service onshore and offshore wind turbines across the globe, and with more than 185 GW of wind turbines in 88 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled more than 154 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 33,000 employees are bringing the world sustainable energy solutions to power a bright future. For updated Vestas photographs and videos, please visit our media images page on: https://www.vestas.com/en/media/images. We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels: · www.twitter.com/vestas  · www.linkedin.com/company/vestas · www.facebook.com/vestas  · www.instagram.com/vestas   · www.youtube.com/vestas

Change in the number of shares and votes in Beyond Frames Entertainment AB (publ)

The Swedish Companies Registration Office has registered an increase in the number of shares and share capital in Beyond Frames Entertainment AB (publ), attributable to employee option program (“kvalificerade personaloptioner”) claimed in relation to the Incentive Program 2021/2024, which was communicated on 22 June 2021. A total of 79 000 shares were issued, which means that the number of shares in the company after registration amounts to 17 544 409. The share capital in the Company has increased by SEK 3 950 and amounts to a total of SEK 877 220.

Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical’s Scientific Advisory Board

“We are thrilled to welcome Dr. Sims to the SAB,” says Dr. Mark Atkinson, Chairman of the Diamyd Medical Scientific Advisory Board. “Her groundbreaking research and clinical expertise will significantly enhance our efforts to advance precision medicine approaches for Type 1 Diabetes. Indeed, as we approach potential market introduction, Emily Sim’s insights will be critical in shaping clinical awareness and positioning our therapy for maximum impact.” Dr. Sims is an Associate Professor of Pediatrics at Indiana University (IU) School of Medicine, a pediatric endocrinologist at Riley Hospital for Children, and a physician scientist at the IU Center for Diabetes and Metabolic Diseases and the Herman B Wells Center for Pediatric Research. Her work focuses on identifying risk factors that predispose individuals to Type 1-Diabetes and developing innovative treatments to prevent or slow disease progression.  “I am honored to be part of Diamyd Medical’s mission to bring precision medicine to Type 1 Diabetes”, says Emily Sims. “As Diamyd Medical prepares to bring its precision medicine approach to patients, I look forward to contributing to its efforts to deliver pioneering treatments. The company’s commitment to advancing innovative therapies aligns with my passion for improving risk prediction and developing treatments that can make a meaningful impact on patients’ lives” About Diamyd MedicalDiamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd[®] is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. Diamyd[®] has been granted Orphan Drug Designation in the U.S. as well as Breakthrough Designation and Fast Track Designation by the U.S. FDA for the treatment of Stage 3 Type 1 Diabetes. Diamyd[® ]has also been granted Fast Track Designation for the treatment of Stage 1 and 2 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company’s prospective European Phase IIb trial, where Diamyd[®] was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd[®]. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB. Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

Nordnet unveils new brand concept

This fall, Nordnet partnered with a new advertising agency, Sweden-based Perfect Fools. The new concept was developed in collaboration between Perfect Fools and Nordnet’s in-house creative team and will roll out broadly across the Nordics starting Monday, December 23. Nordnet’s creative concept takes inspiration from the world of shopping, positioning savings as an alternative to shopping and other forms of consumption. A central element of the concept is various packaging designs in Nordnet’s signature turquoise color. By presenting stocks and funds in a physical and familiar form, the campaign establishes a distinctive and engaging visual identity. “With our new concept, we want to put term ‘the joy of savings’ on the map and show that savings can be just as much fun as shopping. Learning about stocks and funds, and watching your money grow on the stock market, is a wonderful feeling that lasts,” says Rasmus Järborg, Chief Product Officer & Deputy CEO at Nordnet. The first campaign will be widely visible on TV, outdoor advertising, and digital channels, featuring the overarching message: “More Fun Savings in Stocks & Funds.” This campaign marks the beginning of a long-term initiative to change how Nordic individuals view saving and investing. Nordnet has previously announced an increased investment in marketing, reaching a total annual budget of approximately SEK 125 million. Watch Nordnet’s new commercials here: · Swedish: https://youtu.be/92srnFXlego?si=uP0OtiLsO4eLE1rD · Norwegian: https://youtu.be/KSFLPOa-B5c?si=l3RTJ9M2tPUxhVEO · Danish: https://www.youtube.com/watch?v=loJSVAVOY6Q · Finnish: https://youtu.be/kUFVGn8520A

Cessatech updates the milestones for the coming year

On 23 December – Cessatech A/S (“Cessatech” or “the Company”) gives an update on the major milestones for the coming year. We are very pleased with the progress Cessatech has made during 2024, and this is truly the result of an incredible team-effort and partnership collaborations. During 2024 we closed the agreement with Proveca for the commercialization of CT001 – and this was proof that our business model is working; to provide paediatric solutions where there is a large unmet need. During the next years we want more products in development, through partnerships in Europe and with more involvement in the US. Some of the important milestones anticipated for 2025 include: · The US launch has been delayed, mainly due to manufacturing issues – and we believe this has almost been solved, and hence anticipate launch during 1H 2025, more details will follow soon. · The paediatric study 0202 is coming to an end, and we anticipate having last patient in the beginning of 2025. We are very excited about this study and hope to present good results from CT001 in children. · Together with Proveca, we will initiate the regulatory EMA submission for CT001, this also includes the Notify Body process for medical devices.  · In 2025 we will also work hard for new partnerships, look for new opportunities and get moving with CT002. Jes Trygved, CEO, CessatechAs the year 2024 is coming to an end, we want to reflect on the accomplishments during the year and focus on the milestones in progress. We have a great year ahead and look forward to communicating more in detail on the above listed important topics in the year to come.

Vestas announces four new orders for a total of 151 MW

News release from Vestas Wind Systems A/SAarhus, 23 December 2024 Vestas is proud to announce the following orders as part of our Q4 order intake: Country Region Customer Project MW Turbine Service Delivery & name variant agreement commissioningPoland EMEA Eurowind Nowogrodek 29 13 x V110 20-year Delivery planned Energy MW 2.2 MW AOM 5000 in Q1 2026 and A/S Service commissioning Agreement scheduled for Q4 2026Denmark EMEA Hallendrup Hallendrup 27 6 x V136 Multi Delivery begins Gruppen and MW -4.5 MW -year AOM in Q4 2025, Wind 5000 commissioning Estate Service scheduled for Q2 Agreement 2026Italy EMEA GR Value Ferrandina 32 5 x V162 20-year Delivery expected SpA MW -6.2 MW AOM 5000 in Q3 2025, delivered service commissioning in 6.4 MW agreement scheduled in Q4 power 2025 modePortugal EMEA Undisclosed Undisclosed 63 14 x V163 30-year Delivery is -4.5 MW AOM 5000 expected in Q3 Service 2025, Agreement commissioning scheduled for Q4 2025   For more information, please contact:Kristian Holmelund JakobsenLead Specialist, Communications and PressMail: krhja@vestas.com  Tel: +45 5221 1467About VestasVestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service onshore and offshore wind turbines across the globe, and with more than 185 GW of wind turbines in 88 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled more than 154 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 33,000 employees are bringing the world sustainable energy solutions to power a bright future. For updated Vestas photographs and videos, please visit our media images page on: https://www.vestas.com/en/media/images. We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels: · www.twitter.com/vestas  · www.linkedin.com/company/vestas · www.facebook.com/vestas  · www.instagram.com/vestas   · www.youtube.com/vestas

Inna Braverman to Speak at Imagination In Action 2025: Architects of the Global Future at Davos World Economic Forum

As an Ideas Catalyst, Inna will deliver a powerful 90-second “Inspiration Spark,” spotlighting Eco Wave Power’s groundbreaking wave energy technology. This presentation will highlight the Company’s commitment to accelerating the global transition to sustainable energy. Her address will be professionally recorded and featured in a mini documentary on Forbes.com, amplifying her message to a worldwide audience. Additional Speakers Confirmed: · Demis Hassabis, Founder of DeepMind and Nobel Laureate · Dario Amodei, CEO, Anthropic · David Gelles, New York Times Reporter  · Yann LeCun, Chief AI Scientist, Meta · Sally Kornbluth, President, the Massachusetts Institute of Technology (“MIT”) · David Rubenstein, Chairman, the Carlyle Group · will.i.am, Founder and CEO, FYI · Roger Kornberg, Professor and Nobel Laureate · Steve Pagliuca, Former Chairman, Bain Capital & Co-Owner of Boston Celtics · Aidan Gomez, CEO, Cohere · Bill Gross, Founder, Idealab · Ori Goshen, CEO, AI21 Labs · And many others About Imagination In Action 2025 Imagination In Action 2025, hosted at the iconic Dome in Davos, Switzerland, is a cornerstone of the World Economic Forum’s programming, bringing together Nobel laureates, MIT leadership, pioneering executives, and creative visionaries. Under the theme "Architects of the Global Future," the summit will address critical global challenges, including sustainability, generative AI, and data sovereignty, within the framework of the Davos World Economic Forum’s mission to shape a better future. The event provides a unique platform for thought leaders to foster connections and craft actionable strategies for a sustainable and equitable future. Inna Braverman’s Impactful Leadership Inna Braverman’s participation highlights Eco Wave Power’s alignment with the World Economic Forum’s commitment to advancing sustainable energy and addressing global challenges. Her insights into the transformative potential of wave energy technology will underscore the importance of renewable solutions in achieving the sustainability goals championed at Davos, Switzerland. Inna Braverman, photo from Planet Action by Katherine Taylor Inna Braverman, photo from Planet Action by Katherine Taylor About Eco Wave Power Global AB (publ) Eco Wave Power is a leading onshore wave energy company revolutionizing clean energy with its patented, smart, and cost-efficient technology that converts ocean and sea waves into sustainable electricity. Dedicated to combating climate change, Eco Wave Power operates the first grid-connected wave energy system in Israel, co-funded by EDF Renewables IL and the Israeli Energy Ministry, which recognized the technology as a “Pioneering Technology.” Expanding globally, Eco Wave Power is preparing to install projects at the Port of Los Angeles, Taiwan, and Portugal, adding to its impressive project pipeline totalling 404.7 MW. The Company has received support from prestigious institutions such as the European Union Regional Development Fund, Innovate UK, and the Horizon 2020 program, and was honoured with the United Nations’ Global Climate Action Award. Eco Wave Power’s American Depositary Shares (WAVE) are traded on the Nasdaq Capital Market. Learn more atwww.ecowavepower.com. Information on, or accessible through, the websites mentioned above does not form part of this press release. For more information, please contact: Info@ecowavepower.com

Spermosens announces the last day of trading in BTU and the first day of trading in warrants series TO 5 and TO 6

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE The rights issue of units that was announced on 3 October 2023 (the "Rights Issue") in Spermosens AB (publ) ("Spermosens" or the "Company") has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid subscribed units (BTU) will be replaced with shares and warrants series TO 5 and TO 6. The last day of trading with BTU is 30 December 2024, and the stop date with Euroclear Sweden AB is 3 January 2025, whereafter shares and warrants will be booked in each shareholder's VP account/depository on 8 January 2025. The warrants series TO 5 will be traded with ISIN code SE0023134986 and the warrants series TO 6 will be traded with ISIN code SE0023134994. The first day of trading in warrants series TO 5 and TO 6 is expected to be January 8 2025. Advisors Eminova Partners Corporate Finance AB acted as financial advisor and Eminova Fondkommission AB acted as issuing agent in connection with the Rights Issue. For more information please contact:  Tore Duvold, VD info@spermosens.com About Spermosens Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com Important information The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, where such offer would be considered illegal. This press release is not a prospectus for the purposes of the Prospectus Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved or reviewed by any regulatory authority in any jurisdiction. This press release neither identifies nor pretends to identify risks (direct or indirect) that may be attributable to an investment in the Company. The information in this press release is only for the purpose of describing the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance shall be given as to the information in this press release regarding its accuracy or completeness. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States, Russia, Belarus or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations. Forward-looking statements This press release contains forward-looking statements that reflect the Company's intentions, beliefs or current expectations and goals for the Company's future operations, financial situation, liquidity, earnings, prospects, expected growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified with words such as "believe", "expect", "anticipate", "refer", "can", "plan", "appreciate", "will", "should", "could ", "aim" or "maybe" or, in each case, their negative, or similar, expressions. The forward-looking statements in this press release are based on various assumptions, many of which in turn are based on additional assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot give any guarantees that they will occur or prove to be correct. As these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or results may differ significantly from those set forth in the forward-looking statements which are the result of many factors. Such risks, uncertainties, unforeseen events, and other significant factors may cause actual events to differ materially from the expectations expressed or implied in this press release by such forward-looking statements. The Company does not guarantee that the assumptions behind the forward-looking statements in this press release are free from errors and each reader should not place any excessive dependence on the forward-looking statements in this press release. The information, opinions and forward-looking statements in this press release relate only to the situation at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or publish any revisions of forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or by Spotlight Stock Market’s regulations for issuers.

Audientes A/S: Flagging notification

Audientes A/S (“Audientes” or the “Company”), CVR 36047631, has following the completion of the recent directed issue and debt conversion and the issuance of the new shares, received information that various shareholders have changed their shareholdings in the Company. As of closing, December 22, 2024: Kogai Invest AB have passed above the threshold of 20 percent and owns 93,208,745 shares, representing approximately 23.34 percent of the votes and capital in Audientes. Shenzhen Hengtong Partner Co., Ltd. have passed above the threshold of 5 percent and owns 29,876,223 shares, representing approximately 7.48 percent of the votes and capital in Audientes. The following investors have passed below the threshold of five (5) percent: Steen Thygesen owns 17,310,789 shares (unchanged), representing approximately 4.33 percent of the votes and capital in Audientes. OSM Group AB owns 14,800,000 shares (unchanged), representing approximately 3.71 percent of the votes and capital in Audientes. Hossein Jelveh owns 10,197,867 shares (unchanged), representing approximately 2.55 percent of the votes and capital in Audientes. Michael O. Fehrn owns now 8,192,496 shares, representing approximately 2.05 percent of the votes and capital in Audientes. For further information, please contact: Steen Thygesen,CEO, Audientes A/S Phone: ‭+45 77 34 16 80‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ Email:st@audientes.com About Audientes A/S Audientes A/S is a Danish hearing health company specializing in smart, self-fitting and affordable hearing aids and advanced hearables. Audientes’ unique hearing aid solution, Ven™ by Audientes, is available for purchase in the Indian and Nepalese markets and will be introduced in China and other markets in the coming years. Companion by Audientes is an advanced hearable, a consumer electronics product, that is commercially available in Europe, Japan, China and in other markets the coming years. Audientes’ mission is to make high-quality hearing aids and hearables for hearing improvement or hearing enhancement accessible to everyone who needs them globally. Audientes is listed on Spotlight Stock Market Denmark (AUDNTS) and headquartered in Copenhagen, Denmark with subsidiaries in Hyderabad, India and in Tokyo, Japan. For more information, please visit our websites, www.audientes.com, www.audientes.eu, www.audientes.co.jp, or www.audientes.in, or follow us on our social media channels.

MobileCasinoRank Unveils Key Insights into Germany’s Mobile Casino Market

The Role of Geolocation in German Mobile CasinosGeolocation technology plays a pivotal role in ensuring compliance with Germany's Interstate Treaty on Gambling (GlüStV). By pinpointing a user's location, mobile casino operators can confirm that players reside in jurisdictions where online gambling is legally permitted, safeguarding both operators and players from potential legal repercussions. “Geolocation is not just a technical feature—it’s a cornerstone of responsible and compliant gaming in Germany,” says Emily Patel Writer at MobileCasinoRank. “This technology ensures a safer environment for players while allowing operators to meet stringent German legal standards.” Adapting to Germany’s Compliance LandscapeGermany’s legal framework demands robust measures to ensure transparency, player protection, and fair gaming. Key requirements include: · Age Verification: Mandatory checks to confirm that players meet the legal gambling age. · Deposit Limits: Enforced restrictions on deposits to promote responsible gaming. · Data Security: Compliance with GDPR ensures the protection of user information. MobileCasinoRank's analysis reveals that operators leveraging geolocation not only enhance compliance but also improve user trust and engagement by creating a secure and localized experience. Emerging Trends in the German MarketGermany’s mobile casino market is seeing a surge in innovative compliance solutions, including real-time geolocation updates and seamless identity verification systems. This blend of technology and legal adherence positions Germany as a model for regulated online gaming worldwide.  For a comprehensive look at geolocation technology and compliance in Germany’s mobile casino sector, visit MobileCasinoRank's insight to the German market here .

Zwipe AS - Issuance of New Convertible Loan

Reference is made to the stock exchange announcement published by Zwipe AS ("Zwipe" or the "Company") on 23 December 2024, regarding the final allocation of the rights issue of units, consisting of shares and warrants (the "Units"), with preferential rights for existing shareholders raising gross proceeds of approximately NOK 40 million (the "Rights Issue"). In said announcement, it was stated that the Company received subscriptions for a total of 85,757,930 Units, corresponding to approx. 21.6% of the Units offered, during the subscription period for the Rights Issue. Approximately NOK 8.6 million of the Rights Issue was guaranteed through subscription commitments and so-called bottom guarantee commitments (the "Bottom Guarantee Commitments"). Furthermore, the Company had received a so-called top guarantee commitment of an amount corresponding to approximately NOK 5,514,472 million (the "Top Guarantee Commitment"). The Top Guarantee Commitment will be fulfilled through the partial set-off of NOK 5,514,472 of the Company's outstanding convertible loan of NOK 10,514,472 (the "2023 Convertible Loan"). In addition, the accrued interest under the 2023 Convertible Loan, coupled with NOK 1,000,000 from the 2023 Convertible Loan, has been set-off against Fenja Capital II A/S (the "Top Guarantor") commitment under the Bottom Guarantee Commitments. The remaining balance of the 2023 Convertible Loan, in addition to an arrangement fee of NOK 200,000, in total NOK 4,200,000, will be extended in the form of a new convertible loan (the "New Convertible Loan"). Accordingly, the Board of Directors of the Company has today, 23 December 2024, resolved, based on the authorization from the Extraordinary General Meeting on 3 December 2024, on the issuance of the New Convertible Loan to the Top Guarantor. Further, the Top Guarantor has subscribed for and been allotted the New Convertible Loan. The New Convertible Loan is due on 30 November 2025 (the "Maturity Date"). The New Convertible Loan shall accrue at an annual interest rate of STIBOR 3M, where STIBOR is set at minimum 3.00% over the duration, (the "Interest Rate Benchmark") plus an interest margin of 10.00%, (the "Interest Margin") from the day the Top Guarantor pays for the New Convertible Loan until the New Convertible Loan is repaid to the Top Guarantor's account or converted (the "Interest"). The Interest shall become due at the end of each calendar quarter and shall be paid out by the Company quarterly on the last day of the quarter or if this date is not a banking day, on the banking day immediately after such date. The Top Guarantor shall have the right, but no obligation, to convert the Convertible Loan into shares in the Company on the terms set out below. Each request for Conversion by the Top Guarantor must always be for an aggregate nominal amount of at least NOK 1,000,000. The subscription price per share upon conversion of the New Convertible Loan shall be NOK 0.12 per share. However, this subscription price may be subject to adjustment in certain circumstances, such as if the Company undertakes a bonus issue; reverse share split, share split; new share issue under Chapter 10 of the Norwegian Private Limited Liability Companies Act (the "Companies Act"); future rights issue pursuant to Chapter 10 of the Companies Act; an offer to shareholders to purchase securities or other rights, or resolves to distribute securities or rights without consideration; liquidation, merger, de-merger, or bankruptcy; or if any of these actions result in an inequitable financial outcome for the Top Guarantor. Upon full conversion of the New Convertible Loan, the share capital will increase by approximately NOK 3,500,000 through the issuance of 35,000,000 new shares, implying a maximum dilution of approximately 11.6 percent for existing shareholders (calculated on the total number of shares in the Company after the Rights Issue). For further information contact: Robert Puskaric, CEO of Zwipe E-mail: ir@zwipe.com This information is information that Zwipe AS is obligated to make public pursuant to the continuing obligations of companies admitted to trading on Euronext Growth Oslo (Euronext Growth Oslo Rule Book - Part II) and on Nasdaq First North Growth Market. Certified Adviser on Nasdaq First North is FNCA Sweden AB, info@fnca.se. The information was submitted for publication, through the agency of the contact person set out below, at 18:20 CET on 23 December 2024. About Zwipe Zwipe believes the inherent uniqueness of every person is the key to a safer future. We work with great passion across networks of international organizations, industries and cultures to make convenience safe and secure. We are pioneering next-generation biometric card and wearables technology for payment and physical & logical access control and identification solutions. We promise our customers and partners deep insight and frictionless solutions, ensuring a seamless user experience with our innovative biometric products and services. Zwipe is headquartered in Oslo, Norway, with a global presence. To learn more, visit http://www.zwipe.com  

PHI announces outcome of rights issue

Goran Dubravčić, Chairman of PHI and CEO of Altium, comments “Having been part of the capital raising for PHI in the Swedish market has been an exciting experience for me and Altium. Through the rights issue, Altium has become an even larger shareholder, and we stand by our commitment to support PHI, that now has the resources to deliver on set objectives, which is important in the collaboration between Altium and PHI”, says Goran Dubravčić, Chairman of PHI and CEO of Altium. Anders Månsson, new CEO of PHI, comments “In this challenging market, I am humbled by the commitment by the shareholders and new investors in PHI shown through the rights issue. Thank you! As I have mentioned throughout the capital raising period, the rights issue is a strategic move to not only strengthen our financial position but also ensure the resources needed to take the next steps in our development. Now we have the funds to accelerate our growth and advance to the next phase of our development”, says Anders Månsson, CEO of PHI. Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 33.1 million including pre-subscription commitment from Altium SA of approximately SEK 15.2 million, which corresponds to a subscription rate of approximately 51.5 percent. In addition, top and bottom underwriting commitments of a total of approximately SEK 31.2 million have been activated, corresponding to approximately 48.5 percent of the Rights Issue. The activated underwriting commitments refer with approximately SEK 10.7 million to the bottom underwriting commitment and approximately SEK 20.5 million to the top underwriting commitment. The total subscription rate (including underwriting commitments) thus ended at 100 percent, meaning that PHI is provided with approximately SEK 64.3 million before transaction related costs of approximately SEK 9.6 million (of which approximately SEK 5.3 million refers to underwriting fees, provided that all underwriters desire to receive cash compensation) and offsetting of loans. A total of 18,254,089 shares were subscribed for with the support of pre-emptive subscription rights, including pre-subscription commitments. In total, 17,475,253 shares were subscribed without the support of pre-emptive subscription rights, including activated underwriting commitments. Through the Rights Issue, 35,729,342 new shares will be issued. The subscribers who are allocated shares without preferential rights will receive settlement notes, which are planned to be sent out after a formal board decision on allocation. Allotted shares without pre-emptive rights shall be paid in accordance with the instructions on the settlement note. Compensation for underwriting commitments For the bottom underwriting commitment, the underwriters receive an underwriting compensation of 10 percent in cash or 13 percent in the form of shares (at the same terms as in the Rights Issue). For the top underwriting commitment, the underwriters receive an underwriting compensation of 12 percent in cash or 15 percent in the form of shares (at the same terms as in the Rights Issue). Number of shares and share capital When the Rights Issue has been registered with the Swedish Companies Registration Office, the total number of shares will have increased by 35,729,342 shares, from 27,322,438 shares to 63,051,780 shares and the Company's share capital will, upon registration, have increased by SEK 7,145,868.40, from SEK 5,464,487.60 to SEK 12,610,356.00. The shareholders who have not participated in the Rights Issue will be subject to a dilution effect corresponding to approximately 57 percent of the votes and capital. Trading in BTA Trading in BTA's will take place on Spotlight Stock Market until the Rights Issue has been registered with the Swedish Companies Registration Office. The registration is expected to take place around 13 January 2025. Flagging After the Rights Issue, Altium SA has passed the flagging limit of 30 percent. Before the Rights Issue, Altium SA’s holding corresponded to approximately 23.6 percent of votes and capital in the Company. After the Rights Issue, Altium SA’s ownership corresponds to approximately 41.6 percent of votes and capital in the Company. Altium SA, in advance, as previously communicated, has by the Swedish Securities Council (Swe: Aktiemarknadsnämnden) been granted exemption from the mandatory bid requirements if its shareholdings would amount to or exceed 30 percent of the number of votes in the Company because of Altium’s participation in the Rights Issue. Lock up Altium has, through a lock-up agreement, with Navia Corporate Finance AB as counterparty, undertaken, with customary exceptions, not to sell any of the existing shareholding or such shareholding that has been acquired through subscription in the Rights Issue, for a period of six months after the completion of the Rights Issue. Advisors Navia Corporate Finance AB is the financial advisor and Sole Bookrunner in connection with the Rights Issue. HWF Advokater AB is the legal advisor. Nordic Issuing AB is the issuing agent. For more information about the Rights Issue, please contact: Navia Corporate Finance AB E-mail: info@naviacf.se Website: www.naviacorporatefinance.com

Mandatory Notification of Trade

Hamilton, Bermuda, December 23, 2024 - Paratus Energy Services Ltd. (ticker "PLSV") (the "Company") has been notified of a trade completed by a fund managed by Lodbrok Capital LLP, a close associate to board member Joachim Bale. For further information, please see the attached mandatory notification of trade. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For further information, please contact:Baton Haxhimehmedi, CFOBaton.Haxhimehmedi@paratus-energy.com+47 406 39 083

Stena RoRo takes delivery of the battery hybrid vessel Guillaume de Normandie

Just as with four of the five E-Flexer ships that Stena RoRo has delivered to Brittany Ferries, the vessel will be powered by multi-fuel engines as well as the market's largest battery-hybrid package of 12 MWh. With these batteries, the ship will be able to operate in and out of port solely on battery power and even maneuver when docking and undocking without using the ship's diesel engines. This is a unique technical solution that provides significantly lower CO2 emissions for the ship.The E-Flexer concept has been continuously developed in line with future environmental requirements, and through its technical design and high degree of innovation, it can fulfill and exceed both existing and future international requirements.The Guillaume de Normandie is also equipped with a shore connection with an output of 8 MW for high-speed charging of the batteries, which also enables a completely fossil-free stay when in port.  With the installed battery capacity, the vessel can operate at speeds of up to 17.5 knots on batteries alone.The ship's engines can be powered by marine diesel (MGO), liquefied natural gas (LNG), biodiesel or biogas. In addition, the PTI/PTO system with the Battery Power function can be used for propulsion at sea or maneuvering in port. The system is scalable, which means that in the future, the Guillaume de Normandie can operate entirely on batteries or with a combination of the different fuels. The ship's modern interior (designed by Figura Arkitekter AB) has been especially created for the current route and with clear influences from Normandy. The ship is certified for 1300 passengers along with 2410 lane meters of cargo, whereof 176 lane meters for personal cars.The E-Flexer series is based on a basic concept with vessels larger than most existing RoPax ferries and features a highly flexible design. Each ship is tailored to customers' needs, both commercially and technically. An optimized design of the hull, propellers and rudders along with opportunities to incorporate new environmentally friendly technology contribute to the E-Flexer vessels being at the absolute forefront in terms of sustainability and performance as well as cost and energy efficiency.“It is with great satisfaction and pride that we have now taken delivery of the twelfth E-Flexer vessel in the series,” says Stena RoRo AB Managing Director Per Westling. “Within the framework of the E-Flexer concept, there has been continuous technical development and we can offer our customers flexible and future-proof propulsion systems that by a wide margin meet both today's and future environmental requirements. The large battery hybrid system we installed on the Guillaume de Normandie means that the ship can operate optimally, in step with regulatory developments, or in accordance with the operator's own policies.”The Guillaume de Normandie is chartered to Brittany Ferries for 10 years.The total of five E-Flexer ships ordered by Brittany Ferries are renewing and modernizing the company's current fleet of cargo and passenger ships. The first ferry, the Galicia, was delivered in the autumn of 2020, the second in November 2021, the third in December 2023. The Saint-Malo  was delivered in October 2024, which is the fourth vessel in the series, and the Guillaume de Normandie in December 2024, the fifth and final ship.Stena RoRo currently has 15 confirmed orders at CMI Jinling, Weihai shipyard for E-Flexer vessels, as well as two orders for New Max RoRo vessels. Twelve vessels have now been delivered.Stena E-Flexer orders: 1. Stena Line: Stena Line network in the Irish Sea; delivered in 2019 2. Stena Line; Stena Line's network in the Irish Sea, delivered in 2020 3. Brittany Ferries: Brittany Ferries network; delivered in 2020Long-term charter agreement 4. Stena Line: Stena Line network in the Irish Sea; delivered in 2021 5. DFDS; DFDS network; delivered in 2021Long-term charter agreement 6. Brittany Ferries: Brittany Ferries network; delivery 2021Long-term charter agreement; LNG operation 7. Stena Line; Stena Line network, delivered from the shipyard in May 2022Extended version 8. Stena Line; Stena Line's network, delivered from the shipyard in September 2022Extended version 9. Brittany Ferries: Brittany Ferries network; delivered in December 2022Long-term charter agreement, LNG operation10. Marine Atlantic; Marine Atlantic network, delivered in February 2024Long charter agreement; LNG operation with battery-hybrid installation11. Brittany Ferries: Brittany Ferries network, delivered in 2024Long charter agreement; LNG operation with battery-hybrid installation12. Brittany Ferries: Brittany Ferries network, delivered in 2024Long charter agreement; LNG operation with battery-hybrid installation13. Corsica Linea, Corsica Linea network, delivery 2026LNG operation with battery-hybrid installation14. Attica Group, delivery April 2027Methanol-ready, battery-hybrid installation15. Attica Group, delivery August 2027Methanol-ready, battery-hybrid installationE-Flexer No. 12 specifications for Brittany Ferries:Length: 194.7 mDraught: 6.5 mBeam: 27.8 mCapacity: 1300 passengers and 2410 lane meters, of which 176 lane meters are intended for automobilesPassenger cabins: 222 distributed over four decksSpeed: 23 knots (17.5 on batteries onlyPhotos: CMJS Shipyard Captions:1. Guillaume de Normandie – Brittany Ferries2. Batteri room 13. Batteri room 24. Les Planches, the ship's bar on deck 8, shows clear influences from Normandy 5. There is a special lounge on deck 6 for the ship's pod cabin guests6. Riva Bella, the restaurant in the forward section of deck 7 For more information, please contact:Per Westling, Managing Director, Stena RoRo ABTel: +46 31 855154; +46 704 85 51 54Email: per.westling@stena.comSince 1977, Stena RoRo has led development of new marine RoRo, cargo and passenger concepts. We provide custom-built vessels, as well as standardized RoRo and RoPax vessels. The company leases about fifteen vessels to operators worldwide, both other Stena companies and third parties. Stena RoRo specializes above all in using its technical expertise for the design and production of new vessels and the conversion and technical operation of existing vessels in order to deliver tailor-made transport solutions to its customers. We call this “Stenability”. Since 2013, we have had responsibility for the design and completion of Mercy Ships’ new hospital vessel the Global Mercy – the world's largest civilian hospital ship. The ship was delivered in 2021.www.stenaroro.comBrittany Ferries is a French ferry company and tour operator based in Roscoff, France. The company was founded by an agricultural cooperative in Breton for exporting vegetables to the UK. The first ferry voyage was from Roscoff to Plymoth on January 2, 1972, the day after the UK joined the EEC – the European Economic Community, the predecessor to the EU. The cargo consisted of artichokes and cauliflower. The company quickly expanded with more ships and routes when it became clear that the biggest market was British tourists who wanted to explore Brittany and later Normandy as well. Brittany Ferries presently operates 14 routes connecting France, Great Britain, Spain and Ireland. In a normal year, the company has sales of approximately 450 million Euros and transports approximately 2.5 million passengers and 205,000 freight units. The company is still largely owned by French farmers, supported by the regions of Brittany and Normandy, and prides itself on being the largest employer of seafarers in France.www.brittanyferries.com

CS MEDICA Explores Listing and Strategic Options to Protect Shareholder & Company Value

CS MEDICA A/S (“CS MEDICA”) announces its Board of Directors is already in discussions with new trading venue platforms and exploring other solutions to protect company value and shareholder assets. The priority is to protect the company’s growth journey and ensure continued trading by either relisting, moving to a new trade venue, or converting assets through i.e. CANNORDIC. “Our primary goal is to safeguard shareholder assets while maintaining the company’s value and strategic direction,” stated Flemming Heegaard, Chairperson of CS MEDICA. “We are committed to implementing measures that support a transition and align with our long-term plans. Updates will be shared once decisions are finalized and ready to be voted/ approved on a forthcoming EGM.” CS MEDICA will call for an Extraordinary General Meeting start January 2025 to ensure shareholders are informed about the options to protect their investments.  Strategic Actions and Strengthened Position 2024Although Spotlight is considered a growth exchange market, CS MEDICA has faced challenges with its share due to a low free float, as the majority of shares are held by founders and family members, coupled with the financial constraints typical of a scale-up MedTech company. To address these challenges, the company has focused on increasing the number of shares to improve trading volume and liquidity while simultaneously building organic sales growth. Besides these challenges, CS MEDICA's business operation has taken several steps to stabilize the business and support growth, reflected in the share development and market cap prior to Spotlights notification on the 19. December 2024: · Increased Revenue: Achieving growth through product milestones and expanding partnerships in the last year. · Reduced Burn Rate: Implementing cost-saving measures to enhance sustainability. · Converted Founders’ Debt to Shares: Improving the company’s financial baseline. · Mitigated Risks: Addressing challenges proactively and changed strategy to improve operations. · Advanced Spin-off of CANNORDIC: Progressing with the planned share spin-off to secure additional funds for growth on the most mature market for the company's portfolio. While the financial situation remains challenging, as other growth companies on Spotlight, these actions have improved CS MEDICA’s business outlook compared to last year. 

Vestas announces new order in Australia

News release from Vestas Asia PacificSeoul, 24 December 2024Vestas is proud to announce the following order as part of our Q4 order intake: Country Region Customer Project MW Turbine Service Delivery & name variant agreement commissioningAustralia APAC Synergy King 105 17 x 30-year Delivery expected Rocks V162 AOM 5000 in Q3 2026 and Wind -6.2 service commissioning Farm MW agreement expected to commence Q4 2026 For more information, please contact:Kilani FisherAPAC Head of Marketing & CommunicationsMail: klafs@vestas.comTel: +61 436 855 159About VestasVestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service onshore and offshore wind turbines across the globe, and with more than 185 GW of wind turbines in 88 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled more than 154 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 33,000 employees are bringing the world sustainable energy solutions to power a bright future. For updated Vestas photographs and videos, please visit our media images page on: https://www.vestas.com/en/media/images. We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels: · www.twitter.com/vestas  · www.linkedin.com/company/vestas · www.facebook.com/vestas  · www.instagram.com/vestas   · www.youtube.com/vestas

FREYR Battery Closes Transformative Acquisition of Trina Solar’s U.S. Manufacturing Assets

Under the terms of the finalized agreement, FREYR has acquired Trina Solar’s 5 GW solar module manufacturing facility in Wilmer, Texas. The facility commenced production on November 1, 2024, and is expected to ramp up to full production by H2 2025 with 30% of estimated production volumes backed by firm offtake contracts with U.S. customers. Highlights · The Transaction creates a commercial and operating platform to establish a leading integrated U.S.-owned and operated solar and battery storage company with a pathway for value enhancing growth · The transaction leverages Trina Solar’s global leadership in the solar and the renewable energy industries, established U.S. commercial presence, global supply chains, advantaged technology, and a strong track record of manufacturing and project execution for U.S. customers · Total consideration to Trina Solar at closing comprised of $100 million of cash, $50 million repayment of an intercompany loan, $150 million loan note, 9.9% of FREYR outstanding common stock, and an $80 million convertible loan note that would convert into an additional 11.5% of FREYR outstanding common stock after certain conditions are satisfied; in addition, FREYR acquired $235 million in indebtedness in connection with the facility in Wilmer, Texas · FREYR reiterates initial 2025 EBITDA guidance of $75 - $125 million. FREYR expects to exit 2025 at full-year run rate EBITDA of $175 - $225 million and integrated solar module/solar cell production annual run rate EBITDA of $650 - $700 million · Ramp up activities at the Wilmer, TX solar module plant continue as scheduled. Line 1 has been completed and the commissioning on Line 2 commenced in November 2024; FREYR expects the seven-line facility to reach full production in H2 2025 · FREYR intends to submit transaction documentation in Q1 2025 to secure U.S. regulatory consents from relevant organizations, including the Committee on Foreign Investment in the United States (CFIUS) · FREYR received $50 million from Encompass Capital Advisors LLC (“Encompass”) in exchange for the issuance of preferred stock in connection with this closing, and FREYR may receive an additional $50 million from Encompass upon the Company proceeding to start of construction on a solar cell manufacturing facility · FREYR is proceeding with its site selection process for a planned U.S. solar cell facility with a start of construction anticipated in Q2 2025 FREYR is progressing with the implementation of a multi-phase strategic plan to establish a vertically integrated U.S. solar manufacturing footprint. With site selection for the planned 5 GW U.S. solar cell manufacturing plant underway, the Company is evaluating and pursuing debt and equity solutions to fund construction. FREYR is still targeting a start of construction in Q2 2025 with anticipated first solar cell production in H2 2026. The creation of a U.S.-owned and operated company that can provide a turnkey solar technology solution is expected to solve a bottleneck for developers, create up to 1,800 direct jobs, satisfy local content requirements for U.S. solar projects, and competitively differentiate FREYR. “Today is an exciting day for FREYR. The closing of this transaction marks the start of a new chapter for the Company as we execute our strategic plan to build a U.S.-based leader in the solar and storage markets,” remarked Daniel Barcelo, FREYR’s Chairman of the Board and CEO. “We are grateful for the continued support of our shareholders, and we look forward to advancing our key objectives to create meaningful shareholder value and to enhance our competitive position in 2025, highlighted by the planned start of construction of our solar cell manufacturing facility and other project development opportunities that are emerging for FREYR and Trina to mutually pursue.” Transaction details In accordance with the previously disclosed terms of the transaction agreement, the total consideration to Trina Solar consists of $100 million of cash, $50 million repayment of an intercompany loan, a $150 million loan note, 9.9% of FREYR outstanding common stock, and an $80 million convertible loan note that would convert into an additional 11.5% of FREYR outstanding common stock after certain conditions are satisfied. FREYR has secured a $100 million commitment for the issuance of preferred stock to certain funds and accounts managed by Encompass, of which $50 million in preferred stock has been issued to such certain funds and accounts managed by Encompass in connection with this closing, and $14.8 million for a private placement of 7.0% of FREYR outstanding common stock to Ms. Chunyan Wu, a co-founder and significant shareholder of Trina Solar, subject to certain conditions. The funds will be used for general operational and working capital purposes. Transaction advisors Santander served as financial advisor, Skadden, Arps, Slate, Meagher & Flom (UK) LLP served as legal advisor, Arnold & Porter, Ernst & Young, Clean Energy Associates and Rystad Energy served as advisors to FREYR in support of the transaction. Dorsey & Whitney LLP served as U.S. legal advisor, CICC served as financial advisor and Deloitte served as tax advisor to Trina Solar. About FREYR FREYR (NYSE: FREY) is a clean energy solutions provider building an integrated U.S. supply chain for solar and batteries. In November 2024, FREYR announced a transformative transaction, positioning the Company as one of the leading solar manufacturing companies in the U.S., with a complementary solar and battery storage strategy. Based in the U.S. with plans to expand its operations in America, the company is also exploring value optimization opportunities across its portfolio of assets in Europe. To learn more about FREYR, please visit www.freyrbattery.com  and follow @FREYRBattery on social media. Contacts Investor contact:Jeffrey SpittelExecutive Vice President, Investor Relations and Corporate Developmentjeffrey.spittel@freyrbattery.comTel: (+1) 409 599-5706 Media contact:Amy JaickGlobal Head of Communicationsamy.jaick@freyrbattery.comTel: (+1) 973 713-5585 Cautionary Statement Concerning Forward-Looking Statements All statements, other than statements of present or historical fact included in this presentation, including, without limitation, FREYR Battery, Inc.’s, a Delaware corporation, (“FREYR”) ability to establish a commercial presence in the U.S. solar market; the potential benefits of FREYR’s strategic acquisition of Trina Solar US Holding Inc., a Delaware corporation (“Trina”), including value enhancing growth; any projected 2025 EBITDA guidance and run-rate EBITDA figures; the expected timeline of any post-closing activities or events; FREYR’s ability to secure financing options for the solar cell manufacturing facility; the projected ramp up to full production by H2 2025 of Trina’s solar module manufacturing facility; the estimated production volumes backed by firm offtake contracts for the solar module manufacturing facility; the projected start of solar cell manufacturing production in Q2 2025; the construction of a U.S. solar cell manufacturing facility targeting start of production in H2 2026; the integration of U.S. solar module and solar cell capacity; FREYR’s timeline for obtaining regulatory consents for the transaction; FREYR’s ability to become a leading U.S. solar module producer; the establishment of a domestic manufacturing footprint for FREYR’s business; the creation of 1,800 local jobs; the integration of U.S. solar and battery energy storage system manufacturing; the monetization of FREYR’s legacy assets;; the ability for a U.S.-owned and operated solar technology solution company to solve a bottle neck for developers and satisfy local content requirements for U.S. solar projects; and any potential competitive differentiators FREYR may offer are forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against the Company following the closing of the transaction; (2) the risk that the transaction disrupts current plans and operations as a result of the consummation of the transaction; (3) the ability to recognize the anticipated benefits of the transaction and inability to timely secure regulatory consents related to the transaction; (4) costs related to the transaction; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (7) any potential risk that the Chinese equity ownership in the Company may impact FREYR’s ability to develop a solar cell facility in the U.S.; (8) any increases to commodity pricing or US tariff and countervailing duty levels; and (9) potential operational risks associated with commissioning and ramp-up of production. The Company cautions that the foregoing list of factors is not exclusive. Most of these factors are outside FREYR’s control and are difficult to predict. Additional information about factors that could materially affect FREYR is set forth under the “Risk Factors” section in (i) FREYR’s post-effective amendment no. 1 to the Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on January 4, 2024, (ii) FREYR’s Registration Statement on Form S-4 filed with the SEC on September 8, 2023 and subsequent amendments thereto filed on October 13, 2023, October 19, 2023 and October 31, 2023, and (iii) FREYR’s annual report on Form 10-K filed with the SEC on February 29, 2024, and FREYR’s quarterly reports on Form 10-Q filed with the SEC on May 8, August 9 and November 12, 2024, and available on the SEC’s website at www.sec.gov . Except as otherwise required by applicable law, FREYR disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this presentation. Should underlying assumptions prove incorrect, actual results and projections could differ materially from those expressed in any forward-looking statements. FREYR intends to use its website as a channel of distribution to disclose information which may be of interest or material to investors and to communicate with investors and the public. Such disclosures will be included on FREYR’s website in the ‘Investor Relations’ sections. FREYR also intends to use certain social media channels, including, but not limited to, Twitter and LinkedIn, as means of communicating with the public and investors about FREYR, its progress, products and other matters. While not all the information that FREYR posts to its digital platforms may be deemed to be of a material nature, some information may be. As a result, FREYR encourages investors and others interested to review the information that it posts and to monitor such portions of FREYR’s website and social media channels on a regular basis, in addition to following FREYR’s press releases, SEC filings, and public conference calls and webcasts. The contents of FREYR’s website and other social media channels shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Vestas wins 99 MW repowering order from Iberdrola in Spain

News release from Vestas MediterraneanMadrid, 26 December 2024 Iberdrola has placed a 99 MW order of for the repowering of the Molar de Molinar and Isabela wind parks, located in Castilla-La Mancha, Spain. The contracts include the supply and installation of 11 V150-4.5 MW wind turbines and 11 V136-4.5 MW wind turbines respectively, as well as a 10-year Active Output Management (AOM 4000) service agreement. The 22 new wind turbines will replace 139 legacy models currently powering the sites, increasing their energy output by around 30 percent. ‘Thanks to the grants awarded by the Spanish Institute for the Diversification and Saving of Energy (IDAE), through a competitive process, Iberdrola has been able to start these pioneering investments in repowering. The projects required to dismantle the old wind farms, and to adapt the foundations and electrical connections to host larger machines. The installation of more modern wind turbines will allow us to make better use of the wind resource, reducing the environmental impact’, says José González Bujanda, Head of Project Development at Iberdrola Renewable Energy. “We are very proud to partner with Iberdrola for the repowering of these projects. This order underlines the great potential in repowering older onshore turbines with new and efficient technology. It also showcases the suitability of our 4 MW portfolio for the Spanish market. Its full converter technology provides our customers with the reliability they need to operate in the Spanish grid, marked by an increasing participation of renewable sources”, says José Luis del Cerro, Vestas Spain Country Manager. With over 9.9 GW of wind turbines turning 20 years old or more in 2025, Spain’s repowering market is expected to become a driving force of its energy transition in the coming years. Replacing legacy turbines with current technology also allows to considerably increase the onshore wind capacity with fewer turbines, reducing the environmental impact and the use of ground at the site. Turbine delivery is expected by the second quarter of 2025 whilst commissioning is planned by the fourth quarter of 2025. Once operational, both wind parks combined will now prevent 53,000 tonnes of CO\2\ from being emitted into the atmosphere per year. The project’s CO\2\ footprint will also benefit from Vestas’ strong presence in Spain. The company currently manufactures onshore blades in its factory in Daimiel by Ciudad Real. The wind turbine towers will also be manufactured locally. Since 1991, when Vestas installed its first wind turbine in Spain, the company has accumulated over 5.3 GW of installed capacity in the country.For more information, please contact:Andrés DomínguezCommunications SpecialistVestas MediterraneanM +34 649294007Email: andms@vestas.comAbout VestasVestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service onshore and offshore wind turbines across the globe, and with more than 185 GW of wind turbines in 88 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled more than 154 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 33,000 employees are bringing the world sustainable energy solutions to power a bright future. For updated Vestas photographs and videos, please visit our media images page on: https://www.vestas.com/en/media/images. We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels: · www.twitter.com/vestas  · www.linkedin.com/company/vestas · www.facebook.com/vestas  · www.instagram.com/vestas   · www.youtube.com/vestas